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Zusammenfassung
Heterogenität ist ein Markenzeichen biologischer Systeme auf jedweder Skala. In dieser Arbeit
entwickle ich mathematische Methoden, welche die Beschreibung biologischer Heterogenität
ermöglichen und untersuche diese im Kontext zweier biomedizinisch relevanter Anwendungs-
gebiete. Hierbei handelt es sich zum Ersten um das Hervorrufen schützender B-Zell-Immun-
antworten durch Impfung und zum Zweiten um die Wachstumsdynamik eines aggressiven
Gehirntumors.
In der großenMehrheit der derzeit lizensierten Impfungen sind Antikörper-Titer starke Kor-
relate der Immunität. Allerdings widersetzen sich Krankheiten wie Influenza, Tuberkulose und
Malaria bis jetzt der Entwicklung effizienter Impfungen und häufig sind die Mechanismen,
welche etablierten Impfungen zugrunde liegen, nicht vollständig verstanden. Im ersten Teil
dieser Arbeit entwickle ich daher ein dateninspiriertes mathematisches Modell der B-Zell-
Gedächtnisantwort, welches auf einem Ensemble aus computersimulierten Keimzentren ba-
siert. Durch verschiedene pathogen- und patientenspezifische Parameter erlaubt dieses Modell
die Beschreibung von Impfszenarien unterschiedlicher Schwierigkeit. Anhand des Modells zei-
ge ich, dass die Verfügbarkeit hochwertiger Vorläuferzellen als Basis für klonale Selektion und
die Effizienz der Affinitätsreifung in Abhängigkeit der Bindungskomplexität separate Engpässe
für eine erfolgreiche Impfung darstellen. Gemeinsam mit experimentellen Kollaborationspart-
nern nutzen wir diese Resultate zur Erklärung von Einzelzell-Immunoglobulin-Sequenzdaten
aus einer Impfstudie gegen den Malaria-Parasiten Plasmodium falciparum (Pf ). Wie für kom-
plexe Antigene vorhergesagt, offenbart sich die klonale Selektion wirksamer Vorläuferzellen
mit Keimbahn-Sequenzen im Vergleich zur Affinitätsreifung nach wiederholter Vakzination
mit Pf Sporozoiten als der effizientere Mechanismus, da die Mehrheit der Immunoglobulin-
Genmutationen affinitätsneutral ausfällt. Diese Ergebnisse sind für die Entwicklung von po-
tentiell personalisierten Impfprotokollen gegen strukturell komplexe Antigene von grundsätz-
licher Bedeutung.
Ein quantitatives Verständnis der funktionellen Zellheterogenität von wachsenden Tumo-
ren verspricht Einsichten in die Grundlagen der Krebsbiologie. Im zweiten Teil dieser Arbeit
entwickle ich entsprechend mathematische Modelle des Glioblastom-Wachstums. Unter Ver-
wendung einer Bayes’schen Herangehensweise an die Parameterschätzung und einer großen
Menge experimenteller Daten aus Mausmodellen zeige ich, dass das exponentielle Gehirntu-
morwachstum von Gehirntumor-Stammzellen getrieben wird, währendweiter ausdifferenzier-
te Nachkommen dieser Zellen trotz höherer Teilungsraten isoliert nicht zumWachstum beitra-
gen. Aus dem Vergleich einer drei-dimensionalen Tumorwachstumssimulation mit experimen-
tellen Wachstumskurven leite ich ein hoch migratives Verhalten von Tumorstammzellen her.
Auf der Basis von Einzelzell-Tracingdaten und einer Kombination aus deterministischen und
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stochastischenModellanteilen bestimme ich die entsprechendeMigrationsrate und interpretie-
re experimentell beobachtete Klongrößen-Verteilungen. Schlussendlich nutze ich das nunmehr
voll quantifizierte Tumorwachstumsmodell, um das Ansprechen auf therapeutische Interven-
tionen vorherzusagen. Diese Vorhersagen wurden durch unsere Kollaborationspartner experi-
mentell bestätigt, was impliziert, dass ein quantitatives Verständnis der hierarchischen Popu-
lationsstruktur eines Tumors zu informierten Behandlungsentscheidungen beitragen kann.
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Summary
Heterogeneity is a hallmark of biological systems at every conceivable scale. In this work, I
develop computational methods for describing various interacting types of biological hetero-
geneity. I apply them to explore two scenarios of biomedical interest: the evocation of pro-
tective B cell responses by vaccination and the growth dynamics of an aggressive brain tumour.
In the vast majority of currently licensed vaccines, antibody titres are strong correlates of
vaccine-induced immunity. However, diseases like influenza, tuberculosis and malaria con-
tinue to escape efficient vaccination, and the mechanisms behind many established vaccines
remain incompletely understood. In the first part of this work, I therefore develop a data-driven
computational model of the B cell memory response to vaccination based on an ensemble of
simulated germinal centres. This model can address immunisation problems of different dif-
ficulty levels by allowing both pathogen- and host-specific parameters to vary. Using this
framework, I show that two distinct bottlenecks for successful vaccination exist: the availab-
ility of high-quality precursors for clonal selection and the efficiency of affinity maturation
dependent on binding complexity. Together with experimental collaborators, we have used
these results to interpret single-cell immunoglobulin sequencing data from a vaccination trial
targeting the malaria parasite Plasmodium falciparum (Pf ). As predicted for a complex antigen,
after repeated immunisation with Pf sporozoites, the clonal selection of potent germline and
memory B cell precursors against a major surface protein outpaces affinity maturation because
the majority of immunoglobulin gene mutations are affinity-neutral. These findings have im-
plications for the design of potentially personalised vaccination strategies to induce potent B
cell responses against structurally complex antigens.
A quantitative understanding of functional cell heterogeneity in tumour growth promises
insights into the fundamentals of cancer biology. In the second part of this work, I correspond-
ingly developmathematical models of glioblastoma growth. Employing a Bayesian approach to
parameter estimation and incorporating a large body of experimental data frommouse models,
I show that brain tumour stem cells drive exponential tumour growth while more differentiated
tumour progenitor cells, although fast cycling, are unable to sustain expansion by themselves.
Comparing a three-dimensional simulation of tumour growth to experimental growth curves,
I derive that glioblastoma stem cells are highly migratory. Based on single-cell clonal tra-
cing data and a combination of deterministic and stochastic modelling approaches, I identify
their migration rate and explain experimentally observed clone size distributions. Finally, I
employ the resulting fully quantified model of tumour growth to predict the response to two
therapeutic interventions. These predictions were verified experimentally by our collaborat-
ors, suggesting that quantitative knowledge on the hierarchical subpopulation structure of a
tumour may provide valuable guidance for treatment.
3

Introduction
Die Wahrheit ist eben kein Kristall, den man in die Tasche
stecken kann, sondern eine unendliche Flüssigkeit, in die
man hineinfällt.
— Robert Musil, Mann ohne Eigenschaften
Heterogeneity at every conceivable scale is a hallmark of biological systems. While this
is formidable when contemplating natural diversity at the genetic, cellular or species level, it
leads to significant medical challenges in a variety of fields. In this work, computational meth-
ods for describing biological heterogeneity at different scales are explored and developed in
two scenarios of medical interest: the aggressive brain tumour glioblastoma and the evocation
of protective B cell responses by vaccination.
Cancer in general is a highly heterogeneous disease [Meacham and Morrison, 2013, Burrell
et al., 2013, Melo et al., 2013, Fisher et al., 2014]. This heterogeneity begins with differences
between individual cancer patients and continues in the spatio-temporal domain: one meta-
stasis is unlike the next even within a single patient and through mutation-driven evolution
two samples taken as little as a few weeks apart from each other may also be vastly different.
At the cellular level, this diversity is due to both genetic and epigenetic heterogeneity as cancer
cells with identical genomes may be present in different phenotypes reminiscent of specialised
cell types within normal tissue. All these factors make cancer treatment a difficult problem -
because of differences in early mutational events which are thus present throughout the cancer
cell population, what works in one patient has no effect in the next; because of pharmacokin-
etic differences in drug delivery and absorption a metastasis at one site is harder to tackle than
at another; and because of different cellular genomes or phenotypes some cells may be by and
large protected against a treatment at hand.
Similar problems exist in the realm of vaccine development. While a number of established
vaccines reliably lead to long-term protection in the vast majority of patients, this is not true
in all cases [Plotkin et al., 2008, Plotkin, 2014]. Several widely spread diseases escape efficient
vaccination as yet. The malaria parasite Plasmodium falciparum is one example in which the
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Heterogeneous populations of tumour cells, pathogens and people.
most advanced vaccine candidate RTS,S AS01 leads to transient protection in only 25 to 55%
of cases [Neafsey et al., 2015, Olotu et al., 2016]. Several types of heterogeneity prevent the
development of a “one-protocol-fits-all” optimal vaccination strategy to be used across patho-
gens and patients. Pathogens are equipped with diverse strategies and tricks in order to hinder
the efficient development of immune memory. These comprise particularly challenging an-
tibody binding sites, a within-host life cycle set up to confuse the immune system, the rapid
accumulation of mutations in order to continuously present different surface antigens and the
similarity of crucial epitopes to self-peptides. Vaccine recipients on the other hand differ from
each other due to systemic reasons such as immune responses of varying strengths as well as
because of genetic factors such as the availability of correct antibody templates in their genetic
code.
Aspects of both of these medical scenarios are investigated using mathematical methods in
this thesis. In the first part, an agent-based simulation of the B cell immune system is de-
veloped. Agent-based computational models do not summarise individual players, in this case
B cells, into populations, but allow for tracking them individually. Because individuality at the
cellular level is an important aspect of the B cell response, where somatic mutations can alter
the binding strengths between an individual cell’s antigen receptor and its target, this compu-
tational framework is specifically suitable here. Every computational B cell agent is equipped
with a list of personal properties, one of them being its affinity for the vaccine antigen. Based
on these properties individual decisions can be taken. In addition to allowing for this crucial
cell-to-cell variation, the new modelling framework incorporates other types of heterogeneity,
notably the diversity of pathogens. Our model is thus not tied to the description of one spe-
cific vaccine antigen, but allows to vary some of the factors causing pathogenic diversity as
introduced above. These comprise epitope complexity, repertoire availability and aspects of
potential pathogenic life cycles. Patient diversity can be modelled by altering the immunolo-
gical repertoire with which each individual is initially equipped to fight the invader.
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Agent-based models are also employed for two different purposes in the second part of the
thesis in which heterogeneous cell populations within mouse model glioblastomas are invest-
igated. While individual agents are beneficial in the B cell case in order to carry cell-specific
affinities, here wemake use of them because (1) they are easily extendible into the spatial world
and (2) they are a suitable tool for analysing stochastic clonal fates. In the first case, tumour cell
agents are tracked on a three-dimensional grid revealing a fundamental connection between
tumour growth pattern and tumour architecture. In the second case, the agent-based approach
is used to supplement a simple compartmental model based on ordinary differential equations.
While this type of model is able to describe the diverse dynamics of the experimentally iden-
tified cell types glioblastoma stem cells, proliferating progenitors and differentiated tumour
cells, it allows quantification only on the basis of population data. Using a combination of de-
terministic population description and stochastic clonal description, we are able to introduce
single-cell clonal tracing data into the parameter estimation process.
Overall, this thesis explores several dimensions of biological heterogeneity in the context
of medical decision making. Using a combination of analytical and computational methods,
models incorporating such diversity are developed and employed to further mechanistic and
quantitative understanding of the consequences of population heterogeneity. It emerges that
extracting general principles in biology may not mean the same thing as extracting general
principles in physics: while in the latter case, universal laws and universal parameters should
ideally govern systems at all scales, in the former, finding general principles inevitably entails
defining the right parameters for introducing heterogeneity. Mathematical approaches are
necessary to identify these parameters since they largely defy exploration in the natural world.
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Part I.
B Cell Immune Response to Complex
Antigen.
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[…] der Rechenschieber, das ist ein kleines Symbol, das man
in der Brusttasche trägt und als einen harten weißen Strich
über dem Herzen fühlt: wenn man einen Rechenschieber
besitzt, und jemand kommt mit großen Behauptungen oder
großen Gefühlen, so sagt man: Bitte einen Augenblick, wir
wollen vorerst die Fehlergrenzen und den wahrscheinlich-
sten Wert von alledem berechnen!
— Robert Musil, Mann ohne Eigenschaften
In the first part of this thesis, an agent-based model of the B cell immune response is de-
veloped based on a large body of experimental observations and parameters from the literature.
This model is then applied to explore the effect of vaccination for antigens and patients with
different characteristics; finally, properties emerging from the model are employed to explain
experimental data derived from a malaria vaccination study.
Chapter 1 provides a rough introduction to the vertebrate immune system and its compon-
ents with a focus on B cell immunity and the germinal centre reaction as well as to previous
works modelling these processes. Following this, chapter 2 introduces the computer simula-
tion of the B cell memory response to antigen exposure developed in this thesis. The chapter
starts with a motivational section introducing the need for a new type of binding model. In
chapter 3 the model is used to explore a range of varying boundary conditions concerning B
cell-biologic processes, patient- and pathogen specific factors and also effects of choices in vac-
cination protocol design. Developing further on these results, chapter 4 shows how the model
can be used to make more sense of experimental data, in this specific case using single-cell B
cell information from a vaccination trial aimed against the malaria parasite Plasmodium fal-
ciparum. Finally, an integrative discussion of all results is provided in chapter 5.
All experimental work described in chapter 4 was performed by Rajagopal Murugan in the
Division of B Cell Immunology (DKFZ Heidelberg) headed by Hedda Wardemann. Parts of
sections 2.2, 2.3 and 4.1 were previously published in [Murugan et al., 2018] and have been
written by the candidate herself.
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1. Background - B Cell Memory Responses
In order to provide background knowledge for the development and analysis of a comprehens-
ive simulation of the B cell memory response in chapters 2, 3 and 4, this section explores both
the biological and theoretical preliminaries. In section 1.1, an overview of antibody-mediated
immunity, its cellular actors and generating processes is provided. Section 1.2 discusses previ-
ous attempts at translating this complex biological system into equations and simulations.
1.1. The Humoral Immune Response
The antibody-mediated part of vertebrate immunity is an element of humoral immunity which
builds on processes requiring the presence of macromolecules such as antibodies in extracellu-
lar fluids (for example blood, lymph) called humors in ancient greek medicine. Antibodies are
produced by B cells, a constituent of the adaptive immune system. In the following sections, B
cells and associated processes will be introduced shortly. Following a placement of the B cell
immune response within the entire vertebrate immune system in section 1.1.1, development
and functions of B cells will be discussed in section 1.1.2. An important process within the B
cell cosmos, the germinal centre reaction, will be introduced in section 1.1.3.
1.1.1. Role within the Vertebrate Immune System
In general, the vertebrate immune system is composed of several layers of defence systems
against pathogens (viruses, bacteria, fungi and parasites in order of increasing size). These
comprise innate and adaptive immune systems both of which rely on the actions of leukocytes
(white blood cells). All leukocytes are differentiated progenitors of hematopoietic stem cells
and thus parts of the blood-forming system.
Innate Immunity Innate immune cells are characterised by the absence of antigen-specific
receptors on their surfaces and by their ability to respond quickly (within minutes) to threats
entering the body. The innate immune cell types such as macrophages, neutrophils and dend-
ritic cells carry pattern recognition receptors on their surfaces which allow them to recognize
and bind to pathogen-associated molecular patterns such as lipopolysaccharides of the bac-
terial cell wall which are not found in the vertebrate host. While macrophages are mostly
tissue-resident and responsible for taking up and killing invading microorganisms as well as
infected host cells, the granulocyte subtypes eosinophils and basophils release toxic chemicals
into the periphery which help combat invaders too large for uptake. The remaining and most
abundant type of granulocytes, the neutrophils, as well as the dendritic cells, also take up in-
vaders by phagocytosis. Additionally, dendritic cells enzymatically digest the pathogen they
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have taken up and present it to cells of the adaptive immune system which are thus activated
and undergo proliferation [Murphy and Weaver, 2016].
Adaptive Immunity The adaptive part of the immune system in turn consists of so-called
lymphocytes which display antigen-specific receptors on their surface. T lymphocytes are the
mediators of cellular immunity as they interact directly with other host cells in order to ini-
tialise immune processes. The T cell receptor is a protein complex composed of two parts,
predominantly the 𝛼- and 𝛽-chains. These are assembled from a variety of possible gene seg-
ments during the maturation of T cell in thymus in a process referred to as VDJ-recombination
(outlined for B cells in section 1.1.2). As a result, a theoretical diversity of up to 1020 differ-
ent receptors is generated [Miles et al., 2011], thus increasing the probability of recognizing
any given pathogen. T cells are subdivided into three major forms: cytotoxic T cells are re-
sponsible for sending apoptosis signals to other host cells which are infected with intracellular
pathogens; helper T cells interact with other host cells such as B cells and prime them to take
action; and regulatory T cells have a role in limiting the extent of immune responses and thus
avoiding potential damage through overreaction. Through contact with antigen presented by
dendritic cells, T cells become activated, expand clonally and partly differentiate into memory
cells which help retain immunological memory of a past infection for many months or years
[Murphy and Weaver, 2016].
In the following sections and chapters, we will focus on the second pillar of adaptive im-
munity, the B cell immune system. Both branches of the adaptive immune response have in
common that compared to the innate responses it takes longer to activate their cellular players
(several hours) and even longer (several days) to fully develop and mature them by means of
clonal selection and expansion, differentiation into effector cells and, in the case of B cells,
germinal centre reactions (see section 1.1.3). In turn, these responses last longer, are more
specific to the threat at hand and have the potential of leading to immunological memory thus
diminishing the effects of reinfection [Murphy and Weaver, 2016].
1.1.2. Development, Characteristics and Function of B Cells
Before leaving the bone as mature naïve lymphocytes, B cells move through several devel-
opmental stages within the bone marrow where, most importantly, their B cell receptor gene
locus is rearranged. Themature naïve phase of their life ends once they encounter foreign anti-
gen which leads to their activation and a choice of fate which may include entering a germinal
centre or direct differentiation into an effector cell type. In the following, the developmental
steps of B cells and antibodies as well as their functions are outlined.
V(D)J-recombination and B cell development B cells are ultimately derived from hem-
atopoietic stem cells which reside in the bone marrow. These cells first differentiate into mul-
tipotent progenitors which in turn give rise to common lymphoid progenitors. The latter are
able to produce lymphocytes of the B and T lineages as well as to natural killer cells [Höfer
et al., 2016]. Once a common lymphoid progenitor is committed to the B cell lineage, a num-
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CHAPTER 1. BACKGROUND - B CELL MEMORY RESPONSES
λ light chain locus
heavy chain locus
Vl1 … Vl30 Jl1 Cl1 Jl2 Cl2 Jl3 Cl3 Jl4 Cl4
κ light chain locus
Vk1 … Vk38 CkJk1 Jk2 Jk3 Jk4 Jk5
Vh1 … Vh40 Ch1Jh1 … Jh6 … Ch10Dh1 … Dh23
(a) Composition of the genetic loci from which the antibody constituents, the 𝜅 or 𝜆 light chain and the
heavy chain, are composed. The combinatorial diversity from random segment usage alone is on the
order of 300 for the light chains and 11,000 for the heavy chain [Murphy and Weaver, 2016].
light chain
heavy chain
(b) Schematic structure of an antibody. Antibodies are complexes of four proteins, two copies each of
the so called light and heavy chains.
Figure 1.1.: Schemes of immunoglobulin gene loci and an antibody. Colours of the genetic loci
in part a match the colours of the corresponding regions in part b.
ber of further differentiation steps ensues [Welinder et al., 2011]. The developmental stages
of B cells until maturity are termed pro-B and pre-B cells in order of occurrence [Hardy et al.,
1991, Allman et al., 1999].
As introduced above, highly specific antigen-receptors are a hallmark of adaptive immunity.
As sketched in figure 1.1b, the B cell receptor which is similar in structure to its secreted coun-
terpart, the antibody, is a complex consisting of four proteins: two identical copies of a protein
termed heavy chain and two identical copies of a corresponding light chain. For the light
chain, two different gene loci, the 𝜅 and the 𝜆 locus, are present in the genome. It is of major
importance for the functioning of humoral immunity that these B cell receptors are not alike
among naïve B cells but instead may assume one of around 1018 unique forms, as much as
1014 of which can be generated during development [Xu and Davis, 2000, Yaari and Kleinstein,
2015, Elhanati et al., 2015] making use of a process called VDJ-recombination [Hozumi and
Tonegawa, 1976].The germline loci coding for the heavy and light chains contain several dif-
ferent variants of each of three segments necessary for constituting antibody variable regions
(see figure 1.1a). These three types of segments are called V, D and J standing for variable,
diversity and joining segments respectively. Recombination begins at the pro-B differentiation
stage.
While the immunoglobulin heavy chain is composed of V, D and J segments, the light chain
does not possess a diversity region. The rearrangment of the heavy chain ensues first; only
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cells with a viable fully recombined heavy chain pass from the pro-B to the pre-B stage. Here,
the light chain segments are recombined and checks for compatibility with the already existing
heavy chain are performed. Successful recombination of both chains prompts allelic exclusion
so that the recombination process on the other chromosome is abolished. This is necessary to
ensure that every B cell expresses receptors from a single rearrangement of heavy and light
chain genes only. An important factor contributing to the overall resulting diversity of the
B cell receptor repertoire is that the V, D and J segments are not merged faithfully but in
an error-prone way allowing for the introduction or loss of nucleotides between them [Roth,
2014]. As the quasi-random recombination process has the potential to lead to auto-reactive B
cells and indeed this occurs at a high rate, several checkpoints eliminating such cells are part
of the maturation process and the B cell life cycle [Hartley et al., 1993, Wardemann et al., 2003].
Structure and Function of Antibodies B cell receptors are the membrane-bound form of
antibodies which themselves are secreted into the extracellular space [Reth, 1992]. Antibod-
ies lack the transmembrane domain of B cell receptors - this is achieved through alternative
splicing. As shown in figure 1.1b they are composed of two heavy chains and two light chains
which are connected to each other covalently by disulfide bridges to form a Y-shape [Amzel and
Poljak, 1979]. Each chain has a variable domain which is composed via V(D)J-recombination as
described above and a constant domain which is always identical in the case of the light chain
but may assume one of five forms for the heavy chain. These different heavy chain constant
regions lead to different antibody classes (Immunoglobulin M (IgM), IgD, IgE, IgG and IgA)
which differ in their precise functions [Schroeder and Cavacini, 2010]. The variable regions
of both the heavy and the light chain are comprised of three complementarity determining
regions (CDRs) alternating with framework regions (FWRs). Most of the diversity of the anti-
bodies is contained within the CDR regions with CDR3 being the most diverse, as it contains
all of the D segment and the surrounding VD- and DJ-junctions in the heavy chain and the
VJ-junction in the light chain [Xu and Davis, 2000]. In turn, framework regions are mostly,
though not exclusively, responsible for the structural stability of the proteins while showing
less variability. The region with which antibodies bind antigenic epitopes is also called para-
tope and is mostly located at the end of the arms of the Y-shape where heavy and light chain
CDRs come together [Davies and Cohen, 1996].
Antibodies act through a variety of mechanisms. Their most straight forward function is
the direct neutralisation of a pathogen by binding to its surface. This antibody coating inhibits
further interaction with the host such as bacterial or viral entry into host cells. Further, dur-
ing opsonisation, antibodies mark invading agents as pathogenic for phagocytic immune cells
which are thereby primed to engulf the antibody-coated organism. Antibodies with the con-
stant regions IgM and IgG can also activate the complement system ultimately leading to pha-
gocytic clearance or cell destruction. Through antibody-dependent cell-mediated cytotoxicity,
natural killer cells are primed to induce cell death of infected host cells. Additional functions
of antibodies include the inhibition of biofilm formation and cooperation in the presentation
of antigen by follicular dendritic cells to B cells [Lu et al., 2018].
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Types and Functions of Effector B cells Following activation by cognate antigen, naïve B
cells undergo differentiation into one of two main effector cell types, antibody-secreting cells,
also called plasma cells, and memory B cells, which do not continuously perform an effector
function but can be restimulated easily in a secondary infection [Yoshida et al., 2010]. It is gen-
erally accepted that most differentiated B cells derive from germinal centre reactions (see also
section 1.1.3 and figure 1.2), a relationship first suggested in the sixties [Thorbecke et al., 1962],
but there is evidence that some types of memory B cells and plasma cells can be generated in
the absence of germinal centres as well [Matsumoto et al., 1996, Kato et al., 1998, Karrer et al.,
2000]. On the way to becoming a plasma cell starting from a naïve or memory B cell, cells
pass thorugh a precursor stage termed plasmablast. These plasmablast have short life times of
about one week unless they successfully migrate to a survival niche such as the bone marrow
or inflamed tissue where they may persist [Radbruch et al., 2006].
Memory B cells can rapidly differentiate into plasma cells upon secondary infection, not-
ably faster then naïve cells [DiLillo et al., 2008]. In this context, it has been suggested that
long-lived humoral immunity could be due to the constant proliferation and differentiation of
surviving memory B cells into antibody-secreting cells primed by persistent antigen and poly-
clonal stimuli, thereby offering a way of maintaining life-long immunity [Ochsenbein et al.,
2000, Bernasconi et al., 2002]. However, there is no consensus across antigens or studies as
to whether circulating memory B cell numbers and serum tires are correlated [Yoshida et al.,
2010]. In addition to providing a quick pathway to new plasma cells upon reinfection, memory
B cells are importantly also able to join secondary germinal centre reactions. Their memory
function here is a different one: by supplying the germinal centre with cellular material which
has already been selected for and potentially been mutationally improved during previous in-
fections, germinal centres can produce high-quality effector cells more efficiently [Dogan et al.,
2009, Pape et al., 2011, Shlomchik, 2018].
Plasma B cells were traditionally believed to be mostly short-lived because of their poor sur-
vival in culture and the observation that only low levels persist in secondary lymphoid organs
over time [Nossal, 1962, Miller, 1964, Cassese et al., 2003]. However, it was later discovered
that the bone marrow acts as the major niche for the maintenance of plasma cells [Benner
et al., 1974] with additional evidence showing that individual plasma cells can live as long as
memory B cells [Manz et al., 1997]. Here, it was also shown that these long-lived plasma cells
are responsible for the maintenance of serological memory. The continued presence of pro-
tective antibodies in the serum is of major importance for preventing reinfection as it blocks
pathogens even before cells of the innate or adaptive immune system need to be activated.
Serum antibody titres against a number of diseases remain stable for decades even in the total
absence of restimulating antigen [Hammarlund et al., 2003, Amanna et al., 2007].
1.1.3. Germinal Centre Reactions
Germinal centres are transient agglomerations of immune cells which form in secondary lymph-
oid organs such as lymph nodes and the spleen following exposure to T cell-dependent antigen.
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Figure 1.2.: Scheme of the germinal centre reaction. Mature naïve and memory B cells get ac-
tivated to join the reaction by contact with antigen. Inside the germinal centre, they
divide and potentially undergo somatic hypermutation. Based on their affinity to
the antigen presented on follicular dendritic cells (FDCs) and their ability to com-
pete for T follicular helper (Tfh) cell help, they are selected for further expansion or
differentiation into effector cell types or removed from the process via apoptosis.
See also section 1.1.3.
They consist of germinal centre B cells, follicular helper T cells (Tfh cells) and follicular dend-
ritic cells. Figure 1.2 shows an overview of germinal centre architecture. Germinal centre
reactions are the main sites of affinity maturation driven by somatic hypermutation and play
an important role in efficient clonal selection and expansion [Shlomchik and Weisel, 2012]. In
the following, the initiation of the reaction as well as the proceedings in the fully developed
germinal centre are outlined.
Initiation of the Germinal Centre Reaction The construction of germinal centres follows
the architecture of the underlying lymphatic tissue which consists of B cell-rich follicles and
T cell zones. Germinal centres form within the follicles which are build up around a network
of follicular dendritic cells [De Silva and Klein, 2015]. Following antigen exposure and the
transport of this antigen to the follicular site, cognate B cells and T cells each become activated
within the lymph node [Batista and Harwood, 2009], followed by B cell migration towards the
border area between B and T cell zones. Here, they begin to form contacts with each other
leading to full activation [Okada et al., 2005]. Not all thus activated B cells move on to become
germinal centre participants as some also directly differentiate into plasmablasts or unswitched
memory B cells [Paus et al., 2006, O’Connor et al., 2006, Taylor et al., 2012]. Intravital micro-
scopy studies have shown that the migration and activation processes described here happen
as early as one day after vaccination [Kerfoot et al., 2011, Kitano et al., 2011]. In addition, T
cells can be primed to become Tfh cells by contact with follicular dendritic cells at this early
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stage of germinal centre development [Choi et al., 2011]. These new Tfh cells then migrate to
the centre of the follicle around day 3 after intial exposure and are followed by the new ger-
minal centre B cells on day 4 [De Silva and Klein, 2015]. This completes the formation of early
germinal centres which can now be identified histologically in lymph node sections.
Following the initial formation phase, germinal centre B cells begin to rapidly divide and fill
up the entire follicular space defined by the network of follicular dendritic cells [MacLennan,
1994]. The size of the cell agglomeration continuously increases because of this and reaches a
maximum size around day 7 after exposure [Wittenbrink et al., 2011]. By this time, two dif-
ferent zones of the germinal centre can be determined histologically which are referred to as
light and dark zones respectively because of their appearance under light microscopy [Victora
and Nussenzweig, 2012]. The dark zone contains a higher density of B cells which actively pro-
liferate while the light zone is a more heterogeneous cell pool including B cells, Tfh cells and
follicular dendritic cells. It is in this zone that competition for survival signals and subsequent
B cell selection occur (see figure 1.2).
Structure andDynamics of the Germinal Centre Reaction Within the dark zone, B cells
divide at high rates and undergo diversification of their immunoglobulin gene regions through
a process called somatic hypermutation (SHM) [Di Noia and Neuberger, 2007]. The process
is governed by the enzyme activation-induced cytidine deaminase (AID), which creates errors
during DNA transcription and thus induces base pair exchanges [Muramatsu et al., 2000]. The
rate with which these mutations are induced is estimated at around 10−3 per base pair and
cell division in the variable regions of the immunoglobulin genes and is thus one million times
higher than the natural error rate during cell division elsewhere in the body [McKean et al.,
1984, Berek and Milstein, 1987]. Through these point mutations, variants of B cells from the
same clone with altered affinities may arise. AID is also responsible for the exchange of the
antibody heavy chain constant domains and thus for class-switching between the different an-
tibody isotypes IgM, IgG, IgA and IgE [Victora and Nussenzweig, 2012].
During the germinal centre reaction, B cells continuously move between the dark and light
zones. Following division and potential diversification in the dark zone, they transit to the light
zone in order to compete for antigen on follicular dendritic cells and for survival and division
signals from Tfh cells. These cycles of diversification and selection enable affinity improvement
of the germinal centre B cell population and drive affinity maturation, a hallmark of adaptive B
cell immunity [De Silva and Klein, 2015]. While it was originally believed that antigen depots
on follicular dendritic cells represent the most limiting factor for B cell selection [MacLennan,
1994], it has recently emerged that T cell help may in fact pose a stronger constraint [Victora
and Nussenzweig, 2012].
The mechanism underlying this selection works via B cells taking up and digesting antigen
in order to present it to Tfh cells on major histocompatibility complexes (MHCs). If the B cell
receptor’s affinity for the antigen is higher, more of it is taken up and consequently displayed,
thereby directly leading to a higher stimulation from the Tfh cell [Victora et al., 2010]. Because
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the contacts between B and Tfh cells are transient, a single Tfh cell can survey and compare
many B cells in the light zone at the same time thus identifying the best candidates in the en-
tire population [Shulman et al., 2014]. As a result of Tfh stimulation, selected B cells either
reenter the dark zone for further clonal expansion or differentiate into an effector phenotype
[Liu et al., 2015]. Unsuccessful B cells are stringently eliminated from the reaction via apop-
tosis. Because of the random nature of SHM, B cells may acquire self-reactivity as a part of the
germinal centre reaction. Some checkpoints to eliminate these cells are in place, though they
are not able to detect all types of self-reactivity [Chan et al., 2012].
1.2. Computational Models of the B Cell Immune Response
Themain goal of the first part of this thesis is the development of a computational model of the
B cell immune response building on an array of germinal centres as discussed in chapters 2, 3
and 4. A diverse set of theoretical germinal centre models exists in the literature and is briefly
reviewed here starting with an overview of commonly used antibody-antigen binding models
in section 1.2.1. This is followed by a summary of agent-based an analytical germinal centre
models in sections 1.2.2 and 1.2.3. Importantly, in all models reviewed here, “agent-based” also
means “stochastic”, while “analytic” translates to “deterministic”.
1.2.1. Antibody-Antigen Binding Models
A quantitative view of the binding strengths between an antibody or B cell receptor and its
cognate antigen is at the base of each attempt to model a B cell response. A vast number of
different abstractions of this binding process exist, mostly specialised for a chosen modelling
purpose, and some of them are presented below.
Immunological Shape Space Arguably the historically most influential descriptions of
antibody-antigen binding strength are the shape space-type models first introduced by [Perel-
son and Oster, 1979]. Here, the antibody as well as the antigenic epitope are represented by
points in an 𝑛-dimensional space. The antibody is additionally equipped with a binding radius
enabling it to bind to every antigen within, but not outside of, the resulting ball of stimula-
tion. Two major classes of shape space binding models exist: Euclidean shape space, in which
antibody and antigen identities are represented as 𝑛-dimensional vectors of real numbers, and
Hamming shape space, in which the binding partners are characterised by sequences of length
𝑛 in which each position is filled by one of 𝑘 symbols. To complete the definition of a shape
space model, for both cases a specific radius 𝑟 needs to be chosen for the ball of stimulation.
In the case of the Hamming shape space, this translates to the maximum allowed Hamming
distance (number of positions in which corresponding string positions are different) between
the two sequences. Much of the popularity of these shape space models is due to the fact that
[Smith et al., 1997] have estimated sets of {𝑛, (𝑘), 𝑟 } from experimental data for both Euclidean
and Hamming shape spaces. For the former, this results in either {𝑛 = 20, 𝑘 = 4, 𝑟 = 5} or
{𝑛 = 25, 𝑘 = 3, 𝑟 = 6}; for the latter, 𝑛 ∈ {5, 6, 7, 8} and 𝑟 ∈ [0.15, 0.22] are recommended.
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As a result of these estimations, a range of later works build on them or on minor vari-
ations thereof. For example, [Meyer-Hermann et al., 2006] as well as [Chaudhury et al., 2014]
use Hamming shape space models with 𝑛 = 20 and 𝑘 = 4 allowing for approximately 1012
unique sequences. Using a fixed epitope sequence, the quality of these antibody sequences
is then scaled to the physiological range based on the antigen-antibody Hamming distance.
[Meyer-Hermann et al., 2012] also use a four-letter shape space but enhance it by convolving
the originally uniform ball of stimulation with a Gaussian distribution such that antibody se-
quences located further from the epitope have a smaller probability of becoming activated by it.
A variation of the Hamming-distance approach is used by [Luo and Perelson, 2015], who
model an antibody as a single string and HIV as a combination of a conserved and a variable
sequence in an attempt to analyse the co-evolution between immune system and virus. Each
sequence is of length eight and each position is occupied by one of four letters. In order to
determine binding strength, they identify the longest common substring between antibody
and epitope string representations. Importantly, the matches need to be consecutive here. An
even simpler variant of this method building on longest complementarymatches and using two
characters only has been used in the context of natural killer cell receptors and corresponding
MHC molecules [Carrillo-Bustamante et al., 2015]. Variants of Euclidean shape spaces have
likewise been used in the recent modelling literature [Shaffer et al., 2016, Amitai et al., 2017].
Random Energy Landscapes Shape-space models have been criticised for representing “a
rosy view of evolution” [Childs et al., 2015] since mutational walks monotonically increasing
affinity towards an optimum are possible without surprising drawbacks. Random energy land-
scapes as originally proposed for the maturation of the immune response by [Kauffman and
Weinberger, 1989] represent an alternative. Here, 𝑁 represents the length of the sequence
while 𝐾 is a parameter allowing to tune the roughness of the energy landscape between a
smooth setting with a single peak and a multi-peaked noisy scenario. A given value of 𝐾
implies that the functional contribution of each amino acid in the sequence is affected by 𝐾
others. As a result, walks to local optima in the rugged fitness landscape decrease in length
with increasing 𝐾 . This model captures several experimental observations concerning affinity
maturation, for example the fact that some mutations have much stronger effects on affinity
than others and the observation that several matured endpoints can be reached from the same
starting sequence [Kauffman and Weinberger, 1989]. [Deem and Lee, 2003] and [Sun et al.,
2005] have extended the method in the immune context. Recently, [Childs et al., 2015] have
used an NK-fitness model with a five-letter alphabet, a sequence length of 100 letters and an
interacting neighbour number 𝐾 = 5 in a germinal centre simulation. Concerning genetic
evolution in a broader context, real fitness landscapes mapping genotypes to phenotypes have
started to become available thus priming new developments in the modelling of multidimen-
sional epistasis [de Visser and Krug, 2014]. An example for a comprehensive mutational study
yielding an antibody fitness landscape is presented in [Adams et al., 2016].
Affinity Classes and Semi-Empiric Mutation Effects Specifically in the realm of analyt-
ical descriptions of the germinal centre reaction as introduced in section 1.2.3, as individual
cells to which affinities need to be assigned are absent, affinity classes are broadly used. B cells
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are categorised into a number of populations in order to allow a descriptionwith coupled ordin-
ary differential equations instead of having to introduce a continuous affinity dimension and
thus the need for a partial differential description. A classic treatment of somatic hypermuta-
tion processes using affinity classes of germinal centre B cells is given by [Kepler and Perelson,
1993]. [Oprea and Perelson, 1997] do not fix a number of affinity classes from the beginning of
their calculations, but let subsequent affinity classes emerge as soon as the current best class is
sufficiently populated. This leads to the appearance of on the order of three improved classes
over the course of a germinal centre reaction. [Iber and Maini, 2002] restrict themselves to two
affinity classes only, describing “low” and “high” affinity cells. That affinity classes can also
be of use in agent-based approaches is shown by the implementation of [Keşmir and De Boer,
2003], where B cell agents can move up or down one class following stochastically occurring
mutations. A typical observation in all of these models is that each better affinity class comes
to dominate the germinal centre shortly after emergence before being superseded by its suc-
cessor; a major drawback is that germline cells are typically placed in a low affinity class by
definition, thus not allowing for the possibility of varying precursor qualities.
Not all analytic descriptions employ affinity classes though, as shown by [Zhang and Shakh-
novich, 2010]. Here, a distribution of affinity changes caused by single mutations taken from
a protein interaction database is used in order to govern the movement of B cell mass through
affinity space based on a given mutation rate. An empirical component is likewise part of the
sequence-based binding model developed by [Wang et al., 2015b] for antibodies binding to a
HIV sequence composed of a variable and a conserved part. In this case, each sequence posi-
tion may be occupied by the wild type amino acid or by a mutant, the binding energy change
between the two being drawn from an asymmetric distribution with a long tail of deleterious
events. Yet a different approach is taken by [Kleinstein and Singh, 2003], who are interested
in the emergence of key mutant clones in the anti-hapten responses against phOx and NP. Be-
cause in these simple binding scenarios, the identification of a small number of key mutations
is crucial for outcompeting clonal peers their binding model takes the shape of a decision tree
includingmutations in framework and complementarity determining regions, replacement and
silent mutations as well as death, key and blocking events. In order to explain the low experi-
mentally observed number of key mutants as compared to previous models, the suggest a high
number of blocking mutations which hinder further affinity maturation. This concept is also
used in the binding model developed in this thesis and described in section 2.2.
1.2.2. Agent-Based Germinal Centre Models
Agent-based simulations of the germinal centre reaction in which each cell is represented by
a computational object which is able to store properties like mutational status and affinity are
highly suitable for modelling affinity maturation because they allow individuality at a cellular
level by definition. In the last decades, such models have been used both for exploring general
processes within germinal centres and more specific questions building on models tailored
towards given antigens or situations. Some examples for both applications are given in the
following.
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Early and General Germinal Centre Simulations Agent-based germinal centre models
started to gain popularity around the turn of the millennium with computational power in-
creasing and programming languages becoming more accessible to a wider user base. Early
germinal centre simulations typically focus on integrating available experimental observations
in order to facilitate exploration of physiological parameter spaces. An example is provided by
[Shlomchik et al., 1998] who describe their simulation as “a data interpretation tool”. They com-
bine dynamic and mutational information about germinal centres and affinity maturation such
as mutation pattern, replacement-to-silent mutation ratio and the number of cells participating
in a reaction and identify physiological parameters satisfying the resulting constraints. One of
the outcomes of this work is the suggestion that a germinal centremay be seeded bymanymore
cells than previously claimed based on experimental observations [Jacob et al., 1993, Kroese
et al., 1987]. This is of special interest as most recent germinal centre models still insist on a
low number of seeder cells (for example [Childs et al., 2015, Chaudhury et al., 2014, Wang et al.,
2015b]). A work having picked up on the recent strong evidence that much higher numbers
of seeders cells may in fact be involved [Tas et al., 2016] is presented by [Amitai et al., 2017].
Based on this scenario, they compare death- and birth-limited selection mechanisms and con-
clude that the former are more likely to give rise to the observed patterns of clonal diversity
in germinal centres. In a spirit similar to [Shlomchik et al., 1998], [Kleinstein and Singh, 2003]
take a striking experimental observation - the frequency with which antibody key mutations
in anti-hapten responses arise - and explore which features of a model are necessary in order
to reproduce the finding. This way, they identify the need for blocking mutations as part of
their affinity maturation model as discussed in section 1.2.1.
In addition to general dynamic germinal centre models, several attempts at depicting the
spatial structure of the reaction have been published. An early example is given by [Keşmir
and De Boer, 2003] who focus on the affinity-dependent cellular adhesion of B cells on the
surface of follicular dendritic cells. In an attempt to understand which selection mechanism
drives germinal centre B cell competition, [Meyer-Hermann et al., 2006] build a comprehensive
spatial agent-based model using more than 30 experimentally reported parameters. They con-
clude that in the physiological parameter regime, Tfh cell help alone, and not competition for
antigen, can drive affinity maturation. This has since been experimentally confirmed [Victora
and Nussenzweig, 2012].
Targeting Specific Questions with Agent-Based Models In contrast to the examples
given in the previous paragraph, most recent studies including germinal centre simulations
focus on specific questions related to, for example, a special pathogen or vaccination sched-
ule. Below, five examples are discussed in order of appearance. [Chaudhury et al., 2014] focus
on emerging antibody cross-reactivity following administration of the polyvalent malaria vac-
cine AMA1. They ask how polyvalency alters specificity and cross-reactivity of the antibody
response and suggest that polyvalent vaccines containing only a small number of strains may
nevertheless be able to elicit broadly neutralising antibodies by altering selection pressure dur-
ing affinity maturation such that cross-reactive antibodies are favoured. [Wang et al., 2015b]
are likewise interested in the efficient induction of broadly neutralising antibodies albeit in the
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case of the quickly mutating pathogen HIV. They find that if a cocktail of several strains is
administered, affinity maturation may be driven into a frustrated state characterised by con-
flicting selection forces. Instead, they propose to give different strains sequentially in order to
increase the probability of a cross-reactive antibody arising.
Somewhat more generally, [Childs et al., 2015] ask about the trade-offs that come with af-
finity maturation towards complex antigens which they define as displaying more than one
immunogenic epitope. They find that in the presence of several antigens or epitopes, both the
affinity and the relative breadth of the antibody repertoire are reduced. Additionally, not all
epitopes are covered equally well by their simulated B cell immunity as patterns of immun-
odominance emerge. They conclude that the joint display of several epitopes may convey an
evolutionary advantage to pathogens. In contrast to most other studies which focus on re-
peated realisations of individual germinal centres, [Childs et al., 2015] also marginally touch
upon effects emerging in systems of several parallel reactions which their model can accom-
modate. Both [Luo and Perelson, 2015] and [Shaffer et al., 2016] are also concerned with patho-
genic strategies as they focus on quickly mutating viral invaders. Asking whether there is way
in which broadly neutralising antibodies against HIV could be driven to emerge earlier than
they do during natural infection, [Luo and Perelson, 2015] find that although these antibod-
ies have a chance of arising early, they are mostly outcompeted by more specific high-affinity
strains during the initial stage. They show that computational removal of this competition
leads to faster emergence of broad antibodies and suggest that vaccines containing more than
one founder strain may experimentally convey the same effect. [Shaffer et al., 2016] study
immunisation with diverse mixtures of theoretical strains for the same reason. They identify a
“principle of optimal frustration” asserting that a well-composed antigen cocktail should con-
tain strains that are separated by relatively large mutational distances in order to optimise the
probability of eliciting broadly neutralising antibodies.
1.2.3. Analytical Germinal Centre Models
Before the emergence of agent-based simulations, analytical descriptions of germinal centre
reactions were used to analyse the reaction’s properties and even today they remain useful for
some types of questions. An early example of an analytic approach to hypermutation processes
is given in [Kepler and Perelson, 1993] where the authors draw up germinal centre mutations
as an optimal control problem. The total affinity appears as a functional of the mutation rate
which in itself is a function of time; this functional is being optimised. They find a regime in
which expansive mutation-free bursts and phases of fast mutation alternate and interpret this
in a spatial context: cells supposedly enter and leave a part of the germinal centre in which
mutations occur in cyclical fashion. In a much simpler model, [Oprea and Perelson, 1997]
cast B cells into affinity classes and draw up sets of coupled ordinary differential equations of
germinal centre B cells in the light and dark zones respectively and memory B cells for each
class. Using this model, they show that recycling between the two zones of the germinal centre
provides an efficient way of generating high affinity memory cells. The general dynamics of
the reaction are of interest to [Keşmir and De Boer, 2003]. Without the need for an affinity
model, they describe the emergence, duration and termination of a typical germinal centre
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reaction. They find that both the total size of the germinal centre cell population and the dura-
tion of the reaction are only mildly dependent on the initial amount of antigen as the limiting
effect of Tfh cells dominates. [Iber and Maini, 2002] introduce antibody masking into their
compartmental model of germinal centre populations with low and high affinity. They suggest
that this type of antibody feedback can drive affinity maturation as well as introduce outcome
stability vis-à-vis variations in the initial concentration of antigen. The optimality of muta-
tion and selection processes in the germinal centre as discussed by [Kepler and Perelson, 1993]
has more recently been revisited by [Zhang and Shakhnovich, 2010]. They present an analytic
solution to their elaborate deterministic description of a single germinal centre reaction and
find that the optimal mutation rate results from a trade-off between accumulating beneficial
and avoiding deleterious mutations. As far as selection is concerned, an optimal stringency is
dictated by a trade-off between selecting high-affinity cells and avoiding clonal collapse.
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2. Development of a Flexible
Computational Model of B Cell Memory
Formation
In this chapter, the agent-based computer model of the B cell memory response to vaccinations
developed in this thesis is introduced. This model offers a large amount of flexibility regarding
various parameters which characterise individual immunisation processes. These may have to
do with specifics of the pathogen against which a B cell response should be elicited as well
as with factors concerning the vaccinee. The need for a model providing this flexibility is dis-
cussed in section 2.1. Much of the flexibility concerning characteristics of the pathogen, or
more specifically its epitopes, is encoded in the antibody-antigen binding model developed
here and presented in section 2.2. It allows for varying complexities of binding interfaces in
an abstracted way while maintaining key features of mutational processes such as the conser-
vatism of the genetic code. Building on this binding model, section 2.3 introduces the compu-
tational description of the germinal centre reaction as developed in this work. Here, care has
been taken to incorporate recent experimental discoveries while describing key processes in a
condensed way. The chapter’s appendix, section 2.A, contains additional information relevant
for the binding model, a pseudocode version of the simulation algorithm and all simulation
parameters with experimental references where applicable. Parts of sections 2.2 and 2.3 were
previously published in [Murugan et al., 2018] and have been written by the candidate herself.
2.1. Motivation
As outlined in section 1.2, a variety of computational models of the B cell immune response
based on germinal centre models already exist. While older models often try to deduce uni-
versal truths applicable to every vaccination process, newer models tend to focus on more spe-
cific vaccination cases by incorporating details regarding their binding interfaces or specific
dynamics. This section motivates the need for a more flexible modelling approach which al-
lows variation and comparison of pathogen-, patient- and protocol-specific parameters within
a single framework.
WhichMechanisms Drive Successful Vaccination? Historically, most vaccines were de-
veloped empirically, employing principles of trial and error [Plotkin, 2014]. A common feature
of these early vaccinations and newer developments relying on more rational design principles
is that antibody titres are correlates of vaccine-induced immunity in the vast majority of cases
[Plotkin et al., 2008]. The uppermost panel of figure 2.1 shows a sketch of the ideal titre dy-
namics: following antigen exposure, be it through natural infection or a vaccination, the titre
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Figure 2.1.: Pieces of evidence having lead to the common belief that intraclonal affinity mat-
uration is chiefly responsible for the rise of serum antibody titres observed after
vaccination.
begins to rise, reaches a level sufficient for sterile protection and ideally does not decay over
many months or years.
With the discovery of somatic hypermutation as an important process in the B cell immune
response and the increasing availability of sequencing methods for nucleic acids, evidence
emerged that effector B cells such as memory B cells or long-lived plasmablasts may carry
high numbers of mutations. The mean number of mutations of cells within germinal centres
andmemory cells in the periphery rises as a function of time following vaccination [Allen et al.,
1987, Berek, 1992]. Additionally, closer analysis of stereotypical immune responses to haptens
such as 4-hydroxy-3-nitrophenylacetic acid (NP) revealed that, at the level of individual B cell
receptors, the affinity towards a given antigen may rise by more than one order of magnitude
through a single nucleotide exchange alone [Allen et al., 1988, Berek et al., 1991]. Both obser-
vations are likewise sketched in figure 2.1.
In combination, these findings have led to the common interpretation that affinity matur-
ation driven by somatic hypermutation is mainly responsible for the improvement of mean
binding following vaccination. While this interpretation is likely true for some cases, it should
be pointed out that it is not a logically necessary result of the pieces of evidence provided
above. This is because antibody titres are commonly measured from blood serum and thus
represent bulk measurements. Even though mutations within a B cell’s immunoglobulin genes
are measured at a single cell level, the resulting sequences have commonly not been linkedwith
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Figure 2.2.: Two basic mechanisms can underlie an observed rise in antibody serum titre; they
are not mutually exclusive. Mechanism A) shows a scenario in which few clones
seed each germinal centre and mean affinity improvement is then driven by so-
matic hypermutation and following selective expansion. This mechanism histor-
ically dominates explanations of observations. In mechanism B), a higher number
of B cells seed each germinal centre, thus providing a larger base for clonal selec-
tion from the beginning. In this scenario, mutations are not necessarily required
to yield improvement, they may rather lead to clonal drift and diversification while
the selection and expansion of ab initio high-quality binders leads to the observed
mean improvement.
single-cell antibody-antigen affinity measurements and much less with monoclonal protection
assays. Few studies comprising this entire set of information at the single-cell level exist and
in their absence, existing knowledge on haptens, where indeed individual mutations are linked
to strong functional improvement, has been vastly extrapolated.
However, as figure 2.2 illustrates, two basic mechanisms can explain the observed rise in
serum titre after making contact with an antigen. The interpretation discussed above stresses
the importance of intraclonal affinity improvement by somatic hypermutation. On the level
of a germinal centre reaction, this interpretation requires only a few weak precursor B cells
to seed the reaction, affinity improvement of the population is then brought about by reliably
happening beneficialmutations and concomitant expansion of the improved clones. In a second
interpretation, a vast variety of binding qualities may already exist in the precursor repertoire
even though low-quality binders dominate. This leads to an initially low serum titre. Upon
antigen exposure, many precursor B cells are primed to enter the lymph node and participate
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in germinal centre reactions. The high number of participants increases the chance of including
a rare high-quality precursor. This cell then only needs to be identified and expanded relatively
to its competitors; even in the hypothetical absence of somatic hypermutation, in such a system
the average affinity of the population could be greatly improved over time. In this scenario,
mutations are not required to be beneficial to yield the observed improvement. Instead, they
may be affinity-neutral (“mutational drift”), potentially serving to keep up the diversity of the
repertoire while large numbers of clonal members are being produced. Both processes are of
course not mutually exclusive; in any given vaccination scenario, they are likely happening in
parallel while contributing to the overall success with varying proportions.
Patient- and Pathogen-Specific Factors The discussion of the previous paragraph invites
a closer look at factors which may differ between individual vaccinees’ responses to antigenic
contact. While many standard vaccines have a high response rate among human subjects
[Peltola et al., 1994], the success rate for others remains poor [RTSS Clinical Trials Partnership,
2015, Belongia et al., 2016] for reasons that are by and large unclear. Factors that complicate
the development of a stable immunological memory may be specific to a pathogen but can also
depend on characteristics of the patient, thus leading to variable responses in a population.
The problem and a summary of underlying factors are sketched in figure 2.3a.
On the patient-specific side, varying immunoglobulin genes available in the germline may
decide whether good naïve precursor B cells are available to a person. Large-scale studies on
structural variation of human genomes have repeatedly found immunoglobulin genes enriched
in the most variable portions of the genome and differences between ethnic groups have like-
wise been suggested [Roederer et al., 2015, Sudmant et al., 2015, Auton et al., 2015, Galson
et al., 2015]. Additionally, as not only naïve B cells, but also previously formed memory B cells
can participate in novel immune responses, the exposure history of each individual may co-
determine vaccination success. Previous exposure to structurally similar antigensmay have led
to an enrichment of memory B cells that can be used to fight a different (related as well poten-
tially unrelated) pathogen. Factors unrelated to the available repertoire such as strength of the
immune response in general and resulting factors like abundance and size of germinal centres
may additionally account for inter-patient differences. Finally, because of stochastic effects in
B cell activation, recruitment and selection, differences in post-vaccination repertoires can be
observed even in cases with identical starting genomes (twin studies) [Wang et al., 2015a].
As far as pathogen-specific factors are concerned, bacteria, viruses, parasites and other
threats to the human host have evolved to use a vast range of tactics against the innate as well
as the adaptive immune system [Finlay and McFadden, 2006]. As described for Plasmodium
falciparum sporozoites in section 4.1, pathogens may evade immune recognition by quickly
hiding from sight in tissue cells; like the blood stage parasite of Plasmodium falciparum they
may continuously exchange the surface antigens displayed to the immune system; like HIV,
they may mutate these antigens with a high rate thus never allowing the immune system to
reach a fully neutralising solution. Similarity of pathogenic antigens to self-antigensmay allow
longer immune evasion as the precursor repertoire exhibits holes in these areas [Mayer et al.,
2015]. In summary, the challenge of developing broadly successful vaccine antigens and ac-
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(a) Left: Exposed to the same vaccination protocol, individual patients may exhibit vastly different an-
tibody responses. Right: Immunisation problems vary in difficulty depending on the availability of
good B cells and the efficiency of SHM-driven improvement.
(b) While specific mutations yielding affinity improvements of one order of magnitude are routinely
identified in anti-hapten-responses, for example against NP, similarly strong improvements may not
always be possible in responses to more complex targets. This example shows affinity of memory B
cell receptors sampled at intervals of four weeks following each of three vaccination shots (I, II and
III) with Plasmodium falciparum parasites and assigned to B cell clusters. See also section 4. Lower
panel data: Rajagopal Murugan.
Figure 2.3.: Illustrations of patient- and pathogen-specific diversity and potential implications
for immunisation.
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companying schedules comes in diverse levels of difficulty. Two main axes of the problem are
shown in figure 2.3a: availability of good germline binders (for example driven by a person’s
specific repertoire, prior exposures and similarity of the antigen to self-peptides) and difficulty
of reaching a good binder via somatic hypermutation (for example determined by pathogen
escape strategies or patient-specific functionality of germinal centres).
An additional factor that likely contributes to the axis of difficulty of successful affinity mat-
uration is the structural complexity of the antigen - not all antigens represent similarly simple
binding targets for antibodies. This assumption is driven by an observation illustrated in fig-
ure 2.3b: while haptens such as NP, which are often used as model antigens in immunological
studies, are small and fit into pockets in antibody binding sites, protein antigens like the Plas-
modium falciparum sporoziote surface antigen Circumsporozoite Protein (CSP) are larger and
thus require a more complex binding interface. NP is a classic example used to demonstrate
the efficacy of affinity maturation in improving anitbody-antigen binding [Allen et al., 1988].
In contrast, as described in detail in chapter 4, in response to Pf CSP, despite strong clonal
diversification, significant affinity jumps are scarcely observed. Figure 2.3b shows the affinity
of members of two exemplary B cell clones sampled after each of three vaccination boosters.
Thus, structural complexity of the antigen is likely to play a major role for the efficiency of
affinity maturation in germinal centres.
Benefit of a Computational Model In this work, some of the factors governing vaccine
response diversity as outlined above are being explored and quantified with the help of a com-
putational model of the B cell immune response. The basic ideas of this approach are intro-
duced in the following using a toy model; a detailed introduction to the more sophisticated
main model follows in sections 2.2 and 2.3. For the motivational result shown in figure 2.4, the
two axes of vaccination challenge difficulty, availability of germline binders and efficiency of
affinity maturation, were collapsed into one simple parameter each.
In line with the discussion concerning haptens and protein antigens above, the difficulty of
affinity maturation is represented by an abstraction of the structural complexity of antibody-
antigen binding. For an immunological challenge to be considered solved in this picture, a
given number of key positions in an antibody must be represented by exactly the right amino
acid. Mutations in simulated germinal centres can lead to conversion between correct and false
amino acids at each of these key positions. Increasing complexity of the binding interface is en-
coded in an increasing number of such key positions. Figure 2.4 shows results for 1, 2 and 3 key
positions. Concerning the second axis of challenge difficulty, the availability of good germline
binders, this simple model incorporates a binary representation: either the correct amino acid
at the correct key position can be supplied in naïve cells from germline or it cannot. Results for
both cases are shown for each level of binding complexity in figure 2.4. Underlying germinal
centre dynamics and selection mechanisms for this toy model were simulated as described in
section 2.3.
In order to quantify the result of these simulated immune challenges, we run many such
problems within individual germinal centres and measure how long it takes until the cor-
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Figure 2.4.: Fraction of germinal centres that were able to solve a specific antigenic challenge
assuming a simple computational model as described in section 2.1 until a given
time. Three different levels of difficulty (1, 2 and 3 necessary key positions) are
compared; correct keys may be available from germline (solid lines) or only be
accessible via somatic hypermutation (dashed lines).
rect solution (all key positions correctly occupied) is found in each case. Figure 2.4 illustrates
the main results: more complex challenges take longer to solve and patients missing useful
germline input are at a disadvantage compared to their peers who can supply high-quality B
cells from the bone marrow. This simple result illustrates how computational modelling allows
to explore parameter effects on outcomes of interest. The main model as discussed in the fol-
lowing sections provides flexibility for theoretical exploration of a wide range of biologically
interpretable parameters and ultimately assists in developing promising vaccination strategies.
2.2. Binding Model Allowing for Different Antigenic
Complexities
During B cell production in the bone marrow a large variety of different antibody-encoding se-
quences is generated. Heavy and light chain genes are recombined from different available V,
(D) and J segments. Variety is further increased by insertion and deletion of randomnucleotides
at the junctions between these segments. Diversity and variability are not distributed evenly
over the variable region of heavy and light chains (both about 110 amino acids in length), but
peak in three discrete regions of hypervariability in each chain. Of these six complementarity
determining regions (CDRs), CDR3 on the heavy chain is by far the most diverse as it includes
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both the V-D and the D-J junction and hence a high number of random amino acids [Murphy
and Weaver, 2016]. In the folded antibody, the CDRs appear as protruding loops at the arms of
the Y-shaped antibody. They are separated by so-called framework regions (FWRs) responsible
for the stability and shape of the folded antibody. Residues within the CDRs and even more
so in CDRH3 are responsible for determining binding strength to a given antigenic epitope
[Burkovitz et al., 2014].
In general protein-protein binding scenarios, only a fraction of the many residues consti-
tuting either protein directly participate in binding. Their importance can be quantified using
alanine scanning mutagenesis which reveals the existence of a small number of hotspots sig-
nificantly contributing to the binding free energy of the complex [Moreira et al., 2007]. Shape
and electrostatic complementarity as well as the ability to form hydrogen bonds between bind-
ing partners are essential for stable complex formation.
A significant part of current textbook knowledge on the beneficial effects of somatic hyper-
mutations in antibody affinity maturation is derived from studies of immune responses against
haptens. Here, recurring patterns in VDJ-segment usage as well as in mutations in specific
positions along the immunoglobulin gene are observed. Together with the compact form of
haptens which enter into pockets on the antibody surface during binding this has given rise
to a “lock-and-key” picture in which perfect shape complementarity between antibody and
antigen is decided by few key amino acids. Recently, convergent repertoire properties have
been identified also in the context of medically relevant licensed vaccines or vaccination stud-
ies [Galson et al., 2014], including tetanus [Trück et al., 2015], influenza [Jackson et al., 2014],
dengue [Parameswaran et al., 2013] and malaria [Murugan et al., 2018]. However, signatures
in these cases are much more ambiguous than in the hapten responses and are mostly charac-
terised by biased segment usage and/or a specific length of the CDR3 region. While relevant
properties of the CDR3 region were identified in the case of dengue fever using principal com-
ponent analysis in amino acid physicochemical space [Parameswaran et al., 2013], specifically
beneficial single mutations have not been described.
Binding Model Concept In this work, an antibody-antigen binding model which picks up
on the idea of key mutations, but expands it to accommodate more complex epitopes, is de-
veloped. Inspired by the experimental observation that immunoglublin genes composed of
certain VDJ segments preferentially appear in the pool of antibodies binding a given antigen,
this model incorporates two levels of complementarity between the binding partners. Most
amino acids in the antibody variable regions are involved in determining the general shape
of the binding site and therefore whether binding is at all possible or not. These amino acids
are referred to as “scaffold” amino acids in the context of the binding model. Biologically, this
scaffold may roguhly, but not exclusively, correspond to the V and J segment-encoded frame-
work regions. In the simulation, only one epitope is being treated at a time, thus agreement of
this kind is initially assumed for all B cells participating in the simulation. Scaffold-determined
shape agreement can however be lost by detrimental mutations as will be introduced below.
This also means that the corresponding approximately 200 amino acids do not have to be mod-
34
CHAPTER 2. A FLEXIBLE COMPUTATIONAL MODEL OF B CELL IMMUNITY
elled explicitly, a major computational advantage.
The binding quality of these shape-matched antibodies differs due to the second level of bind-
ing which is determined by an explicitly modelled sequence of amino acids. The two levels of
binding are illustrated in figure 2.5a. As shown there, it is the second level of binding which al-
lows for antigenic determinants of various complexities: for an epitope characterised by 𝑛key
amino acid residues on its surface, an equal number of key amino acid positions in the anti-
body are considered strongly relevant for binding. This number may be very low for haptens,
where one key mutation can strongly increase affinity, but is higher for larger and more com-
plex epitopes. To compare B cell immune responses to antigens of different complexities, this
model therefore allows varying numbers of key residues to determine binding strength. The
full physiological amino acid alphabet is being used to fill the 𝑛key explicitly modelled key
region positions in the antibody. Here, as a simplification, each codon (and not each amino
acid) is given equal generation probability. An antigenic epitope of complexity 𝑛key is simil-
arly modelled by 𝑛key random codons.
In order to derive binding energy-like values for each combination of epitope and antibody
key sequences, these are aligned and for every resulting pair of amino acids a free-energy like
value is read off a contact potential matrix derived statistically from a large set of folded protein
structures [Thomas and Dill, 1996]. The contact potential matrix is given in table 2.5. As the
lowest and highest possible binding energies are known in this model, these values are used
to linearly rescale all binding energies into normalized energy values 𝐸bind between 0 (worst
binder) and 1 (best binder). As a result, exchanges of individual amino acids lead to smal-
ler improvements or deteriorations of antibody affinity in cases with longer key sequences as
compared to simpler epitopes with few key residues. This is illustrated in figures 2.5b and 2.5c:
while a single beneficial amino acid exchange goes a long way on the normalised binding scale
in the case of a single key amino acid, the process is less straight forward if several residues
jointly determine binding. Here, while improvements are possible in principle, this random
walk in higher-dimensional space is much less likely to reach high affinity.
As a generic consequence of the law of large numbers, during random generation of antibody
sequences, good binders become increasingly rare with rising numbers of key residues while
the peak at intermediate binding energies becomes sharper, see figure 2.6a. This needs to be
taken into account when comparing antigenic challenges of different 𝑛key (see section 2.3).
Using the experimental observation that antibody affinities usually lie in the range of KD =
{10−5M, 10−9M} an energy scale in units of kB𝑇 , where kB is Boltzmann’s constant and 𝑇 is
temperature, can be deduced. This is calculated using the relation between the standard Gibbs
free energy change and standard equilibrium constant of a binding process,
Δ𝐺−⊖− = −kB𝑇 ln 𝐾−⊖− , (2.1)
which evaluates to Δ𝐺(KD = 10−5M) = −10.5 kB𝑇 and Δ𝐺(KD = 10−9M) = −21.1 kB𝑇 . We fix
the lower end of this energy scale to the normalised energy value 𝐸bind = 0.6 and the upper
end to the ideal binder at 𝐸bind = 1. This setting introduces degeneracy at the lower end of
35
2.2. BINDING MODEL ALLOWING FOR DIFFERENT ANTIGENIC COMPLEXITIES
  
simple Ag:
small nkey
complex Ag:
larger nkey
Ab: binding key
Ab: scaold
(a) Antigens are modelled as sequences of
amino acids; antibodies consist of a scaffold
region determining general shape agree-
ment and a key region whose length
matches that of the antigen sequence.
1 2 5 10 15
nkey
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
m
ea
n 
∆ 
lo
g(
K D
) o
f s
in
gl
e
ke
y 
re
gi
on
 m
ut
at
io
n
(b) Depending on the length of the antibody
key region, each individual mutation to one
of the key amino acids contributes a larger
or smaller effect to the overall affinity.
(c) While the identification of correct key amino acids is straight forward in a mutation process acting
on a simple binding interface (top), finding a perfectly matching sequence is much more difficult in
a complex interface (bottom).
Figure 2.5.: A simple antibody-antigen binding model allowing for different complexities in
binding interfaces.
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the binding scale and moves the sequences commonly competing and dividing in the germinal
centre into an energy region where beneficial mutations are less likely than deleterious ones
as is experimentally observed [Adams et al., 2016], see also figure 2.6b. Weaker binders may
still participate in the reaction but will mostly be outcompeted quickly.
Mutations When a germinal centre B cell divides, mutations are introduced into the se-
quence at a rate of 𝑝bp = 0.001 per base pair and division (see appendix 2.A). Here, the muta-
tion rate is assumed to be uniform over all 220 amino acids in the variable regions. Using the
assumption that every point mutation is independent of all others, the probabilities for 0 to 3
base pair mutations within one codon are
𝑝0 = (1 − 𝑝bp)3 = 0.997
𝑝1 = 3 ⋅ (1 − 𝑝bp)2 ⋅ 𝑝bp = 2.994 ⋅ 10−3
𝑝2 = 3 ⋅ (1 − 𝑝bp) ⋅ 𝑝2bp = 2.997 ⋅ 10−6
𝑝3 = 𝑝3bp = 10−9 .
(2.2)
This shows that it is very unlikely to acquire more than one point mutation within a single
codon and division and this possibility is thus ignored in the following. The error probab-
ility per codon is taken to be 𝑝codon ≡ 𝑝1 ≈ 3 ⋅ 𝑝bp = 0.003. Using this value, the num-
ber of mutations happening within scaffold (key) regions is drawn from a binomial distribu-
tion with 𝑛 = 𝑛scaffold = 220 − 𝑛key (𝑛 = 𝑛key) and 𝑝 = 𝑝codon at every division. For
𝑛key = 10, this results in mean values of 𝑝codon ⋅ 𝑛scaffold = 0.63 mutations in the scaffold
and 𝑝codon ⋅ 𝑛key = 0.03mutations in the key region. This simple calculation shows that even
though error rates within the GC are 106 times higher than during normal replication, muta-
tions in the antibody encoding genes, even before considering only relevant or even beneficial
changes, are still rare events.
Mutations in the key amino acids may change the identity of the specifically modelled
residue in question. Transition probabilities between amino acids are calculated taking into
account all codons coding for both the start and the end amino acid and using only transitions
accessible by single base pair exchanges. All base pair exchanges are assumed to be equally
likely. The transition probabilities calculated this way are shown in table 2.6. Using a full amino
acid alphabet with codon-determined transition probabilities and an interaction energy matrix
based on real protein-protein interactions naturally introduces the conservatism of the genetic
code as silent mutations as well as replacement mutations by a functionally similar amino acid
are much more likely than in a random replacement model. This is shown in figure 2.6c, which
compares the energy distribution resulting from random pairwise replacements with that de-
rived using the transition probability matrix in 2.6. Figure 2.6b shows another important aspect
of this binding model: the higher the affinity of a given key sequence already is, the less likely
it becomes to identify further beneficial mutations as their proportion within the space of all
key region mutations declines as a function of current affinity. Importantly, mutations within
the key region can lead to better, worse or equal affinity according to the stochastically chosen
amino acid transition. In the model they cannot, however, lead to unfoldable antibodies and
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(a) Binding energy distributions resulting from 1000 randomly drawn antigen sequences of lengths 𝑛key
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Figure 2.6.: Properties of the binding model introduced in figure 2.5.
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thus to death of the corresponding B cell unless a STOP codon is generated during replacement.
Conceptually, this is justified because key amino acids are not part of the structural scaffold
but imagined as protruding residues at the interaction surface.
As discussed, the scaffold region consisting of the (220 − 𝑛key) non-key amino acids is re-
sponsible for general shape correspondence with a given epitope and stability of the antibody.
Mutations to this area can lead to one of three different outcomes. On average, 25% of muta-
tions are silent and are not considered further. A fraction 𝑝death of replacement mutations
results in unfoldable antibodies or total loss of antigen-binding and thus in cell death because
the corresponding B cell can no longer receive survival signals via its B cell receptors. For
non-lethal amino acid exchanges, 𝑝block governs the probability of blocking mutations in an-
tibodies that cannot bind the target with higher affinity than their germline ancestor even if
beneficial key region mutations are present. This concept was first introduced by [Kleinstein
and Singh, 2003] and represents a simplified way of introducing epistasis into the model.
2.3. Germinal Centre-Based Model of B Cell Memory Formation
An overview of the simulation scheme described in the following is given in figure 2.7a. The
simulation proceeds in discrete time steps of adjustable length 𝑡step and, unless specifed oth-
erwise, most processes like the migration of B cells to the follicular site or the division of B
cells within the germinal centre proceed with deterministic duration. For an overview of all
simulation parameters and their experimental sources where applicable, see the appendix of
this chapter in section 2.A.
Simulation Rules As a first simulation step, an epitope sequence of length 𝑛key is gener-
ated. Next, a reservoir list of antibody key sequences is engineered such that the distribution
of binding energies between sequences in the reservoir and the epitope sequence conform to a
discretised Gaussian distribution with mean 𝐸bind = 0.5 and standard deviation 0.1, truncated
to values above the activation threshold 𝐸bind = 0.6. This mimics the distribution naturally
arising for randomly drawn sequences for 𝑛key = 10. The possibility of enforcing a given
binding energy distribution has been introduced to allow comparison of germinal centre ef-
ficiencies across challenges of different complexities without artefacts introduced by unequal
quality initial repertories (as illustrated by the randomly drawn repertoires for different key
region lengths in figure 2.6a). New naïve and unspecific memory B cells are then equipped
with randomly picked sequences from the pre-generated reservoir throughout the simulation.
Memory cells are immortal on the simulated time scale of 100 days whereas naïve cells die after
a given lifetime 𝑡n life unless activated. To maintain a constant pool size, naïve cells are added
to the system with rate
𝑟naïve =
𝑛naïve ⋅ 𝑛GC
𝑡n life
, (2.3)
where 𝑛naïve describes the size of the reactive naïve cell pool per germinal centre.
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Figure 2.7.: Coarse overview of basic implementation details.
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When antigen is added to the system at the 𝑖th vaccination time point 𝑡 𝑖vacc, its concentration
decays exponentially from a starting value determined by the assumed vaccination dose with
decay rate 𝜏decay giving the antigen time curve
𝑎(𝑡 − 𝑡 𝑖vacc) = e−(𝑡−𝑡
𝑖vacc)/𝜏decay (2.4)
for 𝑡 > 𝑡 𝑖vacc per antigen exposure. Similarly the number of Tfh cells at a follicular site, which
determines the size of the germinal centre forming there by governing how many B cells can
receive survival signals, is at its maximum value 𝑛LF between the time needed for both B and
Tfh cells to migrate there 𝑡init, and 𝑡GC,max whereafter their number decreases exponentially
with decay constant 𝜏GC decay. This roughly mimics experimentally observed GC growth and
decline dynamics [Wittenbrink et al., 2011]. While antigen is present in the system, every
free B cell (naïve and memory) may get activated and primed to join a germinal centre with a
probability proportional to the antigen concentration at each time step. This activation step is
independent of affinity and competition for antigen because it is assumed to occur in the dilute
settings of the periphery or the lymphoid system.
Once arrived at the follicular site, activated cells enter the germinal centre where they com-
pete for Tfh cells’ signals to either divide and recycle or exit as differentiated effector cells.
Competition is based on each cell’s antigen affinity and the number of currently available Tfh
cells. Dynamics of antigen and Tfhcells at the follicular sites following infection are shown
in figure 2.7b. Winners are drawn based on a Boltzmann distribution at every time step: the
probability 𝑝𝑖 for a cell with binding energy 𝐸𝑖 to be selected in a pool of 𝐽 cells is
𝑝𝑖 =
e−𝑘𝐵𝑇 /?̃?𝑖
∑𝐽𝑖 e−𝑘𝐵𝑇 /?̃?𝑗
, (2.5)
where the energy values ?̃? are the result of mapping the normalised energies 𝐸bind between
0.6. and 1 to the energy range determined by experimentally observed affinities as described.
After receiving signals for a set amount of time 𝑡help, a fraction 𝑝recycle of cells is randomly
chosen to divide and recycle in the germinal centre while the remaining cells differentiate into
effector cells and exit the reaction. Of note, because it has been observed that germinal centre
B cells divide twice on average after having received Tfh signals once [Gitlin et al., 2014], this
is implemented into the model by letting each cell divide once before deciding whether it will
divide again or differentiate into an effector cell in a second round. Cells that do not suc-
cessfully compete for survival and division signals within a fixed time 𝑡GC life are removed
from the model simulating their death. Thus, selection and expansion is death-driven rather
than division-driven in this model as has been argued previously based on both experimental
[Anderson et al., 2009] and theoretical [Amitai et al., 2017] evidence. In agreement with this
hypothesis, division rates in the model presented here do not depend on the B cells affinity for
antigen but are set to a fixed time 𝑡div.
Plasma cells are not modelled explicitly here and therefore cells choosing this fate disappear
from the simulation. Memory B cells on the other hand rejoin the peripheral B cell pool for
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activation and priming to reenter germinal centres during future immune responses. The dy-
namics of peripheral naïve B cells, peripheral memory B cells and germinal centre B cells are
shown in figure 2.7c: the number of compatible naïve cells initially drops because they are re-
cruited into the germinal centre with rate which is higher than their production rate. Because
of this recruitment and the fast proliferation of germinal centre B cells, the population within
the germinal centre quickly rises before declining again as the number of Tfh cells drops (fig-
ure 2.7b). The number of free memory cells begins to rise after the geminal centre has formed
because they are being produced by the germinal centre reaction and enter the periphery.
Experimental observations show that mutations in germinal centres start only after a period
of mutation-free expansion [Kleinstein and Singh, 2003]. Therefore, divisions happening in
the time frame 𝑡AID after a B cell clone first entered the germinal centre are exempt from the
mutational procedure described above.
Simulation Output With the simulation implemented as outlined above, both the popula-
tion dynamics of naïve, memory and germinal centre B cells (as sketched for a small system
with a single germinal centre in figure 2.7c) and the clonal dynamics within individual ger-
minal centres can be examined in detail. In order to record clonal dynamics, each simulated
naïve B cell which is assumed to be uniquely produced in the bone marrow is outfitted not
only with a cellular identification number, but also with a family ID. Upon division within the
germinal centre, both daughters get distinct cellular IDs but inherit their mother’s family ID.
Like this, the number of cells derived from the same original ancestor and present within a
germinal centre (or likewise the entire memory cell pool) can be queried.
In order to make the selection and diversification process intuitively accessible, the simu-
lation script produces visualisations of the type shown in the left column of figure 2.8. Here,
every family ID as described above is associated with a certain colour. As initially many dif-
ferent naïve cells and thus different families seed a germinal centre reaction, many colours
are observed in the first two weeks of the process. As affinity-based selection then identifies
the B cell families with the highest binding potential, most clones disappear and the germinal
centre becomes dominated by one or a few families. This closely matches recent experimental
observations [Tas et al., 2016]. In addition to the clonal dynamics, the underlying affinities are
also accessible. In figure 2.8 the dissociation constants of individual memory cells produced by
the depicted GC over time are shown in the bottom row. Each dot represents a single memory
cell here and can be attributed to the clones shown in the top row via the matching colours.
The selection dynamics shown there are mirrored by the memory cell output: initially, many
different families are present and thus produce memory cells. The initial seeder families have
different affinities to the antigen sequence (governed by the distribution shown for 𝑛key = 10
in figure 2.6a). Until approximately two weeks after antigen exposure, the mean affinity of
the germinal centre’s memory output increases, almost solely driven by selection. Eventually,
the repertoire within the centre is reduced to the strongest clone, depicted in dark blue in this
example. Shifts in the y-direction are now due to mutations; it is directly apparent that in this
specific example, no strong improvements are identified. This conclusion is underlined by the
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Figure 2.8.: Upper left: insight into a single germinal centre reaction seeded by about 100 dif-
ferent clones. Each clone is represented by a different colour so that selective ex-
pansion of the highest affinity clone (dark blue) can be visualised. The number of
cells within the germinal centre reaches a peak at around 800 and then declines
so that the germinal centre disappears by four weeks after the vaccination. Lower
left: Memory cell output of the germinal centre shown above. Each dot represents
one memory cell that has left the germinal centre and gives the production time
(x-axis) and affinity (y-axis) of this cell. Initially, memory cell output is polyclonal
and mean quality rises quickly as selection acts on the seeder pool. Later, in the
pauciclonal phase, mutational drift of the strongest clone (dark blue) occurs. Upper
right: Mean cell and clone number derived from 500 individual simulated germinal
centres. Lower right: Mean quality of the memory output of these 500 germinal
centres. All simulations run with 𝑛key = 10.
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bottom rigth panel which shows the average quality of the memory output of 500 single GC
reactions. The basic pattern shown by the single example is preserved: while there is a fast
selection-driven increase initially, later mutation-driven improvement continues at a much
lower speed.
The parameters used for this example are the default settings listed in tables 2.1-2.4. How-
ever, many parameters, such as the antigen complexity 𝑛key, the number of Tfh cells at the
base of germinal centre size, the shape of the affinity distribution in the naïve repertoire and
the mutation frequency among others are interesting subjects of investigation. With this sim-
ulation set-up at hand, these parameter spaces as well as multi-shot vaccination schedules will
be explored in the chapter 3.
2.A. Supplement: Binding Model Matrices, Pseudocode,
Parameters
This section contains additional information on the B cell memory simulation in described sec-
tions 2.1, 2.2 and 2.3. It comprises a pseudocode version of the implementation (algorithm 1),
the default set of parameters used for running simulations together with experimental sources
where applicable in tables 2.1 to 2.4 and matrices associated with the binding model in tables
2.5 and 2.6.
The full simulation code, which was written in python 2.7, is publicly available at https://
github.com/LiBuchauer/gc_memo under the permanent digital object identifier 10.5281/zen-
odo.1048052 (http://doi.org/10.5281/zenodo.1048052).
44
CHAPTER 2. A FLEXIBLE COMPUTATIONAL MODEL OF B CELL IMMUNITY
Algorithm 1 Pseudocode of the germinal centre-based simulation introduced in section 2.3.
1: function Germinal Centre Model
2: Set 𝑡now = 0.
3: Create an antigenic determinant sequence of length 𝑛key.
4: Create a large (see text) list 𝐿seq of antibody sequences of length 𝑛key so that the distribution of binding
energies between these sequences and the antigen sequence is as requested (see text).
5: Create a list of 𝑛naïve ⋅ 𝑛𝐺𝐶 naïve B cells with sequences drawn from 𝐿seq and mutation count 𝑚V = 0.
6: Create a list of 𝑛freemem ⋅ 𝑛𝐺𝐶 unspecific B cells with sequences drawn from 𝐿seq and
𝑚V = UniformDistribution[0, 40].
7: Create a list of 𝑛GC empty waiting lists.
8: Calculate the time curve 𝐴𝑔(𝑡) of antigenic presence in the system (see text).
9: Calculate the time curve 𝐿𝐹(𝑡) of limiting factor presence in the follicular sites (see text).
10: Open an empty event list for each GC to store events that are executed with a time delay.
11: while 𝑡now < 𝑡max do
12: Remove inactive naïve cells that are older than 𝑡life, naïve.
13: if number of free naïve cells < 𝑛naïve ⋅ 𝑛𝐺𝐶 then
14: Create naïve B cells with rate 𝑛naïve ⋅ 𝑛𝐺𝐶 /𝑡life, naïve.
15: In each GC, remove waiting B cells that have been there for longer than 𝑡life, GC.
% Events consist of (event type, execution time, GC ID, list of cells concerned by the event).
16: if event list contains events with 𝑡execution = 𝑡now then
17: for every one of these events do
18: if event is of type ‘Enter’ then
19: Distribute the cells randomly to the GC waiting lists.
20: else if event is of type ‘Divide’ then
21: Make two possibly mutated daughter cells from every mother (see text).
22: Append the viable daughter cells to the GC’s waiting list.
23: else if event is of type ‘Differentiate’ then
24: Append the cells to the free memory list.
25: Discard event.
26: if antigen is present in the system at 𝑡now then
27: Create empty list 𝐿act for newly activated cells.
28: for every cell in the free naïve and memory pools do
29: Activate with probability 𝐴𝑔(𝑡now) ⋅ 𝑝base.
30: if activation is successful then append cell to 𝐿act
31: Create event of type ‘Enter’ with 𝑡execution = 𝑡now + 𝑡init and 𝐿act.
32: Append event to event list.
33: if limiting factors are present in the follicles at 𝑡now then
34: for every GC do
35: if there are B cells waiting for survival signals then
36: Choose 𝐿𝐹(𝑡now) waiting cells for survival according to Boltzmann-distributed selection
probabilities (see text).
37: In order to incorporate double division after selection, directly make two possibly mutated
daughter sequences from every mother (see text).
38: Create event of type ‘Divide’ with 𝑡execution = 𝑡now +2𝑡div and a randomly selected fraction
𝑝recycle of the viable daughters from the first division round.
39: Create event of type ‘Differentiate’ with 𝑡execution = 𝑡now + 𝑡div + 𝑡diff and the remaining
chosen cells.
40: Append events to the event list.
41: Set 𝑡now = 𝑡now + 𝑡step.
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Table 2.1.: Simulation parameters: Vaccination schedule, antigen an limiting factor dynamics.
symbol default
value
meaning source / reason
𝑡 𝑖vacc [0, 28, 56]
days
Vaccination time points CHMI trial discussed in
chapter 4, [Mordmüller
et al., 2017]
𝜏decay 2 days Time constant of exponen-
tial Ag decay/removal in
the system
[Mandel et al., 1980]
𝑝base 0.005 Base activation probability
per free B cell and timestep
choice leading to 10% activ-
ation
𝑡GC,max day 7 Day until which the GC
stays at maximum size
onset of Plasmodium fal-
ciparum blood stage [Keit-
any et al., 2016]
𝜏GC decay 10 days Time constant of exponen-
tial limiting factor decay
after 𝑡GC,max
set to reduce GC size faster
than normal [Wittenbrink
et al., 2011, Weisel et al.,
2016] due to Plasmodium
falciparum blood stage an-
tigens [Keitany et al., 2016]
Table 2.2.: Simulation parameters: Simulation size.
symbol default
value
meaning source / reason
𝑛GC 50 Number of individual GCs
in the system
see chapter 3
𝑛GC 25 Number of limiting factors
(Tfh cells) per GC
leads to GCs of 500 cells
in steady state, in range of
[Wittenbrink et al., 2010]
𝑛naïve 1000 Steady state number of po-
tentially binding free naïve
cells per GC
estimation: (B cells in
mouse [Matsumoto and
Futamura, 1995]) ⋅ (pre-
cursor frequency [Perelson
and Oster, 1979])/𝑛GC=
109 ⋅ 10−4 ⋅ 10−2 = 𝒪(103)
𝑛free mem 100 Number of binding free
memory cells from former
infections per GC at 𝑡 = 0
[Perez-Andres et al., 2010]
and text
𝑡step 2 hours Simulation timestep chosen to match smallest
simulated time unit (𝑡help)
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Table 2.3.: Simulation parameters: GC dynamics.
symbol default
value
meaning source / reason
𝑡init 3 days Time needed by B cells to
become fully activated and
migrate to the follicle to
form a GC after initial an-
tigenic contact
[De Silva and Klein, 2015]
𝑡AID 3 days Time needed for cells hav-
ing newly joined the GC
before they start acquiring
mutations during divisions
[Berek, 1992, Jacob et al.,
1993, Kleinstein and Singh,
2003]
𝑡help 2 hours Time that selected B cells
need to receive survival
signals before deciding to
divide or differentiate
order of [Allen et al., 2007]
(several contacts of 10-60
minutes)
𝑛div 2 number of divisions B cells
undergo following selec-
tion
mean in [Gitlin et al., 2014]
𝑡div 8 hours Time needed for cell divi-
sion in the GC after having
received survival signal
citeAllen2007b
𝑡diff 8 hours Time needed for differen-
tiation into a memory cell
after having received sur-
vival signal
chosen to match 𝑡div
𝑡GC life 8 hours Maximum survival time of
GC cells while unsuccess-
fully competing for sur-
vival signals
order of [Liu et al., 1989]
𝑡n life 14 days Lifetime of naïve cells that
have not been activated;
new naïve cells are con-
tinuously introduced into
the simulation to keep up
the poolsize 𝑛naïve ⋅ 𝑛GC
[Macallan, 2005]
𝑟 0.9 Fraction of cells choosing
to divide and recycle in-
stead of leaving as a differ-
entiated cell after receiving
survival signal
[Meyer-Hermann et al.,
2012, Kleinstein and Singh,
2003]
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Table 2.4.: Simulation parameters: Binding model and mutations.
symbol default
value
meaning source / reason
𝑛key [1 …15] Number of residues jointly
determining affinity to-
wards a given epitope
sequence
see section 2.2
𝑛V 220 Combined length of the VH
and VL segments
[Murphy and Weaver,
2016]
𝑏thr 0.6 Binding threshold in nor-
malized energy units
see section 2.2
𝐾 thrD 10−5 M Corresponding binding
threshold as dissociation
constant
[Batista and Neuberger,
1998, Childs et al., 2015]
𝑏top 1 Maximum binding
strength in normalized
energy units
see section 2.2
𝐾 topD 10−9 M Corresponding maximum
binding strength as dissoci-
ation constant
[Batista and Neuberger,
1998, Childs et al., 2015]
𝑝err 0.003 Error probability per codon
and division
[McKean et al., 1984]
𝑝death 0.5 Probability that a replace-
ment mutation in a residue
relevant for stability leads
to a non-functional Ab
(and hence cell death)
[Kleinstein and Singh,
2003]
𝑝block 0.55 Probability that a mutation
in a non-key residue results
in blocking of affinity mat-
uration
mean of values given in
[Kleinstein and Singh,
2003]
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0
0.11
0
0.11
0.11
0
0.22
0
0
E
0
0
0
0
0
0.11
0
0
0.11
0.11
0
0
0.11
0
0.11
0.22
0
0
0.11
0
0.11
D
0
0
0
0
0
0.11
0
0.11
0.11
0.11
0
0
0
0.11
0.22
0.11
0.11
0
0
0
0
H
0
0
0
0
0.11
0
0
0.11
0
0
0
0
0.22
0.11
0
0.11
0.11
0.11
0
0.11
0
R
0.04
0.02
0
0.02
0.07
0
0.04
0
0
0.11
0.04
0.11
0.04
0
0
0
0.04
0.33
0.04
0.07
0.04
K
0
0.06
0
0.06
0
0
0
0
0
0
0.11
0
0.11
0.22
0.11
0
0
0.11
0.11
0
0.11
P
0
0
0
0
0.11
0
0
0
0.11
0
0.11
0.11
0.06
0
0
0
0.06
0.11
0
0.33
0
Table2.6.:Algebraictransitionprobabilitiesbetweenaminoacidsbasedontheunderlyingcodons.Eachreplacementofanucleotidebyanother
oneduringsomatichypermutationisassumedtobeequallylikely.Aseachcodonconsistsofthreebasepairs,transitionintoeachofits
(3+3+3)neighboursatHammingdistance1hasequalprobabilityof1/9.Th
etransitionmatrixincludesvalueswhicharenotmultiplesof
1/9becausemostaminoacidsareinitiallyencodedbymorethanonecodon.Th
istransitionprobabilitymatrixisnotsymmetric(andalso
notquadratic),buttobereadinthefollowingway:thetransitionprobabilityuponasinglebasepairexchangeoftheaminoacidinline𝑖
intothecandidateincolumn𝑗isgivenbytheentry{𝑖,𝑗}(andnotviceversa).Th
elastcolumngivestransitionprobabilitiesintotheSTOP
codon.Greybackgroundindicatestransitionprobabilityintoadifferentcodoncodingforthesameaminoacid.
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3. Application of the Model to Vaccination
Scenarios with Various Boundary
Conditions
In this chapter, simulation results for varying parameter regimes and boundary conditions are
explored. These comprise the effects of varying antigen complexity on the affinity maturation
within individual germinal centres in section 3.1 and the influence of germinal centre- and
vaccination protocol-specific parameters in systems of many interacting germinal centres in
section 3.2. In section 3.3, a mechanism underlying successful expansion is introduced and the
influence of patient-specific repertoire differences is examined.
3.1. Antigen Complexity and Clonal Diversity
As outlined in section 2.1, one factor determining the difficulty of vaccination attempts is how
easy it is to generate major antibody affinity improvements via somatic hypermutation in ger-
minal centres. Because patterns of recurring mutations with strong individual effects are de-
scribed for small haptens, but much less for larger protein antigens, the binding model de-
veloped in chapter 2 is set up in such a way that binding interfaces of differing size can be
described by a varying number of key residues 𝑛key. In the following, the effect of this para-
meter on the efficiency of affinity maturation within individual germinal centres is explored in
detail.
Decreasing Efficiency of Affinity Maturation with Complexity In contrast to historic
beliefs [Kroese et al., 1987], newer studies indicate that many seeder cells populate a germinal
centre reaction initially and additional participants may also join throughout an ongoing re-
action [Tas et al., 2016]. Accordingly, the default activation parameters used in this work lead
to 𝒪(100) seeder cells as is illustrated in the introductory example in figure 2.8. In our model,
these around 100 cells enter the germinal centre solely based on whether they bind the an-
tigen presented by the follicular dendritic cells there with at least threshold affinity (without
selection mechanisms acting at this stage). Therefore, the affinity distribution of seeder cells
is equal to the affinity distribution of all precursor cells in the system. As described in section
2.3, our model allows to enforce specific affinity distributions in the precursor pool. According
to the default distribution shown in figure 2.6a for 𝑛key = 10, there is a high number of low
affinity binders, some intermediate binders and very rare strong binders. In the following, this
distribution is used for all antibody-antigen binding complexities.
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(a) Mean affinity towards a given antigen within individual simulated germinal centres as a function
of time after antigen exposure. Different colours show different antigen complexities; as discussed
in section 2.3, affinity distributions of initial seeder cells are equal for all complexities. Thus, the
final differences in mean affinity are not due to pure selection effects on the seeder repertoire, but
necessarily due to mutations.
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(b) Left: number of B cells, B cell clones and different binding regions (cells from the same clone may
have different key regions due to hypermutations) within a single small germinal centre as a function
of time after antigen exposure. The number of clones drops much faster than the number of binding
regions. Right: Resulting interclonal and binding region entropies in a single germinal centre as
a function of time after antigen exposure. While the reduction of clone number leads to a drastic
reduction in clonal entropy, somatic hypermutations diversify the binding region pool leading to a
higher diversity towards the end of the reaction.
Figure 3.1.: Affinity and diversity development within a single simulated germinal centre.
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Figure 3.1a shows what happens when 𝒪(100) randomly sampled cells from this affinity
distribution seed a germinal centre reaction which then proceeds for around 4 weeks. Each
line gives the mean affinity of all germinal centre B cells as a function of time for one of the
complexities 𝑛key = {1, 5, 10, 15}. All four scenarios start with the same mean affinity because
the seeder cells are drawn from the same distribution, but evolve differently afterwards. The
lower the complexity, the steeper the rise in mean affinity and the better the final result. The
overall rise in affinity is brought about by the joint action of beneficial hypermutations and
selective expansion of pre-existing high-affinity clones. However, the effects based on pre-
existing clones are limited to the diversity in the seeder repertoire and are therefore of equal
magnitude for all four complexity cases shown here. This mechanism cannot account for the
observed differences in final affinity outcome. Consequently, the diverse results for the four
difficulties support the initial assumption that affinity maturation against some antigens may
proceed more smoothly then against others - if more residues jointly determine affinity, identi-
fying all changes necessary for a strong binder while at the same time avoiding detrimental or
completely destructive mutations becomes an increasingly difficult challenge.
Somatic HypermutationsMaintain Diversity Onemay provocatively ask whymutation-
driven affinity maturation as an immune process evolutionarily developed in the first place if
it is so inefficient in cases with complex antigens. Firstly, not all pathogenic strategies are
alike and cases in which the precursor repertoire does not only harbour very few adequate B
cells, but none at all, do exist. Here, affinity maturation via hypermutations is the only path to
high-affinity antibodies, however inefficient it may be. In addition, a second aspect of the role
of hypermutations becomes apparent when one looks at the diversity within germinal centres
(and likewise within the memory B cell pool produced by an immune response). Figure 3.1b
shows the number of B cells, the number of clones these belong too and the number of unique
key regions within a germinal centre over the course of the reaction. In this specific example, a
little more than 50 clones seed the reaction. This number is quickly reduced over time until only
one or a few remain. In turn, because of the ongoing diversification by hypermutation, one
clone is likely comprised of individuals carrying different sequences and specifically also dif-
ferent binding regions once it has expanded. As a result, the number of diverse binding regions
does not decrease as drastically as does the number of clones within the reaction. This effect
becomes even clearer when looking at the normalised Shannon entropy within the germinal
centre as defined by
𝐻(X) = −∑
𝑖
𝑃(𝑥𝑖) ⋅ log2 𝑃(𝑥𝑖) , (3.1)
where X is a vector containing the number 𝑥𝑖 of each species 𝑖 within the ensemble and 𝑃(𝑥𝑖)
is the resulting fraction of species 𝑖 within the total mass. The right panel of 3.1b shows that
while the interclonal entropy (the diversity brought about by different clonal origin) drops to
0, this is not true for the bindign region entropy. Thus, while interclonal diversity decreases
strongly due to the nature of the germinal centre reaction, intraclonal diversity rises and thus
reduces the overall diversity loss.
The resulting maintenance of diversity in the memory pool emerges as an important feature
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of an efficient immune system especially in the light of recent findings showing that cross-
reactive memory cells participate in the fight of infections different from the ones that initially
generated them. This is true for both related infections, i.e. different strands of influenza
[McCarthy et al., 2018], and presumably completely unrelated infections, such as the reuse
of existing memory cells in previously malaria-naïve Europeans in a malaria vaccination trial
[Murugan et al., 2018]. Returning to the model, mutations may happen not only within the
𝑛key mutations determining binding strengths within a specific case, but also within the scaf-
fold region. It is conceivable that in the biologic scenario, not all antigens contact a given
antibody at the same position such that amino acids which are part of the key region for one
antigen are not relevant for another. As a result, in principle one should take into account
the diversification of the entire sequence when judging the conservation of diversity by hy-
permutation. While this is not possible in the current model, where the scaffold region is not
modelled as an explicit sequence, it is very likely that rigorous analysis of the development of
this total entropy would reveal even higher stability in diversity..
Stochastic Differences Between Germinal Centre Reactions Because of the stochastic
nature of somatic hypermutation, it is evident that two hypothetical germinal centres sup-
plied with the exact same seeder cells would not produce the same outcome. However, the
magnitude of the resulting variance depends both on the complexity of the antigen and the
number of germinal seeder cells as illustrated in figure 3.2. This figure shows twelve examples
for single germinal centre reactions, two each for six different parameter combinations of com-
plexity and seeder cell number.
Looking at the default scenario with 𝑛key = 10 and many seeder cells as used likewise in fig-
ure 2.8, the final maximum affinity reached by two independent reactions with different seeder
cell ensembles does not differ strongly. This is because the comparatively high seeder number
increases the likelihood of including high quality cells in the seeder pool. The slow speed of
mutation-driven improvement then plays a minor role; effects caused by single mutations in
the 𝑛key = 10 scenario are frequently so small that they are not even fixed as illustrated by
the two examples chosen for this case in figure 3.2 (upper left panel). Here, both in the orange
and the blue dominating clones, clonal members with slightly higher affinity evolved transi-
ently, but did not succeed in taking over the population. Reasons for this may include a quick
succession of the beneficial mutation by a detrimental one, for a example a blocking mutation
which reduced the affinity back to the value of the original clonal ancestor, differentiation of
the improved cell into an effector cell and thus loss from the germinal centre and also failed
selection of the improved candidate due to the Boltzmann-stochastic nature of the implemen-
ted selection process.
Moving to the neighbouring scenario, 𝑛key = 10 and few key seeders, the benefit of re-
cruiting many cells into the reaction is underlined. In the two examples shown here, only two
or three clones seed the reaction; as these are drawn from a precursor affinity distribution
with few high-quality cells, cases in which only low-quality binders are involved are the norm.
Thus, reaching a high average affinity is more dependent on mutations and strong subject to
stochastic effects. Similar general differences between the few- and the many-seeder scenario
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Figure 3.2.: Twelve examples of individual germinal centre reactions, visualised as introduced
in figure 2.8. The inset to each upper panel additionally shows the affinity devel-
opment within the dominating clone as a function of the number of somatic hy-
permutations it has acquired. Complexities 𝑛key = 10, 𝑛key = 5 and 𝑛key = 1 are
compared here; the effect of having few (𝒪 = 3) or many (𝒪 = 100) seeders are
additionally explored.
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are valid for other complexities as well as illustrated for 𝑛key = 5 and 𝑛key = 1 here. However,
as mutations lead to significant improvement more reliably if less key residues are involved in
binding, the low-seeder scenarios more routinely produce high-affinity outcomes in the these
cases.
In summary, variability in the maximum affinity of a germinal centre can be reduced by
bringing more seeder cells into each reaction, for example by increasing antigenic dose in
a vaccination protocol. Keeping the seeder number constant, variation between individual
reactions is also larger in cases with lower complexity because of the larger affinity jumps
caused by individual mutations, but this is not a disadvantage as the mean maximum quality
in cases with challenges of lower complexity is still higher than in more difficult mutation
problems. Stochastic effects are further reduced by large systems in which many germinal
centres interact over the course of several vaccination shots as discussed in section 3.2.
3.2. Multi-Shot Immunisation and General Parameter Space
The exploration of parameter effects in section 3.1 is limited to individual germinal centre
reactions. As much as these are important building blocks of B cell immunity, they cannot in-
dividually mimic a human response to vaccination. Humans have several hundreds of lymph
nodes, each of which can harbour 𝒪(10 − 100) germinal centres following infection or vaccina-
tion. In addition, the spleen is a major site for germinal centre reactions [Murphy and Weaver,
2016]. During a single acute response, germinal centres develop by and large independently,
although some crosstalk in which the same clone is identified within two or more neighbour-
ing reactions is possible [Tas et al., 2016]. Our model allows the analysis of larger systems
with many germinal centres within the same peripheral B cell pool and the following sections
will focus on such a system with 50 germinal centres. This specific choice was made on the
one hand because key read-outs like mean memory pool affinity and entropy did not change
by much if more centres were added after this point and on the other because this choice of
system size, leading to 𝒪(105) B cell objects, is still manageable in the current implementation.
The resulting runtime of one simulation with three vaccination shots and 50 germinal centres
is around 30 minutes for 𝑛key = 10.
A Triple-Shot Vaccination Protocol While the model gives us the freedom to implement
any vaccination schedule, we focus on a specific one for the following parameter exploration.
Specifically, this is a triple-shot scenario with a primary vaccination followed by two boosters
after intervals of four weeks. This specific choice is motivated firstly because of the compar-
ison to a malaria vaccination study using this schedule in chapter 4 and secondly because many
licensed vaccines likewise use a triple-shot schedule with similar time intervals, e.g. the child-
hood vaccines against rotavirus, polio, pneumococcus and hepatitis B [Robert-Koch-Institut,
2017]. Additionally, in the default settings, germinal centres have disappeared by four weeks
after initial exposure and the three vaccinations are thus non-overlapping. Because the current
implementation does not include decay processes of the generated memory (memory B cells
live eternally in the model), it would currently not make sense to increase the time interval
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(a) Sketch of the triple-shot vaccination sched-
ule used for the results in the other panels
and most of chapter 3.
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(b) Total memory cell production of a system
with 50 germinal centres, each dot repres-
enting a new memory cell similar to figure
2.8.
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(c) Development of the clonality of the
memory pool with each colour represent-
ing a B cell clone derived from the same
ancestor.
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(d) Dynamics of mean affinity and normalised
Shannon entropy over the time course of
the triple vaccination schedule in panel a.
Figure 3.3.: Effect of a triple-shot vaccination protocol on B cell clonality and memory cell af-
finity in a system with 50 germinal centres governed by default parameters (tables
2.1 to 2.4).
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beyond this point. The chosen default vaccination schedule is depicted in figure 3.3a.
The remaining panels of figure 3.3 show the effect of the this vaccination schedule on the
memory pool for 𝑛key = 10 and all other parameters set to their default values as given in
section 2.A. Using the same picture language as introduced for individual germinal centres
with colours indicating different clones, we now examine the memory population of the entire
system. Looking at the affinity of each individual memory cell as a function of its production
time point (figure 3.3b), a general trend towards higher affinities at later times is observable
not only within the reaction to each vaccination but also globally: drawing on the advances
following the first two vaccinations, the best memory cells are produced in response to the
third exposure. Comparing all three vaccinations, low-quality memory cells are initially pro-
duced, but the time span during which this happens is reduced in the second and third process,
as the fraction of highly competitive seeder cells from the now pre-selected memory pool is
higher and thus the competitive advantage for selection to act on is larger from the start of
these germinal centre reactions.
Instead of investigating the clonal distribution and the associated entropy within germinal
centres like in section 3.1, we now analyse the clonal entropy within the memory B cell pool
built up during the vaccination protocol. Figure 3.3c shows both the overall increase of memory
cells throughout the triple-shot protocol and how it their clonal entropy is reduced as individual
strong clones gain ground while weak clones are deselected. The peripheral memory cell num-
ber drops transiently directly following vaccination because some memory cells are recruited
into germinal centres to fuel competition there and also to be differentiated into plasmablasts.
Colours are only assigned to clones which expand to at least two cells at any point during the
simulation; the grey base shown in figure 3.3c collects all cells which appear as singletons only.
The entropy of the memory pool as a function of time can be quantified using the normal-
ised version of Shannon’s entropy which reduces effects of unequal population sizes (as they
naturally appear in a growing cell population) and is defined by
𝐻(X) = −
𝑛
∑
𝑖
𝑃(𝑥𝑖) ⋅ log2 𝑃(𝑥𝑖)
log2 𝑛
, (3.2)
where 𝑛 is the number of clonal species present. The result is shown in figure 3.3d. Even
though the entropy of the pool is reduced with each vaccination, the pool remains rather di-
verse because of the underlying structure with many lightly interacting germinal centres. In
comparison to a hypothetical system with only one or a few much larger germinal centres,
this architecture is thus not only beneficial because it allows for decentralised recruitment of
precursors all over the body, but also because it assists in maintaining a diverse repertoire. This
in turn increases the likelihood that some of the clones fighting the current infection will also
react against a different one.
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Exploring Parameter Sensitivity The sensitivity of the simulation outcome to a number
of chosen model parameters is analysed in the following. For this, the chosen parameter is var-
ied while all other parameters remain constant at their default value as given in section 2.A.
The parameters discussed below include germinal centre-specific parameters as well as choices
concerning the vaccination protocol.
First, we analyse the effect of germinal centre peak size on final affinity and entropy after the
default triple-shot vaccination protocol. The default value of 25 Tfh cell was chosen because
it produces germinal centres with around 500 B cells in them at steady state - this is within
the physiological range reported for mice [Wittenbrink et al., 2010], albeit on the smaller end,
and still allows for efficient computation. While varying the number of Tfh cells which act as
limiting factors in germinal centre B cell survival and selection, it becomes apparent that larger
germinal centres lead to slightly higher final mean affinities because the population basis of
mutational processes and thus the absolute probability for beneficial events is higher (figure
3.4a). However, the effect of large germinal centres on the diversity of the pool is much stronger
than their effect on affinity. Thus, keeping in mind the previous discussion on maintaining di-
versity as an important but often overlooked aim of a humoral immune response, intermediate
germinal centre sizes are likely beneficial. Indeed, physiologically, germinal centre sizes span
several orders of magnitude [Wittenbrink et al., 2010], thereby potentially combining benefi-
cial effects of both smaller (more diversity) and larger reactions (higher affinity).
Next, we look at the effect of germinal centre lifetimes. It is reported that germinal centre
reactions start a few days after initial exposure and carry on for 4-10 weeks [Wittenbrink et al.,
2011, Weisel et al., 2016]. Here, we have chosen a decay constant of 10 days as a default value,
which leads to disappearance of the germinal centres after 4 weeks, because of the comparison
to a malaria vaccination trial as described in chapter 4. In this specific case, germinal centre
reactions against the antigen of interest are likely suppressed faster because of new antigens
emerging in following stages of the malaria life cycle. Generally, longer germinal centre life
times lead to a higher final affinity and lower entropy of the peripheral pool (3.4a). This is
expected, because longer reactions lead to a higher total production of cells from the winning
clones, thus both providing a stronger basis for beneficial mutations and simply producing
more effector cells for the periphery. However, in figure 3.4a , a qualitative change becomes
apparent when comparing decay constants 10 and 20 days. This is because for the highest val-
ues shown here (20 and 30 days), individual germinal centre reactions caused by consecutive
vaccinations are not longer cleanly separated in time, but begin to overlap. Thus, the previous
reaction is still ongoing and newly activated Tfh cells and B cells can join it. These refuelled
reactions have an advantage over newly formed ones as they already have a larger high-quality
population from the previous selection round as a starting point. Again, it is a glimpse at the
development of entropy that supplies a potential reason for why physiological germinal centre
reactions subside after a fewweeks: long, and particularly overlapping reactions, lead to strong
diversity loss. However, it is as yet unclear whether the type of germinal centre overlap dis-
cussed here and occurring in simulations really plays a role in biology. Questions like how
new cells join existing germinal centres, how they compete in there and whether older cells
are pushed out by the newcomers remain to be investigated more closely.
59
3.2. MULTI-SHOT IMMUNISATION AND GENERAL PARAMETER SPACE
0 25 50 75 100 1250 25 50 75 100 125
time (days) time (days)
10-9
10-8
10-7
10-6
10-5
0.8
0.6
0.4
0.2
0
1.0
m
ea
n 
K D
 (M
) 
of
 m
em
or
y 
po
ol
GC size varies GC decay constant varies
no
rm
al
ise
d 
Sh
an
no
n 
en
tro
py
5 Tfh cells
100 Tfh cells
50 Tfh cells
25 Tfh cells
10 Tfh cells
2 days
30 days
20 days
10 days
5 days
(a) Effects of germinal centre (GC) size and duration of the reaction.
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Figure 3.4.: Effects of germinal centre determinants and vaccination protocol on mean affinity
of the peripheral memory cell pool and its diversity during a triple-shot vaccination
protocol as shown in figure 3.3a.
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While the parameters discussed above, germinal centre size and lifetime, are governedmainly
by physiological or pathogen-related factors, other parameters such as the vaccination dose or
the number of shots administered are directly within control of the experimentalist or physi-
cian. As figure 3.4b shows, both impact the final outcome strongly. A higher vaccination dose
is assumed to lead to more activation in our model and thus recruits more cells into germinal
centre reactions as seeders. This in turn increases the cell pool on which selection acts. In the
following second and third vaccinations, high doses are additionally important to guarantee
sufficient mixing between germinal centres. The resulting “avalanche effect” is further detailed
in section 3.3. Interestingly, entropy is not strongly affected by higher antigenic doses, as the
basic fact that one or a few clones come to dominate each reaction after a few weeks remains
intact for low-dose regimes and thus for cases with weak seeders only.
Finally, analysing the effect of the number of vaccinations shows no surprises. More shots
lead to a higher final affinity as both expansion of strong binders and beneficial mutation pro-
cesses are possible for a longer period of time. Concomitantly, clonal diversity is reduced by
each additional administration. Thinking about these results in the context of repeated natural
infections, this again underlines the diversifying effects of hypermutations as a monoclonal
and, more importantly, monofunctional repertoire after a couple of infections with the same
pathogen would not be desirable. As we will see in chapter 3.3, repeated vaccinations are
specifically important for challenges with complex antigens and a precursor distribution with
existing but rare high-quality cells. Overall, as (at least in the simulated scenario) each vac-
cination increases the quality of the memory pool further albeit with shrinking increment, it
becomes relevant to ask how good is good enough: In the physiological context, what antibody
titre is required for sterile immunity?; After how many vaccinations can we stop?
3.3. Avalanche Effect and Repertoire Differences
While the previous sections have explored how pathogen-specific effects like the complexity
of the antibody-antigen binding interface with a given epitope (section 3.1) or a pathogen’s
influence on germinal centre life time as well as the vaccination schedule can affect outcomes
(section 3.2), this section focuses on differences between individuals receiving vaccines and on
what may cause differential outcomes. In order to understand these differences, underlying
effects governing selection, expansion and mutation are examined first.
The Avalanche Effect In a system comprised of many weakly connected germinal centres
as described above and mirroring the physiological situation, it is not directly clear how one
single high-affinity B cell can be expanded into a clone of functionally significant size. Spe-
cifically in cases where intraclonal affinity improvement through hypermutations is limited
because of a high number of joint changes necessary for strong improvement, individual ger-
minal centres cannot be relied on to routinely mutate weak seeders into strong candidates.
While highly beneficial changes may be found in a few reactions, scenarios are conceivable
where this happens in a small fraction of germinal centres only.
61
3.3. AVALANCHE EFFECT AND REPERTOIRE DIFFERENCES
0
200
400
600
800
ce
ll
nu
m
be
r i
n 
G
C;
cl
on
al
 c
om
po
sit
io
n
GC site 1
GC site 3
GC site 5
GC site 7
GC site 9
GC site 2
GC site 4
GC site 6
GC site 8
GC site 10
0 20 40 60 80 100
time (days)
vaccination 1 vaccination 2 vaccination 3
0 20 40 60 80 100
time (days)
0
200
400
600
800
ce
ll
nu
m
be
r i
n 
G
C;
cl
on
al
 c
om
po
sit
io
n
0
200
400
600
800
ce
ll
nu
m
be
r i
n 
G
C;
cl
on
al
 c
om
po
sit
io
n
0
200
400
600
800
ce
ll
nu
m
be
r i
n 
G
C;
cl
on
al
 c
om
po
sit
io
n
0
200
400
600
800
ce
ll
nu
m
be
r i
n 
G
C;
cl
on
al
 c
om
po
sit
io
n
vaccination 1 vaccination 2 vaccination 3
Figure 3.5.: Illustration of the avalanche effect for a toy system of ten germinal centre sites.
Each panel depicts the clonal composition forming at each of the ten sites follow-
ing vaccinations 1-3. During the first round, the ten germinal centres are almost
without interaction, each contains its own set of clones. At site 10, the black clone
eventually takes over the reaction after the first exposure. After the subsequent
booster vaccinations, members of this henceforth expanded clone succeed to gain
significant ground in more and more germinal centres (four after the second vac-
cination and all ten after the third), though they do not always become dominant.
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Section 3.2 showed that high vaccination doses as well as having three rather than one or
two vaccinations is strongly beneficial for the final outcome as measured by the mean affinity
of the memory B cell pool in a complex challenge scenario with 𝑛key = 10. As in this complex
case not every germinal centre reaction can be trusted to produce high-affinity B cells from
scratch (see also figure 3.1a), high recruitment and subsequent mixing are of pivotal import-
ance. Here, we focus on the mixing process fuelled by several vaccinations, which we term
“avalanche effect”. This effect is illustrated in figure 3.5, which shows a toy system comprised
of ten germinal centre sites. One may imagine these sites as ten different lymph nodes each
housing one germinal centre. Following the first infection, each of the ten centres is seeded by
independent precursors, both naïve and pre-existing memory cells which have not previously
been expanded in response to the antigen at hand. Each reaction then elapses as described
in chapter 2 with mutation and selection processes leading to one or a few winners in each
centre. Generally, these dominant clones have the most opportunity of producing effector cell
offspring into the periphery and thus they come to occupy larger fractions in the free memory
pool (see also figure 3.3c).
In the next infection, previously generated specific memory B cells may participate as is
their role, and some of them reenter the newly formed germinal centre reactions. Thus, the
best clones from each of several reactions now meet to compete much like in the next round of
a tournament. In the toy example shown in figure 3.5, a black, a dark red and amint green clone
seem to appear and come to domination in several germinal centres each in the second infec-
tion. As these clones are now being expanded at multiple locations, they same goes for their
effector cell progeny which thus reaches an even higher fraction in the periphery. The process
is repeated in the third vaccination - in the toy example, all three clones named above have
now infiltrated all ten germinal centres, mostly it is the black clone which comes to dominate.
The fact that the black clone wins in most but not all reactions shows that while mutations can
still improve affinity even at later stages, there is a strong memory of the affinity with which a
clone entered the competition if antigen complexity is high. Because of the picture presented
here, where each member of a strong clone can go on to seed and dominate a new germinal
centre repeatedly, we term this amplification process the “avalanche effect”.
A Mutational Thought Experiment While the avalanche effect is an important factor in
bringing about high-quality vaccination outcomes in difficult challenges, it relies partly on
strong precursors and partly on beneficial mutations identified early on. With a computational
experiment we can further disentangle the separate effects of mutation-driven improvement
and pure selection. The underlying simulation setting here is again the triple-shot protocol
with default parameters and as a read-out of success the final mean affinity of the memory
pool is used. Instead of varying one parameter at a time, pairs of two parameters are being
varied jointly and the final affinity is encoded in colour as shown figure 3.6a. The parameter
pairs of interest here are {potential precursors per GC; mutation rate} and {vaccination dose;
mutation rate}. Both the number of potential precursors per GC, i.e. the size of the free B cell
pool from which seeder cells can be recruited, and the vaccination dose influence the num-
ber of germinal centre seeders and consequently the initial germinal centre diversity. While
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tion of cells with the indicated affinity has unchanged, improved or impaired affinity compared to
its original ancestor; the distribution on the left side shows the available naïve repertoire. Four scen-
arios are compared here: in the default case, both selection and hypermutation act on the memory
repertoire for a complex antigen of 𝑛key = 10. In the next scenario, no good precursors are available.
In contrast, the third scenario is mutation-free. For comparison, the last case shows the result after
a vaccination campaign with 𝑛key = 3. Here, mutational processes lead to high-end affinities in a
higher fration of cases.
Figure 3.6.: Memory pool quality and composition after a triple-shot vaccination scenario (see
figure 3.3a) and how it is governed by mutation and selection processes.
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these two parameters may vary because of pathogenic specifics or the vaccination protocol, it
is unlikely that the hypermutation rate per codon and division varies strongly between cases
(except for potential pathological cases), but varying it is nevertheless an interesting thought
experiment.
The resulting scenarios without hypermutation (mutation rate = 0) are of particular interest:
even in the total absence of somatic hypermutation, the final affinity can be strongly improved
by recruiting as many seeder cells as possible. The physiological mutation rate has been de-
termined to be around 0.003 mutations per codon and division; this value is close to the op-
timum identified in our simulation. However, there is a minor deviation from this value, as
figure 3.6a suggests that a slightly smaller mutation rate is optimal. This deviation is likely
due to simplifying assumptions in the computational model, specifically the assumption that
mutations are equally likely in all areas of the immunoglobulin variable segments, while bio-
logically mutational hotspots in and around the complementarity-determining regions exist
[Zheng et al., 2005, Wei et al., 2015, Yeap et al., 2015]. Nevertheless, our model clearly shows
that higher mutation rates would lead to worse outcomes as the probability of deathly or block-
ing mutations reaches levels overtaking potential positive effects of key region mutations.
Patient-Specific Repertoire Differences It has emerged as a result of previous sections
that selective expansion of rare high-affinity precursors is a very important process for reach-
ing high affinity at the population level. An alternative way of evaluating the relative con-
tributions of mutations and selection in different vaccination scenarios is presented in figure
3.6b. Here, the distribution on the right of each panel shows how the affinities of memory B
cells are spread out over the modelled affinity range after the default triple-shot vaccination
schedule. On the left of each panel, the affinity distribution of the precursors and thus the
germinal centre founder cells is shown. An additional colour coding in the final distributions
helps identify the fraction of cells in each bin which have i) improved affinity compared to their
germline ancestor, ii) impaired affinity compared to their germline ancestor or iii) unchanged
affinity compared to the ancestor. Looking at the default case (all parameters as given in sec-
tion 2.A with 𝑛key = 10), the difference between the immature precursor repertoire and the
memory repertoire after three vaccinations is striking, however, more than 80% of the memory
cells still have the same affinity as their germline ancestor. In this case, where high-affinity
precursors are available from germline, selecting and expanding them is more efficient than
mutating them and hence produces the bulk of high-affinity cells at the end of the protocol.
The picture changes for the second scenario, in which no good precursors are available. As
discussed in section 2.1, this may be due to genetic characteristics of the vaccinee in question
leading a deficiency of high-quality germline precursors. Additionally, differences in the pre-
cursor repertoire may come about due to the infection history of the patients - even if there
are no high-affinity germline B cells, previous related or unrelated infections may have shaped
efficient antibodies and concomitantly immune memory which can be reactivated in the case
at hand. Returning to the scenario under investigation, if no good precursors exist it is obvious
that somatic hypermutation is the only way towards high-quality binders. Indeed, a small pop-
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ulation of antibodies with an affinity around KD = 10−7M is produced, but it is obvious that the
patient simulated here would still have disadvantages compared to one with a better precursor
repertoire. Additional vaccination rounds could help to further expand the now present decent
precursors. In the spirit of personalized vaccines, an initial screening of precursor repertoire
quality may help predict how many vaccinations at what dose are likely required until protec-
tion in each individual.
For completeness, two additional scenarios are examined in figure 3.6b. The first one is
again concerned with the absence of hypermutations for a scenario with complexity 𝑛key =
10. Compared to the truncated repertoire discussed before, the final repertoire here greatly
resembles that of the default case as selection effects alone yield a competitive result. Finally,
in the case of a mutationally simpler challenge with 𝑛key = 3, a large population of highest-
quality cells is produced via affinity improvement and successfully expanded.
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Human Malaria Infection Trial
In this chapter, the computational vaccination model introduced in chapters 2 and 3 is applied
to increase mechanistic understanding of an experimental study on B cell memory develop-
ment over the course of a malaria vaccination trial with three immunisations. Basic informa-
tion on the malaria parasite Plasmodium falciparum, the vaccination trial and the experimental
methods applied to the resulting blood samples are put together in section 4.1. Following this,
several model predictions are tested against the experimental data and reasons for different
observations at the population and clonal levels are discussed in the context of other recent
findings in the field in section 4.2.
4.1. Introduction to Trial Protocol and Experimental Analysis
Epidemiology of Malaria and the Life Cycle of Plasmodium falciparum Roughly three
bilion people live in areas endangered by malaria, a parasitic disease caused by a parasite with
a complex life cycle. Five different species of the genus Plasmodium are responsible for all
human infections with an estimated 200 million cases and several hundred thousand deaths
occurring annually. More than 90% of the latter are located in sub-Saharan Africa where the
form Plasmodium falciparum (Pf ) predominates and children below the age of five are most
strongly affected. Symptoms are manifold and range from fatigue and muscle aches over ir-
regular fever to coma (specifically for falciparum Malaria), liver injury and severe anaemia
[White et al., 2014]. Longitudinal studies in endemic areas have shown that adults typically
acquire non-sterile immunity to malaria after several parasite exposures, thus acting as asymp-
tomatic parasitic reservoirs [Bousema et al., 2014]. While new-borns and young children are
the most vulnerable to severe malaria disease and related death, asymptomatic carriage can
also be observed in this age group [Males et al., 2008].
The life cycle of Pf takes place in the human host and the Anopheles mosquito. Starting
with the mosquito bite, 15-40 motile Pf sporozoites (Pf SPZ) are released into the dermis [Yuda
and Ishino, 2004, Amino et al., 2006]. From there, they travel to the liver via the blood stream
where they invade hepatocytes in which multiply extensively. After about one week, infec-
ted hepatocytes burst open and release several thousand meorzoites into the blood stream. It
is these merozoites which infect erythrocytes where they continue to replicate exponentially
with an infection to cell rupture period of 48 hours. This phase of malaria infection is re-
ferred to as blood stage; the symptomatic phase of the disease is associated with it. Within
erythrocytes, merozoites can undergo either asexual expansion or choose to differentiate into
sexual gameotcytes. These are then again taken up by Anopheles mosquitoes during blood
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meals. Sexual reproduction within the mosquito host eventually leads to the production of
new sporozoites, thus completing the life cycle [Hafalla et al., 2011, White et al., 2014].
Because of their early position within the human fraction of the malaria life cycle, sporozo-
ites are an attractive target for vaccine development attempts. As early as 1967 it was shown
that sterile protection against live sporozoite challenge could be established by vaccinationwith
radiation-attenuated Plasmodium berghei sporozoites in rodents [Nussenzweig et al., 1967].
Subsequently, circumsporozoite protein (CSP) - the antigen depicted in figure 2.3b - was iden-
tified as the major sporozoite surface protein and it could be shown that monoclonal antibodies
against CSP blocked hepatocyte invasion in Pf and P. vivax [Hollingdale et al., 1984]. CSP con-
sists of three structural domains: between N-terminal and C-terminal domain, a central region
consisting predominantly of several repeats of the amino acid sequence NANP is placed [Dame
et al., 1984]. Albeit with varied length, this repeat region is highly conserved between Pf strains
[Zavala et al., 1983], thus increasing its attractiveness as a vaccine target. The current leading
malaria vaccine candidate RTS,S AS01 (tradenameMosquirix) contains 18.5 NANP repeat units
as well as the C-terminal domain of CSP with the aim of inducing protective antibodies [Neaf-
sey et al., 2015]. Recent phase 3 clinical trials in different age groups in endemic regions have
however resulted in overall low protection between 25 % and 55 %without long-term protection
[Neafsey et al., 2015, Olotu et al., 2016].
Tübingen Controlled HumanMalaria Infection Trial The blood samples analysed in the
experimental work underlying this comparison are derived from a malaria immunisation trial,
the Tübingen Controlled Human Malaria Infection Trial, in which sterile protection against Pf
was induced using a chemoattenuated Pf sporozoite vaccine. All details are given in [Mord-
müller et al., 2017]. In brief, aseptic, purified, cryopreserved, non-irradiated sporozoites where
administered to malaria-naïve, healthy adult volunteers by direct intravenous inoculation.
While [Mordmüller et al., 2017] present result for several doses and vaccination schedules,
the data discussed in the following is derived from a protocol in which 5.12 ⋅ 104 sporozoites
were injected three times at intervals of 28 days under chloroquine antimalarial chemopro-
phylaxis. Blood used in the study discussed below was collected seven days after each of these
infections (see figure 4.1a). As tested by a controlled infection with a lower dose of sporozoites
in the absence of chloroquine ten weeks after the last dose, the immunisation process preven-
ted blood stage infection in all nine participants.
Single-cell processing ofmemory B cells The full experimental proceedings are discussed
in [Murugan et al., 2018] and [Murugan, 2018] and summarised in figure 4.1b. In brief, single
CSP-binding memory B cells (7AAD−CSP+CD19+{IgG or CD27}+) and antigen-unspecific plas-
mablasts (7AAD−CD38+CD27+CD19+) were isolated from suspensions of peripheral blood
mononuclear cells from eight out of the nine study participants using flow cytometry with
index sorting. Immunoglobulin (Ig) heavy, 𝜅 and 𝜆 chain genes were amplified using a high-
throughput robotic platform employing a nested matrix polymerase chain reaction with bar-
coded primers [Tiller et al., 2008, Murugan et al., 2015, Busse et al., 2014] and the resulting
amplicons were sequenced using 454 GS FLX+ (Roche) or MiSeq 2 × 300–base pair (bp) paired-
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(c) Comparison of three representatively sampled donors with model outcomes. H - Shannon’s entropy,
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Figure 4.1.: Controlled human malaria infection trial, experimental processing and comparison
of data and model statistics.
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end (Illumina) sequencing. Only wells with paired full-length functional Ig heavy and light
chain gene sequences were analysed and matched with index-sorting information using the
bioinformatics platform sciReptor [Imkeller et al., 2016]. Recombinant monoclonal antibodies
were generated in human embryonic kidney cells [Tiller et al., 2008]. These antibodies were
purified and their reactivity and affinity were measured using enzyme-linked immunosorb-
ent assays (ELISA) against 10-fold repeats of NANP (NANP10) and surface plasmon resonance
(SPR) with NANP5, respectively. Protective efficacy of antibodies was tested using a Pf SPZ
hepatocyte traversal assay [Sattabongkot et al., 2006, Triller et al., 2017]. All experiments were
performed by Rajagopal Murugan and colleagues from the Division of B Cell Immunolgy lead
by Hedda Wardemann at the DKFZ in collaboration with Elena Levashina and colleagues at
the Vector Biology Unit of the Max Planck Insitute for Infection Biology in Berlin.
4.2. Comparison of Experimental Data and Computational
Model
As described above, a comprehensive set of information at the single-cell level was collected
on B cells following each of the three vaccinations during the malaria immunisation trial out-
lined in section 4.1. In addition to the cell phenotype, its clonal belonging derived from its
antibody gene sequence as well as antibody affinity are known. In the following, this wealth
of experimental information will be compared to observations and predictions generated with
the model introduced and analysed in chapter 2 and 3.
Matching dynamics As an initial test, basic characteristics of the experimentally sampled
memory B cells from three comprehensively sampled donors were compared to the model (fig-
ure 4.1c.) All model parameters used for the comparison are the default values shown in section
2.A with an antigenic complexity of 𝑛key = 10 because the recently published crystal struc-
tures of two different antibody-CSP binding interfaces suggest complicated binding modes
with many contacts [Triller et al., 2017]. First of all, we analyse the number of memory cells
in each sample. For normalisation, the computational sample size was scaled using the mean
experimental sample size at the second time point and decorated with Poisson noise. Sample
sizes at time point II are on the order of 100 cells. We have previously seen in figure 3.3c that
the size of the modelled memory pool increases with each infections as germinal centres help
expand the population. Figure 4.1c shows that the dynamics of this increase agree well with
the number of memory B cells found in the experimental samples from three representative
donors with prominent anti-Pf CSP response. The same goes for the average number of hyper-
mutations identified in the variable segments. It may at first seem surprising that there is no
significant increase in mean mutation number over the course of the three time points neither
in the model nor the experiment and reasons for this observation will be discussed below. The
lower two panels of figure 4.1c are concerned with the diversity of the samples. The decreasing
clonal entropy of the full simulated memory pool was previously shown in figure 3.3d and this
behaviour passed down to a smaller sample. Experimentally, a similar degree of clonal expan-
sion with concomitant diversity loss is observed.
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Overall, these simple comparisons underline that large agent-based models like the one at
hand have the ability of integrating a vast pool of experimental knowledge in a useful way. The
fact that themodel builds onmore than 25 parametersmay seem disconcerting at first, however,
almost all of these parameters are available in the experimental literature and there is thus no
need to allow free variation. Such modelling approaches can therefore be viewed as a method
of reassembling biological complexity which has had to be taken apart experimentally in order
to determine individual quantities. A bottom-up approach of this type can help understand
processes in complex systems whose individual components have already been quantified.
Intra- and interclonal affinity improvement We have previously observed that the con-
tribution of hypermutations to overall affinity improvement can be minor in comparison with
clonal selection in section 3.3. In the model as well as in the experimental data, mutational ef-
fects within individual clones can be examined in addition to the bulk dynamics. A small subset
of four individual clones each is shown in figure 4.2a which gives the affinity of individual B
cells as a function of their mutational status. It becomes apparent that the textbook logics as
shown in figure 2.1, where more hypermutations in general mean more affinity does not apply
to this case. Overall, computationally as well as experimentally, strong improvements within
B cell clones are scarcely observed at this level of binding complexity albeit larger jumps do
occur. In the majority of cases, clones retain a strong memory of their germline ancestor’s
affinity towards the antigen and do not change it significantly over the course of many base
pair replacements.
Instead of focusing on the mutational changes of affinity within individual clones, figure
4.2b shows the mutational status of the entire sampled memory pool from one representative
simulation in the computational case and all eight donors pooled in the experimental case. Fo-
cusing on the model prediction first, the sample contains no high-quality binders at the first
time point (seven days after infection I) althoughwe know that they are present in themodelled
repertoire by design. However, their frequency in the population is too low at this point in or-
der to reliably appear in small samples. Moving on to the second time point, high-affinity cells
suddenly appear at the lowly mutated end of the spectrum. The colour code applied to the dots
representing single cells indicates whether the sampled memory cell derives from an ancestor
that was recruited into the response from the naïve compartment (red) or from the popula-
tion of pre-existing memory cells (grey). This shows that the newly appeared high-affinity
cells with low mutation frequencies overwhelmingly stem from naïve ancestors. Following
the third exposure, this population is expanded further and slowly starts to acquire low levels
of hypermutations. Underlying these observations is the avalanche effect (section 3.3) - only a
few good precursors need to be activated in order to multiply them into strongly contributing
populations after two or three vaccination shots. Strong mutational effects are not required for
improvement at the population level if such precursors are present. Moving on to the experi-
mental data plotted in the same way in the lower panels of figure 4.2b, the model prediction is
precisely confirmed. Even though no high-affinity cells are sampled at time point I, increasing
numbers of lowly mutated strong binders appear after the second and third vaccination.
Another curiosity appears when examining the single-cell affinity as a function of muta-
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Figure 4.3.: Affinity as a function of mutational state similar to figure 4.2b. However, donors are
shown individually here while all time points and clones are pooled. Each dot/circle
represents one monoclonal antibody. bp - base pair. Data: Rajagopal Murugan.
tional state for each of the eight patients individually (figure 4.3). Here, all cells from all three
time points were pooled. It becomes apparent that the selection-based avalanche process out-
lined in the previous paragraph only worked in half of the participants. While the donors
{D42, D71, D72, D73} show the described expanded population with strong affinity and few
mutations, this is not the case in donors {D17, D26, D35, D51}. These donors have mostly low
affinity B cells distributed over the entire spectrum of hypermutation states. Looking back
at the modelled repertoire distributions in figure 3.6b, specifically at the scenario where no
good precursors for efficient selection are available, this is what would expected: an overall
low quality of the response with few better candidates emerging late while the majority of cell
has trouble mutating away from its germline ancestor’s affinity even with a high number of
mutations.
It is important to point out that all eight donors developed fully protected from infection in
the sporozoite challenge. First of all, analysis here focused on the central region of CSP, an
important and predominant surface antigen with functional implications, but by no means the
only surface antigen of Pf sporozoites. It is conceivable that the remaining donors developed
immunity against another part of CSP or even against another surface antigen because their
precursor repertoire was better equipped for these tasks. Additionally, it is a matter of cur-
rent debate which branches of the immune response are mainly responsible for anti-malaria
immunity and/or whether this may differ from patient to patient. The efficacy of anti-CSP an-
tibodies for preventing infection has however been demonstrated [Triller et al., 2017, Murugan
et al., 2018].
Finally, it is of interest to put these results into the context of the lower-dose variants of
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the TUCHMI trial [Mordmüller et al., 2017] and also the outcomes of long-term natural expos-
ure [Triller et al., 2017]. In the first case, the same vaccination schedule using 4 and 16 times
less sporozoite induced protection in six out of nine and three out of nine donors respectively.
This is in line with the finding presented here that an avalanche effect driven by high antigen
doses for selection and subsequent mixing could be underlying affinity improvement processes
against CSP. In the second case, the authors find that even after long-term natural Pf expos-
ure of adults in Gabon only a weak anti-CSP B cell memory developed. They further examine
two affinity matured NANP-reactive memory B cell antibodies and find that repeat recognition
was mostly mediated by germline encoded antibody features. Hypermutations in turn lead to a
stabilisation of the binding interface. A major difference between the vaccination scenario de-
scribed above and the natural exposure is the number of sporozoites on display to the immune
system, the number in natural infections being as low as 20 [Yuda and Ishino, 2004]. This in
combination with the short time that sporozoites are available for immune recognition before
homing to hepatocytes may promote their immune-escape and hinder the activation of suffi-
cient B cells. It may also explain why, even though in general malaria has strongly shaped the
human genome in regions where it is endemic [White et al., 2014] and supposedly vice versa,
sporozoites remain vulnerable to antibodies encoded in the germline. Because of the short ex-
posure at low concentration, there may not have been sufficient evolutionary pressure on the
parasite’s genome for removing this vulnerability. Repeated long-term exposure in endemic
regions may eventually compensate for these deficits and contribute to the partial immunity
often found in their inhabitants.
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In this thesis, a flexible computational model of the humoral immune response has been de-
veloped. This model allows to vary and explore the effects of a vast range of biologically in-
terpretable parameters connected to characteristics describing specific pathogens, patients or
vaccination processes. To this end, the model integrates quantified experimental knowledge
from several decades of research on B cell biology, germinal centres and antibody-antigen in-
teraction. Using a newly developed binding model combining advantages of shape-space and
NK-type binding models, the simulation introduced here allows to vary epitope complexity
in an intuitively accessible way. Additionally, a novel method for visualising selection and
mutation effects in simulated germinal centres is introduced and facilitates understanding and
comparison to experimental observations. Using this computational model, we have been able
to disentangle mutation and selection effects both at the level of individual germinal centre
reactions and at the level of the resulting memory B cell population. The importance of the
thus predicted avalanche effect could be demonstrated in a direct comparison to experimental
data from a malaria vaccination study. The complete computational framework is available at
https://github.com/LiBuchauer/gc_memo.
Modelling Diverse Challenges within a Unified Framework In chapter 2, we have in-
troduced a new computational model of the B cell immune response in detail. The necessity
for this new approach is inferred from the observation that affinity maturation, the process of
B cell affinity improvement via somatic hypermutation mostly in germinal centres, does not
function with equal efficiency for all antigens. While anti-hapten responses routinely lead to a
small number of characteristic beneficial mutations, the same is not observed when analysing
matured repertoires against more complex pathogens where larger proteins are targeted by
the immune system. Because of this, we have abstracted the binding interface between anti-
gen and antibody into a set amino acids chiefly responsible for determining relative binding
strengths. This set is of size 𝑛key, a crucial quantity taking low values for structurally simple
binding problems with fewer contacts and higher values for larger binding interfaces typically
observed in protein-protein binding.
Akin to shape-space models, our binding model essentially derives affinity from matching
two sequences against each other. However, instead of taking arbitrary symbols and evaluat-
ing matches, our model uses the 20 physiological amino acids and binding strength is assessed
using true energy-like quantities derived from a study on folded proteins [Thomas and Dill,
1996]. This, together with the codon-based mutation procedure implemented here, makes our
model more realistic as it introduces the conservatism of the genetic code into the challenge of
improving affinity mutationally. The genetic code has evolved to guarantee maximal stability
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in the face of random mutations; this property is necessarily also part of affinity maturation
in germinal centres. Single base pair replacements lead to replacement by the same or a func-
tionally similar amino acid much more frequently than in a random replacement model. In
the context of desired mutations in the germinal centre, this provides a dampening factor on
affinity diversification.
A general flaw of sequence-based binding models that evaluate pairwise interactions only is
that they have a single optimal solution in sequence space and smooth mutation paths lead to-
wards it. This is biologically not realistic because of epistatic effects in protein-protein binding
situations: amino acid replacements happening outside of the actual binding site can never-
theless affect binding quality because of resulting structural changes. Our model incorporates
this threat by allowing non-lethal mutations to the scaffold region to exert blocking effects on
the binding strengths of the antibody: if a blocking mutation is present in the scaffold region,
the antibody is no longer able to affinity mature via key region mutations. Taken together, the
codon-based mutation model, the binding energy-based binding model and the introduction
of mutations blocking affinity maturation via long-range effects represent improvements to
existing shape-space models because the resulting situation is closer to the reality of evolution
in affinity maturation.
Our dynamic model of individual germinal centre reactions builds on a cycle of stochastic
competition for survival signals based on antigen affinity, receiving these signals via Tfh con-
tact, division and reentry into the competition process or differentiation into a peripheral ef-
fector cell type. Importantly, we allow the colonisation of new germinal centres not only by
naïve cells but also by pre-existing memory B cells. As B cell identities are defined by their key
region sequence alone in our model, there is no reason why pre-existing memory cells from
unrelated infections should not be able to participate in a new primary infection. Thus, the
participation of mutated memory cells in addition to fresh naïve cells is part of the model and
indeed the participation of highly mutated memory cells in primary exposures of European
donors to Plasmodium falciparum is observed experimentally (see also section 4). Concerning
seeder cells, our model differs from most recent germinal centre simulations in that it picks up
on the experimental finding that on the order of hundred different B cell clones likely seed a
germinal centre upon formation [Tas et al., 2016]. In our model, the number of actual seeder
cells depends on their concentration in the entire B cell pool as well as on the antigenic dose
chosen for the simulation: more antigen increases the probability of activation for every ex-
isting B cell. Building on these straight-forward assumptions, we have shown that number of
seeder cells has a strong impact on the final quality of the memory B cell pool. This indicates
that individuals partly or completely lacking strong precursors have decreased likelihood of
developing protective vaccine responses.
While we provide experimentally backed suggestions for the choice of default parameters,
each parameter can be varied computationally and often such exploration is biologically mo-
tivated. As examples, the size and lifetime of germinal centres may depend on specifics of
the antigens towards which they develop. If information about such properties is available,
incorporating it into the simulation can help to find mechanistic explanations for observed
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outcomes. An example is given by the vaccination study examined in chapter 4, where shorter
germinal centre lifetimes are implemented because of the pathogen’s life cycle - as a result, the
decreased time window available for mutational changes contributes to the weak intraclonal
improvement observed within B cell clusters over time.
Joint Action of Individual Players In contrast to a real life situation, a computational
model allows access to all simulated processes at a high resolution. Here, we have developed
an intuitive depiction of clonal selection and mutation processes during germinal centre reac-
tions on top of the underlying simulation. These figures illustrate how germinal centres set
out with a diverse repertoire of seeder cells which is consecutively narrowed down to one or a
few clones because of stringent selection by Tfh cells and resulting expansion. The mutational
effects occurring throughout the process are mirrored by the memory cell output produced by
the reaction. An analysis of this output shows how, initially, the mean quality of newly pro-
duced memory cells increases quickly as selection acts upon the diverse seeder pool. However,
the speed of improvement is reduced or even stalled once mono- or pauciclonality is reached
and further improvements need to be brought about by mutations.
Mutational improvement is more strongly affected by stochastic effects than is selection. We
have shown that individual germinal centre reactions under similar conditions (same dynam-
ics, same epitope complexity, similar number of seeder cells) can lead to varying outcomes -
while a set of beneficial mutation is discovered in one reaction and becomes fixed in its popula-
tion, another germinal centre remains at low affinity over its entire time course. This outcome
diversity is reduced by increasing the number of seeder cells, as this shifts the burden of popu-
lation improvement from the inefficient mechanism of mutation to the more reliable workings
of selection. Analysing different antigen complexities, we have shown that this is especially
important for antigenic challenges with higher numbers of key residues jointly determining
affinity. Because the mutational randomwalk proceeds in higher-dimensional space here, find-
ing the optimum is a more difficult endeavour. The efficiency of selection on the other hand
is unaffected by the increase in complexity. Thus, clonal selection from a sufficiently rich pre-
cursor repertoire outpaces affinity maturation by somatic hypermutation in cases of complex
binding interfaces.
In order to understand physiological B cell reactions which rely not only on one but on
several hundreds or thousands of germinal centres at different sites in the body, we have em-
bedded on the order of 100 individual germinal centre simulations within a joint pool of free
B cell objects. This allows to explore effects emerging from the presence of several weakly in-
teracting sites of affinity maturation. Investigating a vaccination schedule comprised of three
consecutive immunisation shots at intervals of four weeks, we have found that repeated expos-
ures are important for further reduction of stochastic activation, selection andmutation effects.
We have identified the underlying mechanism to work as follows: individual strong binders
present at very low frequency in the naïve or pre-existingmemory precursor repertoire become
activated during the first exposure and succeed to join one or a few of the hundred available
germinal centre reactions. Within this reaction, they become expanded to occupy 𝒪(1/100) of
the newly generated memory pool, a much enhanced fraction compared to their previous pres-
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ence. During the following immunisations, in the case that general activation is high enough,
the probability that a member of this high-affinity clone joins each new reaction as a seeder
increases. Consequently, its expansion is amplified. We show that even in the complete ab-
sence of somatic hypermutations, multi-exposure selection processes can produce high-quality
memory pools. Notably, this situation is strongly preferred over one with working hypermuta-
tion but suffering from total absence of good precursors.
As briefly discussed in chapter 4, following the second and third immunisation, members
of individual clones occupy much higher fractions of the total memory repertoire than could
be explained by expansion in a single GC alone. This provides experimental confirmation of
the theoretically predicted avalanche effect. Importantly, we predict that the magnitude of this
multiplication effect is dependent on the strength of activation and thus on antigen dose, as this
is not only crucial for initial activation of rare good precursors but also for sufficient mixing of
seeder cells during booster vaccinations. During the malaria vaccination study underlying the
experimental data in chapter 4, lower vaccination doses were tested likewise [Mordmüller et al.,
2017]. However, they did not lead to protection in all subjects. The relevance of high doses
for precursor activation and exploitation of the avalanche effect may in part explain this result.
The Importance ofMaintainingDiversity Whydoes the size of individual germinal centres
not exceed a few thousand cells physiologically? Might it not be beneficial to focus competi-
tion at one given site instead of having a distributed system of several hundreds or thousands
of reactions? As part of a parameter sensitivity analysis we have found that larger germinal
centres lead to higher mean affinities in the memory cell pool: At one centralised site, an indi-
vidual B cell outcompeting all peers could hence be expanded much more efficiently. However,
we have also looked at inter- and intraclonal diversity within both individual germinal centres
and the entire population. While clonal selection quickly reduces the number of clones present
within a reaction, the actions of somatic hypermutation increase the number of different bind-
ing regions present. Thus, the increase of intraclonal diversity bymutation counteracts to some
extent the clonal focus introduced by selection. In our model, the amino acids with less relev-
ance for the binding process at hand are not modelled specifically and mutations happening
within this scaffold area are merely counted. It is therefore impossible here to evaluate the
diversity increase introduced into the entire sequence, but it is certain that overall sequence
diversity is maintained at an even higher level compared to key region diversity alone because
no selection acts on it. What has been discussed for individual germinal centres is likewise
true a population level, where clonal entropy decreases with each additional vaccination shot,
largely due to the avalanche effect described above.
Based on theoretical as well as experimental observations, we have argued that memory
cells stemming from unrelated previous infections are likely to be recruited into current B cell
responses. Is it thus obvious why maintenance of repertoire diversity is beneficial - instead of
filling the entire available memory B cell niche with exact duplicates of a high-quality binder,
having variations of this cell with very similar affinity is a more promising strategy when
looking at potential future threats. While variations within the key binding region may be
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particularly relevant for related antigens such as mutational variants or regionally different
strains, variability within the entire sequence could be relevant for protection towards com-
pletely unrelated threats. These may bind to the antibody in a different way at a different po-
sition on its three-dimensional structure thus defining new key amino acids. Taken together,
it is likely that maintaining diversity, even though mostly treated as the poor cousin of im-
proving affinity, is a major reason for somatic hypermutation in germinal centres. Germinal
centres enable strong selection and expansion and can therefore put the diversity of the host’s
memory B cell repertoire as a whole at risk. Here we have shown that there are cases in which
the affinity-improving effects of somatic hypermutations are minimal; at the same time, their
diversification benefits remain present.
In an evolutionary light, this interpretation of the workings of affinity maturation could
have lead to an optimal germinal centre size. While we have shown that a set of larger ger-
minal centres produces a memory B cell pool of higher quality, it also leads to decreased clonal
diversity overall. At the same time, having a higher number of germinal centres naturally
increases this diversity. As a third level, vaccination strategies comprised of several immun-
isations as well as repeated natural exposures likewise lead to a progressive reduction of clonal
diversity with concomitant affinity increases. Based on our model we have found that even
during avalanching scenarios where the same strong clone is distributed to all germinal centre
sites, this clone does not necessarily take over in all of them because of stochastic selection and
mutation effects. In combination, while large germinal centres and repeated exposure increase
affinity, having a highly distributed system guarantees diversity.
Addressing Inter-Patient Variability In section 3.3 we have shown that differences in pre-
cursor repertoires between individuals can strongly influence vaccination success. While a
triple-shot vaccination protocol is highly efficient in amplifying initially rare cell populations
and can lead to decent final repertoires even without mutational help, the picture is less rosy
if such precursors are absent. Here, mutation remains as the only road to better B cells, and
in the case of high-complexity antigens this path requires a long time and constant simula-
tion. The importance of efficient precursor identification and amplification could be confirmed
experimentally in chapter 4 by analysing single-cell affinity as a function of mutational state
over time. Additionally, looking at the same measure within individual participants of the vac-
cination trial revealed evidence for differing precursor repertoires similar to theoretical cases
(with and without good precursors) described above: while some donors seem to have identi-
fied a high-quality low-mutated population early on in the protocol and then go onto expand it,
others failed to produce good CSP-binders over the entire period of the trial even though their
weak binders display up to 60 base pair mutations compared to germline by the end of the trial.
While the existence of differing vaccination outcomes has been known for a long time, an
understanding at this level of detail, where single-cell sequencing data is brought together with
affinity measurements of monoclonally expressed antibodies as in [Murugan et al., 2018] are
a recent development. In combination with functional assays and crystal structure analyses
of antibody-antigen complexes they have the potential to drive rational vaccine development.
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Focusing on differences between human subjects, it may become possible to develop person-
alised vaccination strategies in the future. Following the identification of a protective B cell
epitope on the antigen under examination, a thorough analysis of the binding interface and
the effect of individual mutations can produce an estimate for the complexity of this interface
and the resulting challenges for somatic hypermutation. More importantly, with increasing
availability and decreasing cost of single-cell methods like antigen-specific flow cytometry or
immunoglobulin gene sequencing methods it may become possible to routinely query the pre-
cursor repertoire of each individual and develop an optimal vaccination strategy based on the
result. If the person has a precursor repertoire containing many useful B cells for the prob-
lem at hand, low activation doses and fewer vaccinations may be sufficient for full protection,
while in cases with worse starting conditions, higher doses, longer intervals and also more
immunisations may be required. Vaccine administration, specifically in the case of expensive
vaccines, could thus be optimised both in economic terms and regarding comfort of the patient.
Additionally, in cases where several protective vaccine targets are known, a prior screening of
the available repertoire may allow an informed choice of vaccine composition thus making
optimal use of the given boundary conditions. Computational models like the one introduced
here and enhanced with specific information concerning antigen and patient on a case-to-case
basis will help to identify optimal schedules in this vision of the future.
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Part II.
Stem Cell-Driven Glioblastoma
Growth
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Und ist schon jemals ein Ziegel so vom Dach gefallen, wie es
das Gesetz vorschreibt? Niemals! Nicht einmal im
Laboratorium zeigen sich die Dinge so, wie sie sein sollen.
Sie weichen regellos nach allen Richtungen davon ab, und es
ist einigermaßen eine Fiktion, dass wir das als Fehler der
Ausführung ansehen und in ihrer Mitte einen wahren Wert
vermuten.
— Robert Musil, Mann ohne Eigenschaften
In the second part of this thesis, a mathematical model of glioblastoma growth is developed
based on qualitative experimental observations. All parameters of this model are thereafter
estimated based on quantitative experimental data; finally, the quantified model is used to pre-
dict and understand further experimental observations not used for parameter estimation.
Chapter 6 provides a rough overview of the fields of both mouse models and mathematical
models in glioblastoma research with a slight focus on brain cancer stem cells. Data analysis
begins in chapter 7, in which experimentally observed tumour growth curves are analysed with
phenomenological models and a simple three-dimensional simulation of tumour growth is de-
veloped. Chapter 8 takes mathematical modelling from the phenomenological to the mechan-
istic level by introducing a system of differential equations describing the different behaviours
of brain tumour stem cells and their progenitors. This basic model is then modified to describe
a vast set of experimental observations; ultimately, division, differentiation and death rates of
the various cellular phenotypes are estimated. Based on this quantified model, chapter 9 intro-
duces advanced experimental procedures including cancer treatments and single-cell labeling
approaches and how their outcomes can be predicted as well as interpreted in the context of the
simple description from chapter 8. Finally, an integrative discussion of all results is provided
in chapter 10.
All experimental work described in the following chapter was performed by Muhammad
Amir Khan, Yue Zhuo and Peng Zou in the Division of Molecular Neurogenetics (DKFZHeidel-
berg) headed by Hai-Kun Liu.
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6. Background - Cancer Stem Cells in
Glioblastoma
In this chapter, the frame for the scientific work following in chapters 7, 8 and 9 is set by
giving background information in three major areas. Section 6.1 introduces the malignant
brain tumour glioblastoma, its properties as well as general mouse model techniques used to
explore it; section 6.2 discusses mathematical modelling attempts to stem-cell driven cancers,
three-dimensional solid tumours and to glioblastoma more specifically; and section 6.3 gives
details of experimental techniques and mouse models used in the laboratory of Dr. Hai-Kun
Liu at the DKFZ and thus directly underlying this work.
6.1. Glioblastoma Multiforme
The aggressive brain tumour Glioblastoma multiforme, its most prominent pathological and
genomic characteristics and its response to treatment efforts are roughly introduced in section
6.1.1. As basic as well as applied research into this topic relies heavily on mouse models, the
most important forms of brain tumour mouse models are discussed briefly in section 6.1.2.
Finally, in section 6.1.3, the notion of cancer stem cells, specifically in the neural context, is
defined and the clinical relevance of the concept is described.
6.1.1. Epidemiology and Pathology of Glioblastoma
Tumours of the central nervous system comprise heterogeneous groups of benign and malig-
nant neoplasias, most of which are of glial origin and thus called gliomas [Ohgaki and Kleihues,
2005]. According to the specific type of glial cell these tumours originate from, a further differ-
entiation into astrocytic, oligodendroglial and ependymal as well as hybrid forms is possible
[Louis et al., 2007].
Prognosis and Pathological Features Among gliomas, the high-grade astrocytoma, also
calledGlioblastomamultiforme (GBM), is the most prevalent and aggressive form - about 45% of
all gliomas fall into this category in which relative 5-year survival rates are below 5% [Ostrom
et al., 2014]. Glioblastomas are characterised specifically by active angiogenesis, pseudopalis-
ading necrosis and diffuse invasion into neighbouring brain tissue [Louis et al., 2007]. Although
glioblastoma cells tend to migrate between brain hemispheres thus often causing a symmet-
ric lesion also referred to as “butterfly glioblastoma” [Dziurzynski et al., 2012], extracranial
migration is rare [Schweitzer et al., 2001].
Glioblastoma Genome In a comprehensive attempt at identifying common genomic char-
acteristics of glioblastoma, an international consortium of scientists (The Cancer Genome Atlas)
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analysed DNA copy number, gene expression and DNA methylation aberrations in 206 glio-
blastomas and additionally looked at sequence aberrations in 91 out of these [McLendon et al.,
2008]. Overall, 90% of glioblastoma patients carried at least one amplification or mutation in
receptor or downstream kinase genes such as EGFR, PDGFR or PIK(3)K or, alternatively, a
deletion or mutation within inhibitor genes of these kinases such as PTEN. The most abund-
ant disturbed pathway was the p53 pathway with alterations (deletion or mutation in TP53 or
amplification of proteins inhibiting p53) ocurring in 86% of subjects. In addition to these path-
ways commonly associated with well-regulated cell cycling and survival, deletion or mutation
of NF1 was observed in 23 % of cases. Significant evidence for NF1 being a tumour suppressor
had previously been found in mice, although its role in human remained under debate. This
finding underlines the importance of large-scale collaborative efforts for the extraction of ro-
bust statistics from comprehensive data sets and the subsequent identification of potential drug
targets.
Treatment The standard of care for glioblastoma comprises surgical resection, radiotherapy
and administration of the chemotherapeutic temozolomide (TMZ) [Stupp et al., 2005,Malmström
et al., 2012]. As a result of longitudinal studies, it has been reported that TMZ treatment leads to
greatly increased numbers of mutations in the relapse tumour compared to the primary sample
[Choi et al., 2018]. Interestingly, a longitudinal genomic study of 114 patients, in which only
15% showed hypermutation signatures at relapse, finds evidence for highly branched tumour
evolution [Wang et al., 2016]. Notably it is estimated that most tumour clones dominating the
relapse typically existed years before diagnosis, indicating that while they may not have been
competitive in the original setting, a potentially higher resistance to treatment allowed them
to reconstitute the regrowth.
Overall, in spite of many conceptual advances in the field of glioblastoma research during
the last decades, a significant improvement of patient survival rates remains wanting. Next
to genetic diversification during treatment as outlined above, a major roadblock is the high
invasiveness of glioblastoma cells. They are highly motile, able to detach themselves from the
tumour bulk either individually or in small groups and travel easily among various brain struc-
tures. The resulting satellites cannot be reliably distinguished from the surrounding healthy
tissue during operation or using magentic resonance imaging [Louis et al., 2007]. Thus, fur-
ther investigation of the properties of migrating cells, the characteristics of potential functional
subtypes within the tumour bulk as well as associated molecular targets is necessary.
6.1.2. Glioblastoma Mouse Models
Murine cancer models in general represent a useful tool for basic cancer research and pre-
clinical drug study as they, in contrast to in vitro settings, capture complex aspects of human
neoplasias including tissue-defined space constraints, vascularisation and invasion of host im-
mune cells. Two major groups of mouse models for cancer and specifically for glioblastoma
are available: xenograft models and genetically engineered models. Both types are introduced
briefly in the following.
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Xenograft Models Xenograft models are further subdivided into two categories, cell-line-
derived (CDX) and patient-derived xenograft (PDX) models. The former rely on human or
mouse cell lines which are implanted into selected organs of immunocompromised mice. CDX
models are fairly easy to establish and have been key to the identification of a number of cyto-
toxic drugs [Day et al., 2015]. Specifically in glioblastoma, important histopathological features
could be recapitulated using cell lines, among them infiltrative invasion into the brain paren-
chyma, palisading necrosis and angiogenesis [Camphausen et al., 2005, Wachsberger et al.,
2005]. However, CDX models are frequently of little help in predicting outcomes of more ad-
vanced treatment strategies as they do not depict the entire heterogeneous complexity of a
natural tumour and its immune- and microenvironments [Day et al., 2015].
Patient-derived xenograft models overcome part of these issues as intact tumour tissue pre-
serving tumour architecture is directly implanted into immunocompromised mice [Hidalgo
et al., 2014]. The additional step of in vitro selection and homogenisation is omitted. Examples
of the use of PDX models in glioblastoma research include testing the efficacy of therapeutic
antibodies [Reilly et al., 2015] and a study of emerging resistance against radiotherapy and te-
mozolomide [Anderson et al., 2014]. In laboratory practice, the applicability of this method is
limited by the availability of fresh biopsy tissue. Although experimental cohorts can be expan-
ded by serial transplantation, the resulting tumours become successively less representative of
the original setting [Day et al., 2015].
Genetically Engineered Models Another possibility of in vivo tumour study is offered by
genetically engineered mouse models (GEMMs), in which techniques manipulating the mouse
genome are exploited to introduce driver mutations into specific tissues. In general, these mod-
els provide a good approximation of cancer development as tumours can be followed from ini-
tiation through progression while being immersed in intrinsic stroma and a working immune
system. If treatment is administered, evolution under potential treatment-induced selection
pressure can additionally be studied. Both germline and non-germline GEMMs are available.
Germline GEMMs are mouse lines which are engineered to harbour a genetic modification
such as an overexpression of oncogenes or the silencing of tumour suppressors in the germline.
These modifications may be constitutive or inducible (for example via the Cre-LoxP system)
and are passed on through breeding. Examples of mouse lines developing glioblastoma or
other types of glioma include heterozygous mice carrying null mutations in both TP53 and
NF1 [Reilly et al., 2000] and mice carrying a null mutation of TP53, a homozygous deletion of
NF1 as well as a heterozygous deletion of Pten [Kwon et al., 2008]. Next to the considerable
investment necessary for developing a germline mouse model, inducible systems additionally
have the disadvantage of reserving the induction process for triggering driver mutations, thus
blocking the possibility to investigate other gene functions this way.
Finally, in non-germline GEMMs oncogenes or silencing constructs for tumour suppressors
are delivered into somatic cells by viruses. In this way, delivery can be site-specific, and mul-
tiple genes can be introduced into the host genome at once. In glioblastoma, approaches using
viral transduction have been successful. A method using the RCAS/Tva-system is employed in
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the experimental work underlying this study and is further described in section 6.3.1. Alternat-
ively, DNA can be transfected non-virally, an approach which has been used increasingly since
the introduction of CRISPR/Cas9-based tumour models. Here, double-strand breaks induced
at specific genomic sites can be repaired using genetic material from a donor vector. Examples
of mouse model tumours induced this way include myeloid malignancies [Heckl et al., 2014],
liver tumours [Xue et al., 2014] and also glioblastomas [Zuckermann et al., 2015].
6.1.3. Cancer Stem Cells in Glioblastoma
Stem cells in general are defined as undifferentiated cells which are able to self-renew as well as
to produce more differentiated cell types [Tannishtha et al., 2001]. In order to fulfil these tasks,
stem cells can make use of symmetric as well as asymmetric division [Morrison and Kimble,
2006].
Adult Stem Cells While embryonic stem cells eventually give rise to all of the several hun-
dreds of cell types in the human body, adult stem cells are more restricted in their possible
fates. In contrast to embryonic stem cells, they are found in the body throughout the entire
life of an organism and take care of replenishing tissue populations that are lost due to routine
turnover. In addition, they are often capable of reconstituting damaged tissue by symmetric
division and thus self-multiplication in the case of damage. A tissue may contain more than
one type of stem cell as defined by the landmark capabilities of being self-renewable and giv-
ing rise to (several) differentiated cell types [Goodell et al., 2015]. Starting from the 1980s,
one or several types of tissue-specific stem cells were identified, isolated and characterised in a
variety of organs including hematopoietic system [Spangrude et al., 1988], intestine [Bjerknes
and Cheng, 1999] and epidermis [Oshima et al., 2001, Blanpain et al., 2004]. In these examples
as well as more generally, maintenance of stemness as well as stem cell number homeostasis
are tightly linked to the existence of a stem cell niche, a cellular microenvironment nurturing,
protecting and commanding its stem cell inhabitants [Moore and Lemischka, 2006].
Normal Neurogenesis In the mammalian brain, first evidence for continued production of
neurons and astrocytes throughout adult life was uncovered in 1992, overwriting the previous
belief that neurogenesis in the mammalian central nervous system came to an end in infancy
[Reynolds and Weiss, 1992]. It has since been found that adult neurogenesis takes place in
restricted brain regions, notably the subgranular zone (SGZ) in the dentate gyrus which pro-
duces dentate granule cells and the subventricular zone (SVZ) which generates neurons that
subsequently migrate to the olfactory bulb [Doetsch et al., 1999, Ming and Song, 2011]. In the
SVZ, radial glia-like cells (also called B cells in this context) lie at the apex of the stem-cell hier-
archy. They give rise to oligodendrocytes as well as to transit amplifying cells (C cells) which
in turn produce neuroblasts (A cells). These then migrate to their final destination and become
mature neurons, also called interneurons. It is unclear whether astrocytes derive directly from
B cells or their transit amplifying progeny [Ming and Song, 2011, Ponti et al., 2013]. Nestin
and GFAP are common markers for the radial glia-like stem cell stage whereas proliferating
progenitors (C and A cells) are characterised by the expression of Mash1 and Dlx2 [Ming and
Song, 2011].
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Cancer Stem Cells Following the first discovery of a subpopulation of human acute myel-
oid cells able to initiate cancer upon transplantation into immunodeficient mice [Lapidot et al.,
1994], evidence for populations with stem cell-like capabilities in the cancer context have been
identified in a vast variety of malignancies including breast, colon, lung, liver and pancreatic
tumours [Pattabiraman and Weinberg, 2014]. Therefore, the general existence of tumour sub-
populations which are able to faithfully reconstitute complete “tumour tissue” (for example
following transplantation into a new host) while others fail to do so is no longer a matter of
active debate. However, this does not rule out cases in which many or all of the tumour cells
can function as tumour stem cells in this sense [Goodell et al., 2015]. What the tumour hier-
archy looks like in each specific case and what fraction of cells carries malignant stemness
depends on the original phenotypic hierarchy of the tissue, its dynamics and most importantly
on how this hierarchy was disturbed, i.e. which normally regulated process was uncaged by
the malignant transformation [Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011].
In the context of the “cancer stem cell dispute” [Pattabiraman and Weinberg, 2014] it is spe-
cifically important to point out the difference between a cancer stem cell (CSC) as introduced
above and the cell-of-origin of a cancer - the latter describes the cell in which the initial trans-
formation event occurred. This cell’s population within the normal context may, but need not
be, equivalent to the corresponding population in the cancerous hierarchy [Rycaj and Tang,
2015]. The number of stem cell divisions in a given tissue over a lifetime has recently been
found to be a strong correlate of the risk of developing cancer in this specific tissue [Tomasetti
and Vogelstein, 2015], thus suggesting that original malignant events in the stem cell compart-
ments are common.
An important although somewhat trivial consequence of the identification of stem-like sub-
sets in some cancers is that genetically identical cancer cells exist in two or more alternative
phenotypes: CSCs and their progeny. It follows that these phenotypes may display diverging
behaviour, for example differential expression of signalling pathways. While this fact appears
to be at the basis of treatment escape of CSC populations in many cases, it also opens research
directions for the specific targeting of the self-renewing subpopulation [Cojoc et al., 2015].
Brain Cancer Stem Cells Initial evidence for a stem cell-like population in brain tumours
based on self-renewal and sphere-forming assays appeared in 2003. The surface marker CD133
was found to discriminate between sphere-forming and non-sphere-forming cells [Singh et al.,
2003]. In a follow-up study, isolated CD133+ glioma cells displayed the ability to initiate tumour
growth when transplanted into immunodeficient mice while CD133− cells where unable to do
so. The tumours developed from the former exhibited histopathological similarities to human
brain tumours [Singh et al., 2004]. The previously mentioned neural stem cell marker Nestin
has likewise been found to differentiate between distinct glioblastoma cell populations: using a
glioma-prone mouse line subjected to chemotherapeutic treatment with temozolomide (TMZ)
when tumours had developed, [Chen et al., 2012] showed that the population reconstituting
tumour growth following initial proliferation arrest was expressing Nestin. They hypothesize
that the enhanced survival of this population is due to its relative quiescence. Next to CD133
and Nestin, the nuclear receptor Tailless (Tlx or NR2E1) which is expressed in the mouse brain
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during development [Monaghan et al., 1995] is also able to discriminate between functional
subsets in glioblastoma [Zhu et al., 2014].
Glioma stem cells share surface markers as well as important signalling pathways with nor-
mal neural stem cells suggesting a close relationship [Sandberg et al., 2013]. However, it has
also been shown using in vitro reprogramming that it is possible to turn differentiated glio-
blastoma cells back into tumour-propagating cells by activating a set of four neurodevelop-
mental transcription factors [Suvà et al., 2014]. Thus, even though a cancer stem cell origin in
neural stem cells may seemmanifest, it can currently not be excluded that they physiologically
originate from more differentiated cells that have undergone reprogramming. In any case, a
variety of pathways which are differentially expressed in glioblastoma stem cells compared to
neural stem cells have been identified [Purow et al., 2005, Bruggeman et al., 2007, Bleau et al.,
2009, Sandberg et al., 2013]. An emerging pattern from these studies seems to be the longer
term or even permanent expression of stem cell activating factors which are normally only
transiently produced, thus driving stem cells into excess proliferation.
6.2. Mathematical Models of Cancer
In this section, a rough overview of mathematical modelling approaches to specific aspects of
cancer is given. Section 6.2.1 introduces various models dealing specifically with glioblastoma,
while sections 6.2.2 and 6.2.3 deal with general questions of tumour modelling. In section
6.2.2, spatial aspects of solid tumours and approaches to model these are introduced; section
6.2.3 briefly discusses published theoretical work on cancer stem cells.
6.2.1. Models of Glioblastoma
As will become apparent in the following, glioblastoma growth has been modelled using a
wide array of mathematical methods and approaches including ordinary differential equations
(ODEs), partial differential equations (PDEs), different simulation approaches, hybrid models
and stochastic processes. However, a vast majority of published work falls into one of two
categories: (1) purely theoretical studies in which (mostly) complicated models building on a
high number of assumptions are developed and resulting hypotheses are at most qualitatively
compared to data and (2) data-driven studies which aim at optimising treatment schedules or
patient-specific survival prognoses using simplified descriptive models which are not always
mechanistically motivated, thus leading to little biological insight.
Theoretical Exploration In the first category, recent investigations have focused on tumour
glioblastoma invasiveness and angiogenesis as well as pharmacokinetic aspects of treatment
delivery [Alfonso et al., 2017]. One simulation study investigated the avascular phase of tu-
mour development including blood perfusion, vessel dilation and the distribution of chemical
substances such as oxygen and growth factors thus allowing to examine impact of the loca-
tion and local environment of the initial lesion [Cai et al., 2015]. In another purely theoretical
study analysing the response of glioblastoma stem cells to different mathematically modelled
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treatment strategies, their enhanced resistance was attributed to alleged transdifferentiation
into vascular endothelial cells [Yan et al., 2017]. [Boujelben et al., 2016] build a model of the
tumour environment including blood flow, vascular permeability and diffusion to examine
whether antiangiogenic treatment is beneficial or detrimental for the delivery of drugs e.g.
across the blood-brain barrier. Varying treatment efficacy between patients motivates [Alf-
onso et al., 2016] to develop a computational model built on the assumption that glioblastoma
cells either proliferate or migrate. They calculate a potentially patient-specific critical prolifer-
ation/diffusion ratio which separates glioma into two differently treatable fractions. None of
these examples produce testable predictions and thus illustrate a difficulty of this field.
Treatment Optimisation and Growth Predictions The fact that model results need not
necessarily be correct or useful is illustrated by the fist example from the second category, in
which the aim is to optimise treatment strategies. Built on a model incorporating toxicity data
from clinical trials, drug efficacy information from in vitro studies and diffusive glioblastoma
growth, [Stein et al., 2018] aim to identify optimum lapatinib dosing schedules. While the
theoretical result suggests that continuous dosing is superior to pulsatile administration, the
authors also find that the dosage needed for tumour control is far beyond toxicity limits. In
a more successful example, [Leder et al., 2014] have optimised radiation dosing schedules in
experiment-theory iterations using a mouse model and a mathematical model with treatment-
susceptible differentiated and more protected stem-like cancer cells. They were able to identify
schedules leading to superior survival of irradiated mice. Furthermore, [Wang et al., 2009]
have introduced a model allowing to deduct two key parameters characterising proliferation
and invasion respectively from routinely obtained magnetic resonance images of individual
patients. This characterisation allows for patient-specific growth predictions which can help
schedule control examinations. There is a growing role for this type of model in the clinical
setting [Jackson et al., 2015].
Investigation of Underlying Mechanisms Finally, mathematical modelling approaches
are being used to examine cellular mechanisms underlying glioblastoma development, pro-
gression and growth. This includes both genomic evolution and heterogeneity and phenotypic
heterogeneity. Based on glioblastoma data from The Cancer Genome Atlas project, [Cheng
et al., 2012] have developed a mathematical method for determining the temporal order of
pathway alterations during gliomagenesis. In a similar spirit, [Sottoriva et al., 2013] analyse
several spatially distinct tumour samples from each of 11 glioblastoma patients and reconstruct
their phylogeny. In addition to the identification of general early and late mutation events,
this revealed patient-specific patterns of cancer evolution and heterogeneity. Recently, intrat-
umoural functional heterogeneity between glioblastoma cells has been experimentally scrutin-
ised for the first time using a lineage-tracing approach with barcoded human glioblastoma cells
in immuno-deficient mice [Lan et al., 2017]. This study has shown that glioblastoma retain a
proliferative hierarchy reminiscent of the normal system with comparably slow-cycling stem
cells at the apex using the critical birth-death process as a model. This approach also allowed
for the conclusion that faster cycling glioblastoma progenitors have extensive self-maintenance
capabilities before giving rise to unproliferative terminal cells. Further studies into both gen-
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omic and phenotypic heterogeneity in glioblastoma are needed to increase the knowledge base
on which both theoretical explorations and treatment optimisation models as described above
can draw.
6.2.2. Models of Spatial Aspects of Solid Tumour Growth
In the past 20 years, spatial models of solid tumours have received growing interest from
mathematical and computational biologists with or without direct clinical application in mind.
Mathematical models which explicitly take the spatial structure of tumours into account are set
up to address diverse areas of interest such as early tumour development, vascularisation and
angiogenesis, invasion of surrounding tissue and the response to varied treatment attempts.
Recently, these models are increasingly being applied to patient-specific data and finding their
way into the clinics to help determine personalised treatment strategies [Karolak et al., 2018].
In general, truly spatial models either build on agent-based stochastic simulations or sets of
coupled partial differential equations (or a hybrid of the two). Here, a third related category,
“pseudo-spatial models” are included, which treat spatial dimensions implicitly rather than
explicitly.
Pseudo-Spatial Models The cultivation of tumour spheroids in vitro has long been an im-
portant part of cancer research as they reproduce features of in vivo tumours more faithfully
than monolayer cell cultures. While spheroids start out as a small undifferentiated cell mass,
characteristic features such as a necrotic core, a quiescent layer around this core and a pro-
liferating outer shell quickly become apparent before the spheroid, in many cases, ceases to
grow entirely. Thus, in a simplified approach at describing spheroid spatial structure, three
coupled ODEs governing proliferating, quiescent and necrotic cells are set up. [Wallace and
Guo, 2013] analyse a comprehensive set of specific modelling choices within this framework
and show that a model including a growth term proportional to the surface area can explain
many experimental observations. Importantly, the total tumour size as a function of time can
adopt functionally different forms depending on modelling assumptions. This is of clinical rel-
evance, as even today simple growth models are often used to predict cancer progression in
the clinic. Common choices for ODE models for this task include exponential, logistic, linear,
surface-proportional and Gompertzian relations which may result in differences of predicted
clinical doubling times of the tumour volume as large as one order of magnitude [Murphy et al.,
2016].
Agent-Based Models In agent-based modelling, each cancer cell is treated as an individual
computational object acting either on a grid or a differently structured space. The approach
thus allows to include both heterogeneous cell populations and cell-to-cell diversity. Because
of these advantages it has being widely used in computational cancer research [Wang et al.,
2015c], each model being set up with a specific research question in mind. [Enderling et al.,
2009] analyse the effect of migration rates on tumour growth in two and three dimensions and
find that migration is pivotal for tumour growth and progression, as migrating cells spread
into the surrounding tissue to form micrometastases. [Sottoriva et al., 2010] focus on the role
of cancer stem cells in a spatial setting and conclude that the joint presence of stem-like can-
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cer cells as well as more differentiated cells leads to higher spatial heterogeneity and resulting
therapy resistance. In an attempt to combine three-dimensional modelling with mutational
progression, [Waclaw et al., 2015] develop an evolutionary simulation which predicts that cel-
lular dispersal and turnover limit genetic heterogeneity. They, too, find that migration is cru-
cial for fast expansion and suggest clinically targeting short-range cellular migratory activity
to improve survival. Agent-based models have also been used to examine tumour metabolism
and treatment schedules: [Carmona-Fontaine et al., 2017] show in an experiment-theory col-
laboration how altered metabolite concentrations in the tumour microenvironment affect the
behaviour of invading immune cells while [Gallaher et al., 2018] use an off-lattice agent-based
model to find that modulating the dose of anti-proliferative drugs leads to efficient growth
control.
PDE Models and Hybrids Tumour models building on partial differential equations pre-
cede the rise of complex agent-based models in time because of the high computational power
necessary for the execution of the latter. However, as the following sample of studies shows,
agent-based models have by no means replaced PDE-based approaches as both strategies con-
tinue to coexist and intermix. In an early reaction-diffusionmodel of cancer invsaion, [Gatenby
and Gawlinski, 1996] let normal and malignant cells compete in a spatial setting. Tumour cells
produce an acidic medium from which normal cells are not protected, thus allowing a travel-
ling wave of tumour cells to proceed into surrounding tissue. The spheroid-modelling problem
discussed in the paragraph on pseudo-spatial models was picked up by [Sherratt and Chaplain,
2001]who formulated it in terms of continuumdensities of proliferating, quiescent and necrotic
cells. More recently, [Hawkins-Daarud et al., 2013] extended a previously developed continu-
ous glioma model to include edema formation during anti-angiogenic therapy. Comparing
their results to magnetic-resonance images they conclude that anti-angiogenic treatment may
have little effect on the growth dynamics of the overall tumour cell number. [Swan et al., 2017]
have developed a patient-specific anisotropic diffusion model which allows to predict spatial
tumour spread based on a diffusion tensor imaging, a novel MRI-based imaging technique.
They apply their efforts to 10 tumours and find increased prediction accuracy compared to the
commonly employed Proliferation-Infiltration model [Swanson et al., 2000]. [Swan et al., 2017]
also outline how their results could be applied clinically in the future: using their model, re-
gions where most invasion has occurred could be identified thus enabling informed decisions
where the clinical target volume for irradiation or excision should be extended the furthest.
6.2.3. Models of Cancer Stem Cells
This section will briefly focus on compartmental mathematical models including cancer stem
cells. Of course, spatial modelling approaches also allow the inclusion of several distinct cel-
lular phenotypes and indeed some of the models introduced in section 6.2.2 have stem cell
agents (e.g. [Sottoriva et al., 2010]). While cancer stem cells were initially believed to con-
stitute only a small fraction (i.e. on the order of 1%) of the tumour bulk, later observations
showed that this is not always the case [Enderling, 2015]. Compartmental models thus explore
mechanisms leading to certain ratios between stem and non-stem tumour cells which include
phenotype-specific kinetics and feedback loops introducing interactions between phenotypic
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populations.
CompartmentalModels Most compartmental models of stem-cell driven cancers incorpor-
ate three major cellular phenotypes or minor variations of these - stem cells, transit amplifying
cells and differentiated cells. This is true for all models introduced in the following. [Ganguly
and Puri, 2006] set up this same hierarchy for both normal and abnormal cells and allow cells
within the two upstream compartments to transit from normal to malignant via mutations.
They find that mutations within the stem cell compartment are more significant for the initi-
ation of cancer than mutations within early progenitor cells. [Molina-Peña and Álvarez, 2012]
place the (now overcome) assumption of small stem cell fractions at start of their study. They
allow for several proliferating progenitor phenotypes with decreasing potential in their model
and derive relationships between model parameters dictated by the assumption that the can-
cer stem cell fraction should remain below 1% of the overall cell number. Interestingly, the
previously published work by [Johnston et al., 2010] already shows that this assumption is not
justifiable. Based on a model comprising the same three phenotypes as above and no specific
feedback loops between them they describe how cancer stem cells can make up any fraction
of the tumour thus governing its aggressiveness. [Weekes et al., 2014] introduce an age struc-
tured model which allows for differentially capable progenitors. They show that the overall
expansion rate of the tumour in the exponential growth phase is governed by the symmet-
ric division rate of the stem cell compartment alone. As previously discussed, experimentally
observed tumour growth can be described by a variety of different mathematical functions
and Gompertzian growth is often identified. Because of this, [Liu et al., 2013] investigate how
a three-compartment model can be refined such as to exhibit Gompertzian behaviour. They
conclude that negative feedbacks proportional to the number of differentiated tumour cells on
both the division rates of stem cells and proliferating progenitors and their self-renewal prob-
abilities are required to control population balance. Overall, while mathematical properties of
simple compartmental models have been studied excessively, research aiming at the estimation
of their parameters is scarce.
Identifying Topology by Lineage Tracing In recent years, lineage-tracing and genetic la-
belling techniques have been increasingly used to investigate the hierarchical dynamics of stem
and progenitor cells. Often, these data require advanced statistical approaches to unravel their
full informative potential [Blanpain and Simons, 2013]. This combination of experimental and
theoretical techniques has not only been used in developmental and homoeostatic contexts,
but also in cancer. [Driessens et al., 2012] have applied it to identify lineages in squamous skin
tumours via an unbiased genetic labelling strategy. They do not only identify a stem-cell like
population but derive that it cycles twice as fast as downstream cells. In a slightly different ex-
perimental approach again in skin tumours, [Sánchez-Danés et al., 2016] where able to initiate
tumour growth by malignant transformation of stem cells but not progenitors. Transformed
stem cells were characterised by increased symmetric divisions. Lately, [Lan et al., 2017] have
used lentiviral barcoding to examine the lineage topology in glioblastoma as outlined above.
Reasoning via stochastic processes, they recovered the three basic cellular phenotypes so prom-
inently featuring in the compartmental models described above.
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6.3. Mouse Models and Experiments Underlying this Work
This section introduces the transgenic mouse models and specific techniques underlying the
experimental work on which this theoretical study is built. This includes the non-germline
tumour model developed and used by our experimental collaborators, the group of Dr. Hai-
Kun Liu at the DKFZ, in section 6.3.1 as well as several useful modifications of this model in
sections 6.3.2 to 6.3.6.
6.3.1. Induction of Glioblastoma Growth
The glioblastoma tumours analysed here are induced in the subventricular zone of newborn
mice via a procedure using targeted viral transfection of growth-related genes (described by
[Zhu et al., 2014]). The avian retroviral vector RCAS (derived from avian leukosis virus (ALV),
subgroup A) is engineered to express Akt and platelet-derived growth factor 𝛽 (Pdgfb). This
construct is then administered to a transgenic mouse line expressing the receptor for ALV-A
under the promoter of Nestin, a commonly used marker of neural stem cells [Rietze et al., 2001,
Kriegstein andAlvarez-Buylla, 2009, Fuentealba et al., 2012]. Akt and Pdgfb are thus exclusively
implanted into neural stem cells. [Zhu et al., 2014] show that this system induces high-grade
brain tumours which recapitulate important histological features of human glioblastomas. The
process is summarised in figure 6.1a.
6.3.2. Co-Expression of Tlx and GFP
The nuclear receptor Tlx has been shown to be expressed specifically by neural stem cells
[Liu et al., 2008]. It is important for maintaining their undifferentiated state and governs their
proliferation [Shi et al., 2004]. A previously introduced transgenic mouse line features the
expression of green fluorescent protein (GFP) under the Tlx-promoter [Feng et al., 2013], thus
allowing the identification of stem cells in fluorescence microscopy or fluorescence-based cell
sorting. [Zhu et al., 2014] have confirmed that both the usability of Tlx as amarker for stem cells
and its functional implications remain valid in the context of the glioblastoma model discussed
in section 6.3.1. If the gene encoding red fluorescent protein (RFP) is additionally included in
the induction process outlined in section 6.3.1, this mouse model can be used to quantify the
fraction of Tlx+ cells within the tumour bulk using flow cytometry as shown in figure 6.1b.
6.3.3. Bioluminescence Imaging of Tumour Volume
Bioluminescence imaging describes a technique which allows time series imaging of in vivo
processes [Contag et al., 1997, Massoud et al., 2003]. The biological structure to be imaged
has to express the gene for an oxidative enzyme (Luciferase), which leads to the emission of
photons upon the administration of a substrate consumed in the process of bioluminescence.
This technique has been used previously in the context of imaging diverse types of mouse
model brain tumours, for example [Uhrbom et al., 2004, Shah et al., 2003, Hashizume et al.,
2010].
For the BLI data analysed in this study, Luciferase is transfected into Nestin+ cells using
the RCAS system described in section 6.3.1 (administered in parallel with the RCAS-driven
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induction of tumour growth). The photon flux emitted by the tumour-bearingmice is thereafter
monitored regularly using a CCD camera. Importantly, tumour-derived light emission has
been shown to be highly correlated with tumour volumes measured using magnetic resonance
imaging (MRI) [Szentirmai et al., 2006] justifying its use as a proportional proxy of cancer cell
number in this study. The resulting bioluminescence time series of an exemplary animal is
shown in figure 6.1c.
6.3.4. Viral dsRed-Labeling of Proliferating Progeny
Via the administration of a retrovirus carrying the gene for dsRed, a red fluorescent protein,
actively dividing tumour cells and their progeny can be labelled genetically. We have found
that these viruses almost exclusively enter proliferating Tlx− cells, as co-labelling of Tlx-GFP
(as described in section 6.3.2) with dsRed has never been observed. This is thus a useful method
for labelling all Tlx− cells (and their potential progeny) which are actively proliferating at a
given time point without having to sacrifice the animal (this in turn is necessary for staining
for proliferation markers such as Ki67 or GFAP).
6.3.5. TAM-Induced Expression of Rosa26-Brainbow Colours
Using a transgenic mouse line combining the modifications described in sections 6.3.1 and 6.3.2
with stem-cell specific inducible genetic labelling allows tracing the fate of individual cancer
stem cells and their progeny in glioblastoma. Here, inducible genetic labelling is enabled via
the transgenic expression of CreERT2 under the Tlx-promoter. CreERT2 is a fusion of the site-
specific recombinase Cre and a mutated hormone-binding domain of the estrogen receptor.
Cre itself catalyzes recombination between specific DNA recognition sites (called loxP sites)
and can thus be used for excision or inversion of the loxP-flanked DNA segment [Feil et al.,
2009]. In turn, CreERT2 recombinases are per se inactive but can be activated by administration
of tamoxifen (TAM, a synthetic estrogen receptor ligand) [Feil et al., 1997]. Thus, Cre-driven
recombination can be transiently activated in cells expressing the CreERT2 gene - as CreERT2
is expressed under the Tlx-promoter in our mouse model, here this applies to cancer stem cells
only.
Furthermore, the DNA segment flanked by loxP sites in this labelling approach contains a
Brainbow-2.1 cassette [Livet et al., 2007] under the CAGG-promoter. UponCre/loxP-recombination,
a stop cassette is excised from the Brainbow segment and the expression of one of four fluor-
escent proteins (nGFP, YFP, RFP or mCFP) is started stochastically [Schepers et al., 2012]. Tlx-
expressing cells are thus labelled genetically and pass on the label to their progeny upon divi-
sion. Importantly, the expression of the fluorescent protein is independent of the Tlx-promoter,
so that Tlx− progeny of the initially labelled cell can nevertheless be identified via their fluor-
escent colour. As the Cre recombinase is active only transiently following administration of
tamoxifen, no further inversions of the colour cassettes happen after TAM has disappeared.
With the aim of allowing unambiguous identification and quantification of clones (mean-
ing both Tlx+ and Tlx− progeny derived from one initially labelled Tlx+ cell) by fluorescence
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microscopy of brain tumour slices, the dose of TAM was chosen such as to ensure a sparse
initial labelling thus minimising the risk of clonal overlap at later time points. Four exemplary
clusters of brainbow-labelled glioblastoma cells are depicted in figure 6.1d.
6.3.6. TAM-Induced miRNA Knock-Down of Tlx and Switch of Fluorescent
Protein Cassettes
A disadvantage of the Cre-loxP system for gene knockout as described in section 6.3.5 is that
for each specific gene a transgenic mouse line has to be generated, thus making the process
costly. In an alternative approach, an irreversible Cre-driven flipping knockdown system (miR-
Flex) allowing flexible targeting of different genes can be used [Stern et al., 2008, Koo et al.,
2012]. This structure contains a forward dsRed sequence together with an inverted GFP and
a likewise inverted artificial microRNA-coding sequence between opposing loxP-sites. Upon
Cre-driven recombination, the entire sequence is inverted: originally red cells then turn green
and start expressing the microRNA which is now in forward orientation. The entire construct
is assembled using plasmid cloning and delivered to target cells using the retroviral system
introduced in section 6.3.1. Using a microRNA targeting Tlx, a knockdown efficiency of 80%
could be reached using this approach [Zou, 2016]. In combination with the transgenic expres-
sion of CreERT2 under the Tlx-promoter, the colour switch can be triggered specifically in Tlx+
cells thus marking stem cells (and their recent progeny).
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tumour induction tumor development analysis
RCAS virus
(a) Induction procedure of model glioblastoma
inmice as described in section 6.3.1. Figure:
Yue Zhuo.
(b) Populations of stem (RFP+GFP+) and non-
stem (RFP+GFP−) tumour cells after flow
sorting of a dissociated tumour with char-
acteristics as described in section 6.3.2.
Data: M. Amir Khan.
(c) Exemplary time course of tumour growth
as shown by bioluminescence imaging, see
section 6.3.3. Figure: Peng Zou.
(d) Four examples for brainbow clusters of
glioblastoma cells, presumably derived
from one initially labelled cell, see section
6.3.5. Figure: M. Amir Khan.
Figure 6.1.: Illustration of selected experimental procedures.
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7. Exponential Tumour Growth and Cellular
Migration
Before analysing individual cellular populations within the tumour mass as well as their dy-
namics and roles in chapter 8, we take a coarser look at the system. As described in section 7.1,
we observe exponential tumour growth in untreated mice. While this may not seem very sur-
prising at first glance, section 7.2 shows that such a growth behaviour does not trivially come
about in a spatial setting. Exponential growth has direct implications for cellular behaviour
which will play important roles later on in chapter 9.
7.1. Phenomenological Modelling of Tumour Growth Curves
Figures 7.1 to 7.3 show the bioluminescence imaging (BLI) curves recorded from 23 glioblastoma-
bearing animals over periods of several weeks using the mouse model introduced in section
6.3.3. The BLI values given on the 𝑦-axes therein correspond to the flux of photons emitted per
second by the tumour in arbitrary units. We are interested in the dynamics of this growth phase
and also want to make use of it later on for estimating parameters of glioblastoma growth in
section 8.3. However, because the BLI data points from the individual animals were not taken
at regular time intervals and the signal strengths vary strongly in magnitude (due to different
tumour positions within the brain, varying transmission characteristics of mice of different
colours and other animal-specific factors), deriving a meaningful average from the set of 23
mice is not straightforward.
In order to solve this problem, we start by fitting a number of phenomenological growth
curves to each individual’s tumour volume as a function of time. A wide range of mathemat-
ical models have been proposed for modelling tumour growth both in vitro and in vivo without
a consensus regarding a best choice of equation having emerged across studies or diseases.
Commonly employed models include exponential, Gompertzian and power-law growth [Wal-
lace and Guo, 2013, Talkington and Durrett, 2015, Murphy et al., 2016]. Here, we have fitted
these three models to the 23 experimental time series in figures 7.1 to 7.3 using the Nelder-
Mead method.
In the simplest case, the exponential model, growth is governed by rate 𝜆0,
𝑁exp(𝑡) = 𝑁0e𝜆0𝑡 , (7.1)
where 𝑁exp(𝑡) describes the number of cells at time 𝑡 assuming 𝑁0 cells at 𝑡 = 0. The Gom-
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pertzian growth function is given by
𝑁Gom(𝑡) = 𝐾0elog(𝑁0/𝐾0) exp(−𝑔0𝑡), (7.2)
where 𝑁Gom(𝑡) is again the number of cells at time 𝑡 when having started from 𝑁0 cells at
𝑡 = 0. The Gompertzian curve describes a sigmoidal behaviour where growth slows down at
the end of the process - this behaviour is mediated by the carrying capacity 𝐾0. The parameter
𝑔0 is related to the proliferation speed of cells. Lastly, the power-law model incorporates the
idea that only the cells on the surface of a solid tumour are able to proliferate, for example
because of nutrient constraints in the core. The tumour volume 𝑉pow(𝑡) at time 𝑡 thus depends
on the initial radius of the tumour, 𝑅0, and the linear growth rate 𝑟0 of the tumour’s radius.
This results in the function
𝑉pow(𝑡) =
4𝜋
3 (𝑟0𝑡 + 𝑅0)
3 . (7.3)
While the power-law model yields significantly worse fit results than exponential and Gom-
pertzian growth curves by measure of comparing the resulting 𝜒2 values, these two models
perform similarly well. However, the Gompertzian model requires an additional parameter
as compared to the exponential growth model. Using Akaike’s information criterion [Akaike,
1998], which includes a penalty for more complexmodels, we find that the exponential model is
preferable in 18 out of the 23 cases analysed. In the remaining five cases, Gompertzian growth
fits the data best. These results suggest that while glioblastoma growth reaches a capacity limit
eventually, our study focuses on the phase of tumour expansion where growth is still expo-
nential.
In order to describe the mean dynamics of this exponential growth phase, we take the mean
of the 23 fitted values of 𝜆0 resulting in
𝜆0 ± 𝜎𝜆0 = (0.21 ± 0.02) day−1 ,
where 𝜎𝜆0 is the associated standard error of mean. This corresponds to a fast tumour doubling
time of 𝑡2 = log 2/𝜆0 = 3.3 days.
When fitting each of the three models in equations (7.1), (7.2) and (7.3) to the data, the initial
values 𝑁0 (respectively 𝑅0) were allowed to vary freely in ℝ+ in addition to the model para-
meters of interest. This absorbs much of the animal-to-animal variability which may be due
to different numbers of initially transformed malignant cells or the positions of the tumour in
the brain with respect to the skull and measurement devices. It is likewise for this reason that
their values carry no information accessible or relevant to the current discussion.
7.2. Three-dimensional Tumour Growth Simulation
In order to better understand the characteristics and constraints of biological glioblastoma pro-
gression, we implemented a computational tumour growth simulation on a three-dimensional
Cartesian grid. This simulation comprises a self-renewing cell type (type 𝐴) and a derived cell
type which is unable to divide (type 𝐵) as well as behavioural rules associated with cell types
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Figure 7.1.: Time course of glioblastoma growth in 23 individual animals as shown by the in-
crease of bioluminescence over time after birth (and induction of tumour growth)
in days. Red dots show measured BLI values with an assumed relative error of
1/3, black lines show best fits of the exponential model in equation (7.1). The res-
ulting best fit values of 𝜆0 are given above each individual plot in units of day−1.
Experimental data: Peng Zou.
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Figure 7.2.: Time course of glioblastoma growth in 23 individual animals as shown by the in-
crease of bioluminescence over time after birth (and induction of tumour growth)
in days. Red dots show measured BLI values with an assumed relative error of 1/3,
black lines show best fits of the Gompertzian model in equation (7.2). The resulting
best fit values of 𝐾0 (without unit) and 𝑔0 (units of day−1) are given above each
individual plot. Experimental data: Peng Zou.
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Figure 7.3.: Time course of glioblastoma growth in 23 individual animals as shown by the in-
crease of bioluminescence over time after birth (and induction of tumour growth)
in days. Red dots show measured BLI values with an assumed relative error of 1/3,
black lines show best fits of the power-law model in equation (7.3). The resulting
best fit values of 𝑟0 are given above each individual plot. Experimental data: Peng
Zou.
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𝐴 and 𝐵.
Self-renewing cells of type 𝐴 can divide symmetrically (𝐴 → 2𝐴, rate 𝜆𝑆 ) or asymmetrically
(𝐴 → 𝐴 + 𝐵, rate 𝜆𝐴) while cells of type 𝐵 are not proliferative. Cells of type 𝐵 are lost from
the system via cell death while cells of type 𝐴 live infinitely in this scenario. In addition, one
or both of the cell types can be allowed to migrate around the grid. Different rules governing
these migration processes are conceivable, and some options will be discussed below. Fig-
ure 7.4 gives an overview of the modelled processes in this simplified scenario; the algorithm
in pseudo code below it summarizes the main logics of the corresponding python simulation
which relies on Gillespie’s stochastic simulation algorithm [Gillespie, 1977].
Importantly, in our simulation, cells are only allowed to divide if at least one of their 26
Moore neighbours is empty. We have chosen this assumption over the competing “expand-
ing universe”-type growth (in which cells are always able to divide and all surrounding cells
get pushed outwards by the newborn daughter) because of the biological notions of nutrient
scarcity at crowded interior tumour sites and cell-to-cell contact inhibition of replication [Yu
et al., 2015]. Other recent grid-based simulations likewise operate on the space-limited assump-
tion [Waclaw et al., 2015]. During migration, we do allow cells to move to grid sites which are
already occupied. However, as a consequence, cells on overcrowded grid points are no longer
able to divide until one of the occupants has left the site.
With this basic simulation setup at hand, we are now able to test effects of different migra-
tion scenarios on the resulting growth curves. As baseline, we start with a scenario in which
neither cell type can migrate, resulting in a situation where only cells on the outer shell of the
tumour can divide. As figure 7.5a shows (grey line), this scenario does not lead to sustained
exponential growth. In fact, because only the outer shell can proliferate, the functional form of
the resulting growth curve resembles what is described in equation (7.3), the power-lawmodel.
As a next step, we allow cellular migration which is a known feature not only of the devel-
oping but also the adult mammalian brain. However, in the adult case, migration out of the
subventricular zone (SVZ) is mostly performed by fate-restricted progenitors of neural stem
cells, which themselves reside in the SVZ [Cayre et al., 2009]. Thus, in the simulated scenario,
we begin by allowing differentiated cells of type 𝐵 to migrate. We assume that cells move
towards the outside of the tumour bulk, as this is were cell density decreases and nutrient
availability improves. The direction for the simulated moves is set to the unit vector between
the centre of mass of the tumour and the current position of the cell. In order to enforce faster
migration and thus dispersal into the area surrounding the tumour, we set cells to take more
than one step into the chosen direction. Uniform integer random noise was added to each com-
ponent of the migration vector independently in order to avoid restriction of movement to the
26 Moore axes only. As shown by the red line in figure 7.5a, although this slightly increases the
simulated tumour size at late time points as compared to the scenario without migration, ex-
ponential growth is not reached here. Even though the edges of the tumour are more dispersed
in this scenario, the basic fact that many self-renewing cells are stuck on the dense inside of
the tumour and thus cannot replicate remains intact.
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Figure 7.4.: Summary of rules of the three-dimensional tumour growth simulation on a grid as
discussed in section 7.2.
Algorithm 2 Simulation algorithm of three-dimensional tumour growth with migration.
1: function Tumour Growth(symmetric division rate, asymmetric division rate, migration
rate(s), desired migration behaviour (random or directed))
2: Initialise an empty three-dimensional Cartesian grid.
3: Put one cell of type 𝐴 into the middle of the grid.
4: while 𝑡now < 𝑡end do
5: Based on a random number generator, the current cell population in the grid and
the rates associated with the possible events, decide which type of event will happen next
and after what time increment Δ𝑡 .
6: if event is symmetric division of cell type 𝐴 then
7: Select one cell of type 𝐴 at random.
8: if this cell has one or more empty neighbour sites then
9: Choose a random empty neighbour and add a new cell of type 𝐴 there.
10: else
11: Do not divide.
12: else if event is asymmetric division of cell type 𝐴 then
13: Select one cell of type 𝐴 at random.
14: if this cell has one or more empty neighbour sites then
15: Choose a random empty neighbour and add a new cell of type 𝐵 there.
16: else
17: Do not divide.
18: else if event is migration of cell type 𝐴 (or 𝐵) then
19: Select one cell of type 𝐴 (or 𝐵) at random.
20: According to the chosen migration behaviour (random migration or migration
directed outwards), move the cell to its new position.
21: Update time, 𝑡now ← 𝑡now + Δ𝑡
22: return the current occupancy of the grid with cells of type 𝐴 and 𝐵.
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Lastly, we allow migration of the self-renewing cells of type 𝐴 instead. We find that this
approach allows for sustained exponential growth, as self-renewing cells migrate away from
the tumour shell and thus find a situation similar to the one encountered by the first founder
cell - not surrounded by any competing malignant cells. The resulting growth curve is given
by the green line in figure 7.5a. The parameter values used for all simulations underlying this
figure are as follows: symmetric division of stem cells 𝜆𝑆 = 0.25 d−1, asymmetric division of
stem cells 𝜆𝐴 = 0.65 d−1 and outwards migration of both stem and differentiated cells where
applicable 𝛽 = 0.4 d−1. The dispersal factor used is 𝑁disp = 3 with uniform random noise
𝑁noise ∈ {−2, −1, 0, 1, 2} drawn separately for each spatial dimension.
This examination of different migrational behaviours shows that if persistent exponential
tumour growth is observed in vivo, for example via bioluminescence imaging, the underlying
process must permit replication of a steady fraction of the cells driving tumour growth. This
is specifically not the case if cells are only allowed to proliferate on the surface of a radially
growing tumour, as here the surface scales with 𝑟2 whereas the tumour volume scales with
𝑟3. Two options that do allow for exponential growth are outwards migration at a rate high
enough to exhibit dispersal as discussed here or “expanding-universe” growth, which we have
argued against above.
Next, we seek experimental confirmation for the theoretically derived conclusion that self-
renewing cells are outwards-migrating. For this, we analyse the spatial structure of simulated
tumours. Figure 7.5b shows a tumour where cells were not allowed to migrate. It has a dense,
round shape; when cut open (not shown), cells of type 𝐴 and 𝐵 are mixed throughout the en-
tire bulk. In comparison, a tumour produced by application of the outwards migration rule is
shown in figure 7.5c. Because cells are set to migrate away from the current centre of mass,
initial stochastic deviations from a spherical shape lead to the formation of main migrational
axes which manifest themselves as fingers. This effect is most likely an artefact of the simula-
tion procedure, as in the experimental setting, physiological structures in the host tissue (here
the brain) would likely dominate the detailed directions taken by migrating cells. More im-
portantly however, we observe the accumulation of stem cells on the outer shell of the tumour
entity. This becomes more clear when looking at a cut through the tumour as shown in figure
7.5d. Using the mouse model introduced in section 6.3.6, experiments can directly scrutinize
this prediction. Figure 7.5e shows a detail of a tumour section where the outside of the tumour
is towards the lower right corner, thus confirming the proposed outwards migration of self-
renewing tumour cells.
Of interest, Dr. Chunxuan Shao from the Division of Molecular Neurogenetics at DKFZ has
analysed recently published RNA sequencing data from human glioblastoma samples [Dar-
manis et al., 2017]. In this study, RNA was sequenced using the Smart-seq2 protocol and tu-
mour samples were separated into core and surrounding tissue parts prior to the analysis. He
found that the nuclear receptor Tlx is strongly enriched in the tumour shell compared to the
core, indicating that these findings hold true also in the human context.
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(a) Tumour growth curves for three different
migration scenarios including dispersal, see
section 7.2. Curves show means of 40 real-
isations.
(b) A tumour in which cells do not migrate
after 50 days of growth.
(c) A tumour in which stem cells migrate out-
wards after 50 days of growth.
(d) As in part c, but cut in half to show interior
structure.
(e) Cut through a mouse-model glioblastoma: stem
cells and their recent progeny are labelled in
green, differentiated cells in red.
Figure 7.5.: Tumour growth outcomes for different simulated migration rules.
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8. Model Development and Calibration
This section introduces the mathematical model used for a joint description of several of the
experimental data sets described in section 6.3 as well as the Markov Chain Monte Carlo-based
framework used for parameter estimation and model-based predictions. The resulting estim-
ates for division, differentiation and death rates of the cell populations constituting the tumour
are presented with corresponding confidence regions. Because our mathematical model builds
on three cellular subpopulations (stem cells 𝑆, dividing progeny 𝑃 and terminally differentiated
progeny 𝐷), we refer to our model as SPD-model in the following.
8.1. A Mathematical Model of Glioblastoma Growth
Based on our own earlier observations [Zhu, 2013, Zhu et al., 2014] as well as recently published
findings [Lan et al., 2017], we here choose to model glioblastoma growth with a simple math-
ematical model comprising three cell types: cancer stem cells, their actively dividing progeny
and terminally differentiated cells which are no longer able to proliferate. It is noteworthy that
this hierarchy mirrors what has been found in the case of non-malignant neurogenesis in the
subventricular zone which similarly displays (quiescent and active) stem cells as well as two
types of further differentiated cell types with decreasing self-renewal capacity [Ponti et al.,
2013].
[Zhu et al., 2014] have shown that only the Tlx+ subset of glioblastoma cells is able to initiate
tumour growth recapitulating the histological features of the primary tumour upon xenotrans-
plantation. Furthermore, they give evidence that not all Tlx− cells are proliferating, suggesting
that these further differentiated cells eventually cease to divide and remain in a terminal state.
These findings form the basis for a mathematical model assuming three distinct cell types.
[Lan et al., 2017] have named these cell types 𝑆, 𝑃 and 𝐷 for stem cells, proliferating cells and
differentiated cells respectively and show that a simple model topology as described by figure
8.1 and equation (8.1) is able to qualitatively explain their observations of glioblastoma growth
at the clonal level in the context of a critical birth-death process with immigration. Here, we
set out to quantitatively determine all rates used in the model.
As illustrated by figure 8.1, we include the following cellular processes into our mathemat-
ical analysis: symmetric division of stem cells (𝑆 → 2𝑆) with rate 𝜆𝑆 , asymmetric division of
stem cells (𝑆 → 𝑆 + 𝑃 ) with rate 𝜆𝐴, symmetric division of progeny (𝑃 → 2𝑃 ) with rate 𝜆1,
differentiation of an actively dividing progeny cell into a terminally differentiated cell (𝑃 → 𝐷)
with rate 𝑑1 and finally loss of terminally differentiated cells (𝐷 → ∅) with rate 𝜇1. Assum-
ing mass-action kinetics, the dynamics of this system are formalised by the following set of
109
8.1. A MATHEMATICAL MODEL OF GLIOBLASTOMA GROWTH
ordinary differential equations in the limit of large cell numbers,
̇𝑆(𝑡) = 𝜆𝑆𝑆(𝑡)
̇𝑃(𝑡) = 𝜆𝐴𝑆(𝑡) + (𝜆1 − 𝑑1)𝑃(𝑡)
?̇?(𝑡) = 𝑑1𝑃(𝑡) − 𝜇1𝐷(𝑡) .
(8.1)
Explicit solutions for this system of equations are readily available. Assuming tumour growth
to start from one stem cell at time point 𝑡 = 0 (initial conditions 𝑆(0) = 1, 𝑃(0) = 0, 𝐷(0) = 0),
we find
𝑆(𝑡) = e𝜆𝑆 𝑡
𝑃(𝑡) = 𝜆𝐴𝜆𝑆 + 𝑑1 − 𝜆1 (
e𝜆𝑆 𝑡 − e(𝜆1−𝑑1)𝑡)
𝐷(𝑡) = 𝜉 [(𝑑1 − 𝜆1 − 𝜇1)e𝜆𝑆 𝑡 + (𝜆𝑆 + 𝜇1)e(𝜆1−𝑑1)𝑡 + (𝜆1 − 𝑑1 − 𝜆𝑆 )e−𝜇1𝑡] ,
𝜉 = 𝜆𝐴𝑑1(𝜆𝑆 + 𝜇1)(𝜆1 − 𝑑1 + 𝜇1)(𝜆𝑆 + 𝑑1 − 𝜆1)
.
(8.2)
Because of the experimental observation by [Zhu et al., 2014] that Tlx− cells (cells of type 𝑃
and 𝐷 in the language of the model) cannot in general sustain tumour growth by themselves,
we require that cells of type 𝑃 always be lost via differentiation at least as fast as they divide,
𝜆1 − 𝑑1 ≤ 0 . (8.3)
Revisiting equation (8.2) with equation (8.3) in mind, we see that the second term in 𝑃(𝑡) as well
as the second and third term in 𝐷(𝑡) become irrelevant at later times because their exponents
assume negative values for all times. The only remaining terms are governed by the symmetric
division rate of stem cells 𝜆𝑆 for all three populations. Defining the overall tumour dynamics
𝑁(𝑡) via
𝑁(𝑡) = 𝑆(𝑡) + 𝑃(𝑡) + 𝐷(𝑡) , (8.4)
we thus find the effective growth rate of the whole tumour to be governed only by the sym-
metric division rate of stem cells for 𝑡 ≫ 0,
𝑁(𝑡) ∝ e𝜆𝑆 𝑡 . (8.5)
As a further property of this model, the fractional composition of the tumour bulk reaches
a steady state dependent on the five rates defining the model even though the tumour cell
population grows exponentially for 𝜆𝑆 > 0. These stationary fractions are given by
⟨ 𝑆𝑁 ⟩ = 𝜅(𝜆𝑆 + 𝑑1 − 𝜆1)(𝜆𝑆 + 𝜇1)
⟨ 𝑃𝑁 ⟩ = 𝜅𝜆𝐴(𝜆𝑆 + 𝜇1)
⟨ 𝐷𝑁 ⟩ = 𝜅𝜆𝐴𝑑1 ,
𝜅 = 1(𝜆𝑆 + 𝜆𝐴 − 𝜆1)(𝜆𝑆 + 𝜇1) + 𝑑1(𝜆𝐴 + 𝜆𝑆 + 𝜇1)
.
(8.6)
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Figure 8.1.: Model of glioblastoma growth consisting of stem cells 𝑆, dividing progeny 𝑃 and
differentiated cells 𝐷. 𝜆𝑆 and 𝜆𝐴 describe symmetric and asymmetric division rates
of stem cells respectively; 𝜆1 and 𝑑1 give the symmetric division rate of progeny
cells and their differentiation speed into terminally differentiated cells; 𝜇1 gives the
death rate of these.
8.2. Simulation of Population Experiments
Here we describe how the experimentally observed quantities concerning the mean behaviour
of tumour cells can be calculated using the mathematical model described in the previous sec-
tion as a basis. The experiments discussed in sections 8.2.1, 8.2.2 and 8.2.3 are used for para-
meter estimation in this section; further scenarios simulated for purposes of prediction and
qualitative comparison are presented in sections 9.1, 9.2 and 9.3.
8.2.1. BLI Growth Curves
The phenomenological growth curve description of equation (7.1) exactly matches the func-
tional form of the mechanistically derived model growth curve of equation (8.5). Thus, in order
to describe the BLI tumour growth data adequately with our model, we must seek to minim-
ise the difference between 𝜆𝑆 and the experimental value of 𝜆0 derived above. Assuming the
experimentally measured values 𝜆0 to stem from a Gaussian distribution, this results in the
following likelihood function for the BLI data given the model parameter 𝜆𝑆 :
ℒ𝐵𝐿𝐼 (𝜆0, 𝜎𝜆0 |𝜆𝑆 ) =
1
√2𝜋𝜎
2𝜆0
exp(−
(𝜆0 − 𝜆𝑆 )2
2𝜎2𝜆0 )
. (8.7)
Thus, we find for the logarithm of the likelihood
logℒ𝐵𝐿𝐼 (𝜆0, 𝜎𝜆0 |𝜆𝑆 ) = const. +
(𝜆0 − 𝜆𝑆 )2
2𝜎2𝜆0
, (8.8)
which will form part of the composite log-likelihood function at the basis of parameter estim-
ation in section 8.3.
8.2.2. Decline of proliferation index in the progeny compartment
In this experiment, the development of the proliferative capacity of Tlx− (progeny) cells was
measured over time. To this end, viral vectors carrying the gene for the red fluorescent protein
dsRed were administered as described in section 6.3.4 approximately 30 days after birth, thus
genetically labelling all currently dividing progeny cells. In the following, the time point of
this labelling defines 𝑡dsRed, the start of experiment and simulation. A total of 13 animals were
then sacrificed at time points 𝑡dsRed + Δ𝑡𝑖 , Δ𝑡𝑖 ∈ [1 day … 13 days], and tumour sections were
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stained for the proliferation marker Ki67. The fraction of dsRed+ cells which were stained pos-
itive for Ki67, ℱ Ki67exp , was evaluated and the result is shown in figure 8.2. Each experimental
point here represents between one and three animals, the error bars show rough estimates of
the standard error of the mean (SEM). For this estimation, the sample standard deviation was
calculated on the time point with the largest sample size available (day 6, 𝑛 = 3) and used as
an estimator for the population standard deviation 𝜎𝐾𝑖67 of all time points. The SEM estimate
for each time point Δ𝑡𝑖 was then calculated using the number of animals available at this time
point, 𝑛(Δ𝑡𝑖), giving 𝜎ℱ (Δ𝑡𝑖) = 𝜎𝐾𝑖67/√𝑛(Δ𝑡𝑖).
In order to simulate this experiment, we first evolve the tumour model given by equations
(8.1) until day 30, the approximate starting point of the real experiment. However, it is im-
portant to note that the exact starting point of the simulated experiment does not influence
the outcome, as - like in the experimental case - we are interested only in the fraction of cells
still proliferating after time intervals Δ𝑡 . The time course of this fraction is independent of the
starting time because all rates in the model are assumed to be stationary (constant in time).
Let the viral vector introduce dsRed into all cells of type 𝑃 at 𝑡dsRed = 30 days while not
labelling any stem cells or terminally differentiated cells. This gives as initial conditions for
our experiment:
𝑆dsRed(𝑡dsRed) = 0
𝑃dsRed(𝑡dsRed) = 𝑃(30 days)
𝐷dsRed(𝑡dsRed) = 0 .
(8.9)
Using these initial conditions, we solve equations (8.1) numerically resulting in solutions 𝑃dsRed(𝑡dsRed+
Δ𝑡) and 𝐷dsRed(𝑡dsRed + Δ𝑡). 𝑆dsRed(𝑡dsRed + Δ𝑡) = const. = 0 because no stem cells incorpor-
ate dsRed and there is no dedifferentiation in the model. The modelled proliferative fraction
ℱ Ki67mod within the dsRed population at Δ𝑡 is then readily calculated as
ℱ Ki67mod (Δ𝑡) =
𝑃dsRed(𝑡dsRed + Δ𝑡)
𝑃dsRed(𝑡dsRed + Δ𝑡) + 𝐷dsRed(𝑡dsRed + Δ𝑡)
. (8.10)
In analogy to equations (8.7) and (8.8), we can now derive the parameter-dependent logar-
ithmic likelihood of the experimental Ki67-fractions as shown in figure 8.2 for a given set of
model parameters 𝜃 = {𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1, 𝜇1} to
logℒKi67({ℱ Ki67exp , 𝜎ℱ }|𝜃) = const. +∑
𝑖
(ℱ Ki67exp (Δ𝑡𝑖) − ℱ Ki67mod (Δ𝑡𝑖 ; 𝜃))
2
2 (𝜎(Δ𝑡𝑖))
2 , (8.11)
where the sum runs over all time points where experimental information is available.
8.2.3. Tumour composition information
As discussed in section 8.1, the fractional decomposition of the tumour into its three popu-
lations 𝑆, 𝑃 and 𝐷 is stationary for 𝑡 ≫ 0 and is given by equation (8.6). Unfortunately, the
fractions of proliferating and terminal progenitors are currently not accessible experimentally.
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Figure 8.2.: Time course of proliferative capacity of progeny cells as a function of time. Shown
is the fraction of descendants of progeny proliferating (model population 𝑃 ) at 𝑡 = 0
which is still proliferating at the given later time, see also section 8.2.2. Each exper-
imental data point (dark red) represents between one and three animals together
with an estimate of the corresponding standard error of mean. Themodel bands de-
rive from 20,000 simulations of equation (8.10) with parameter sets 𝜃 drawn from
the posterior distribution and satisfying 𝑝(𝜃|𝜃MAP) > 0.05 (see section 8.3). The
simulation generated from the maximum likelihood set of parameters is shown ad-
ditionally. Experimental data: Yue Zhuo.
The fraction of stem cells within the tumour bulk was assessed by flow cytometry using a
mouse model which expresses RFP in all glioblastoma cells and additionally GFP in Tlx+ cells
(stem cells). Additionally, the fraction of actively proliferating cells within the tumour bulk
(ℱ prolif/bulkexp ) and the fraction of proliferating stem cells within the population of prolifer-
ating cells (ℱ stem/prolifexp ) were measured by a combination of staining for the proliferation
marker Ki67 and the mouse model co-expressing GFP and Tlx. The value of ℱ stem/prolifexp was
previously published in [Zhu, 2013] as the fraction of tumour cells stained positively for the
proliferationmarker PCNA; the value forℱ prolif/bulkexp shown here is a weighted average of val-
ues from [Zhu, 2013, Zhu et al., 2014] and new data reported here, all based on Ki67-stainings:
ℱ stem/bulkexp = (0.23 ± 0.04)% ,
ℱ prolif/bulkexp = (0.22 ± 0.04)% ,
ℱ stem/prolifexp = (0.09 ± 0.02)% .
These experimental ratios and their model counterparts are visualised in figure 8.3 together
with the model estimations for the experimentally inaccessible subpopulation fractions.
In order to construct equivalent ratios from ourmathematical model, wemust make assump-
tions about the proliferative action of the three populations 𝑆, 𝑃 and𝐷. Fully differentiated cells
of type 𝐷 are not proliferative per model definition. Similarly, all proliferating progeny of type
113
8.3. PARAMETER ESTIMATION, METHOD AND RESULTS
𝑃 is actively dividing by construction of the model. The case of stem cells 𝑆 however is less
clear, as we know that neural stem cells, like stem cells in general, enter and exit the cell cycle
depending on external and internal cues, thus switching between active and quiescent states
[Li and Clevers, 2010, Ponti et al., 2013, Bond et al., 2015]. Here, we have chosen not to include
two separate stem cell populations into the model because we have insufficient information
for estimating all rates resulting from an additional cell population. Nevertheless, cell cycle
analysis in our tumour model indicates that 𝑓G0 = (83 ± 6)% of Tlx+ cells are in the G0-phase
at any one time [Zhu, 2013]. We make use of this information directly in modelling the two
experimentally observed ratios introduced above without an explicit quiescent population by
assuming the remaining 17% to be actively proliferating. This value is in agreement with the
fraction of Tlx+ cells staining positively for PCNA [Zhu et al., 2014]. As a result, we define for
comparison with experimental observations
ℱ stem/bulkmod = lim𝑡→∞
𝑆(𝑡)
𝑁 (𝑡) ,
ℱ prolif/bulkmod = lim𝑡→∞
(1 − 𝑓G0 )𝑆(𝑡) + 𝑃(𝑡)
𝑁 (𝑡) ,
ℱ stem/prolifmod = lim𝑡→∞
(1 − 𝑓G0 )𝑆(𝑡)
(1 − 𝑓G0 )𝑆(𝑡) + 𝑃(𝑡)
.
(8.12)
The stationarity of the second and third model ratios follows directly from the stationarity of
the subpopulation fractions given in equation (8.6). Their values were calculated numerically.
As in the previous sections, these considerations lead to a parameter-dependent logarithmic
likelihood contribution from the tumour composition data of the form
logℒcomp(ℱ s/bexp, ℱ p/bexp, ℱ s/pexp, 𝜎ℱs/b , 𝜎ℱp/b , 𝜎ℱs/p |𝜃) = const. +
(ℱ s/bexp − ℱ s/bmod(𝜃))2
2𝜎2ℱs/b
+ (ℱ
p/b
exp − ℱ p/bmod(𝜃))2
2𝜎2ℱp/b
+ (ℱ
s/p
exp − ℱ s/pmod(𝜃))2
2𝜎2ℱs/p
,
(8.13)
which is used for joint parameter estimation in section 8.3.
8.3. Parameter Estimation, Method and Results
In order to calibrate the model introduced in section 8.1 to the data using the likelihoods de-
rived in section 8.2, we use a Bayesian framework in which we approximate the posterior
distribution of model parameters with Markov chain Monte Carlo (MCMC) sampling. This
section comprises a short summary of the principles of Bayesian parameter estimation (sec-
tion 8.3.1), a summary of how MCMC sampling was employed (section 8.3.2) and an overview
of the resulting parameter estimates and their confidence bounds (section 8.3.3).
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Figure 8.3.: Tumour composition (left 𝑦-axis) as discussed in section 8.2.3 and effective tumour
growth rate (right 𝑦-axis) as discussed in section 8.2.1. Red bars indicate experi-
mental values with black bars showing standard error estimates; grey bars show the
result of the maximum a posteriori probability parameter set 𝜃MAP with black bars
derived by simulating tumours from 20,000 parameter sets 𝜃 drawn from the pos-
terior distribution and satisfying 𝑝(𝜃|𝜃MAP) > 0.05 (see section 8.3). Experimental
information is not available for the fractions of stem cells, proliferating progeny
and differentiated cells. Experimental data: Zhe Zhu, Peng Zou, M. Amir Khan.
8.3.1. Short Introduction to Bayesian Parameter Estimation
At the heart of Bayesian parameter estimation (see for example [Sorensen and Gianola, 2002,
MacKay, 2005, Box and Tiao, 2011]) lies Bayes’ Theorem which provides the probability dis-
tribution of parameters 𝜃 as a function of the available experimental data 𝐷, a chosen model
topology ℋ , an error model and distribution conveying prior information on the distribution
of parameters,
𝑃(𝜃|𝐷,ℋ ) = ℒ(𝐷|𝜃,ℋ ) 𝜋(𝜃|ℋ )𝑃(𝐷|ℋ ) . (8.14)
This resulting probability distribution 𝑃(𝜃|𝐷,ℋ ) over parameters is called posterior distribution
or simply posterior. Data𝐷 as well as model and error assumptions enter the calculation via the
likelihood functionℒ(𝐷|𝜃,ℋ ), potential prior information is encoded in the prior distribution
(or prior) 𝜋(𝜃). The normalising constant 𝑃(𝐷|ℋ ) naturally gives the total probability of the
data given the chosen model when taking into account all possible parameter sets 𝜃 ,
𝑃(𝐷|ℋ ) = ∫ d𝜃 ℒ(𝐷|𝜃,ℋ ) 𝜋(𝜃|ℋ ) , (8.15)
and is thus also called evidence for the chosen modelℋ . Although this constant does not affect
model fitting and parameter estimation and will therefore be dropped in the following, it plays
a major role in Bayesian model selection, where comparing evidence values of several models
allows to rank their agreement with the data [MacKay, 2005].
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We have previously introduced all components necessary for making use of Bayes’ theorem
as shown in equation (8.14) - a mathematical model in section 8.1, experimental data and as-
sociated error models in sections 8.2.1 to 8.2.3. Specifically we have given likelihood functions
for all datasets in equations (8.8), (8.11) and (8.13). Since these experiments are independent of
each other, we arrive at a combined likelihood function ℒtotal by multiplying the individual
likelihood contributions. This gives, up to a constant, a total logarithmic likelihood of
logℒtotal(𝐷|𝜃) = logℒ𝐵𝐿𝐼 (𝜆0, 𝜎𝜆0 |𝜆𝑆 ) + logℒKi67({ℱ Ki67exp , 𝜎ℱ }|𝜃)+
logℒcomp(ℱ p/bexp, ℱ s/pexp, 𝜎ℱp/b , 𝜎ℱs/p |𝜃) ,
(8.16)
where 𝜃 = {𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1, 𝜇1} as previously. We assume uniform prior distributions within
biologically reasonable bounds over these parameters. Furthermore we assume prior inde-
pendence of parameters allowing us to give distributions 𝜋†(𝛽) for each parameter separately.
For convenience, we choose the same bounds for all five rates (0 and 4 day−1),
𝜋†(𝛽) =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
0 for 𝛼 < 0,
1
4 , for 0 ≤ 𝛼 ≤ 4
0 for 𝛼 > 4
, for 𝛽 in {𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1, 𝜇1} (8.17)
and construct 𝜋(𝜃) as the product of the five individual priors. As discussed above (equation
(8.3)), we require 𝑑1 ≤ 𝜆1 because of previous observations and thus assign a prior probability
of zero to any parameter set that does not fulfil this constraint. As we will see below, our data
yield fully identifiable parameter estimates far away from the somewhat arbitrarily chosen
upper bound of 4 /day, thus confirming its minor importance for our inference. After dropping
all constants from equation (8.14) in our context, we redefine
𝑃(𝜃|𝐷) = ℒ(𝐷|𝜃)total 𝜋†(𝜆𝑆 )𝜋†(𝜆𝐴)𝜋†(𝜆1)𝜋†(𝑑1)𝜋†(𝜇1) (8.18)
for the following discussion. It is of note that this choice of constant prior implies that
𝑃(𝜃|𝐷) ∝ ℒtotal(𝐷|𝜃) (8.19)
within the given bounds, illustrating that seeking the maximum of 𝑃(𝜃|𝐷) is equivalent to max-
imising the likelihoodℒ(𝐷|𝜃). Thus, in the case of uniform prior distributions, the most prob-
able parameter set 𝜃MAP (MAP - maximum a posteriori probability) resulting from Bayesian
analysis and dervied as described in section 8.3.3 is numerically equivalent to the maximum
likelihood estimate (MLE) [Sorensen and Gianola, 2002].
8.3.2. MCMC Sampling of the Posterior Distribution
Because of the complicated form of equation 8.16, the posterior parameter distribution 𝑃(𝜃|𝐷) is
not accessible analytically. Instead, we approximate it using an MCMC-approach. In general,
MCMC-methods construct a Markov chain whose equilibrium distribution is the requested
probability distribution [Sorensen and Gianola, 2002]. Samples taken from this chain after it
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has reached equilibrium may thus be regarded as samples of the target distribution. The calcu-
lations underlying this work have been performed in the programming language python and
rely on the MCMC-package emcee [Foreman-Mackey et al., 2013]. This package uses an affine-
invariant ensemble sampling method [Goodman and Weare, 2010], which runs many Markov
chains in parallel and constructs informed choices for the next step of each single chain on the
basis of the current positions of all others.
Sampling the posterior parameter distribution defined by equations (8.16) and (8.17) yields
a five-dimensional cloud of points encoding the probability associated with each region of
parameter-space in two different ways. First, the density of points in each region is repres-
entative of its relative probability, because as discussed above it is a key feature of MCMC-
sampling that it produces samples from the target distribution once equilibrated. Second, in
addition to recording each sample’s parameter values, we can record the value 𝑃(𝜃|𝐷) associ-
ated with the parameter set, thus allowing us to locate regions of a given likelihood directly if
the sample size is large enough. Because the visualisation of a 5-dimensional cloud of points
is not straightforward, we resort to an analysis of one- and two-dimensional projections of
the cloud. Figure 8.4 shows all five one-dimensional histograms and all ten ten-dimensional
histograms resulting from the five model parameters. These histograms are approximations of
the corresponding marginal posterior distributions in which a subset of parameters has been
integrated out, that is
𝑃(𝜃1|𝐷) = ∫ d𝜃2 d𝜃3 d𝜃4 d𝜃5 𝑃(𝜃|𝐷) (8.20)
for the marginal posterior of parameter 𝜃1 and
𝑃(𝜃1, 𝜃2|𝐷) = ∫ d𝜃3 d𝜃4 d𝜃5𝑃(𝜃|𝐷) (8.21)
for the joint marginal posterior of 𝜃1 and 𝜃2. It is important to note that, in general, the com-
ponents of the joint modal vector (mode of the full 𝑛-dimensional posterior, 𝜃MAP), are not
equal to the modes of the 𝑛 marginal distributions [Sorensen and Gianola, 2002]. This can also
be observed in figure 8.4, where the red lines have been added to indicate the components of
the full modal vector - deviations from the marginal modes in one dimension are evident espe-
cially for 𝜆𝐴 and 𝜇1. Nevertheless, this visualisation of the posterior sample is useful because
it conveys information about the general spread of sampled parameters and the correlations
between pairs of parameters. We observe that the marginal posterior of 𝜆𝐴 is positively skewed
and portrays a significant heavy tail, indicating that the currently available data do not strongly
exclude high asymmetric division rates of stem cells. Furthermore, 𝜆1 and 𝑑1 are strongly cor-
related indicating that even though both can assume a range of parameter values, in any given
sampled set their values do not deviate much from each other. This fit result is in agreement
with the criticality of the progeny compartment suggested by [Lan et al., 2017], where division
and differentiation rates of proliferating progeny need be equal (or very similar).
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Figure 8.4.: One- and two-dimensional projections of the posterior probability distribution of
the model parameters 𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1 and 𝜇1. The red lines indicate the position of
the components of the most probable parameter set 𝜃MAP. As discussed in section
8.3, the components of the joint modal vector do not generally coincide with the
marginal modes as is obvious for 𝜆𝐴 and 𝜇1 here in particular. The one and two-
dimensional histograms shown here are built from close to one million samples.
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Figure 8.5.: Posterior profiles of the five model parameters 𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1 and 𝜇1 as discussed in
section 8.3. The logarithm of the relative probability as defined in equation (8.23) is
shown on the 𝑦-axis, with values above the red line corresponding to less than 5%
of the probability associated with the best parameter set. The shaded area shows
which relative probabilities are accessible for a given parameter value (shown on
the 𝑥-axis). We define the parameter values where the red line cuts the shaded
area as boundaries of the credible region of 5% relative probability and give the
associated values in table 8.1. The plot was constructed from close to one million
MCMC-samples.
8.3.3. MAP Parameter Estimates and Confidence Intervals
In order to summarise the full parameter distribution shown in figure 8.5, we quote the max-
imum a posteriori (MAP) parameter set, i.e. the mode of the 5-dimensional posterior prob-
ability distribution. This choice of estimator is linked to the decision-theoretic loss function
𝐺(𝑥0, 𝑥) = 𝛿(𝑥0 − 𝑥), where 𝛿 is Dirac’s delta function, 𝑥0 is the true value, but unknown,
parameter value and 𝑥 is our chosen estimate [Jaynes et al., 2003]. With this loss function,
𝜃MAP = argmax𝜃 ∫𝛿(𝜃 − 𝜃
′)𝑃(𝜃′|𝐷)d𝜃′. (8.22)
In practice, we make use of the probability values associated with each sampled set of the
MCMC-chain for finding the most probable set 𝜃MAP and defining credible regions around it.
As this method is obviously vulnerable to random effects governing the sampling procedure,
we have simulated MCMC-chains long enough to ascertain two stable decimal places for all
values in 𝜃MAP when repeating the entire approximation of the posterior. The results for the
individual parameters are shown in figure 8.5 and can be found in table 8.1 as well.
In order to construct credible regions on these MAP estimates, we define the relative prob-
ability of every other parameter set 𝜃 as
𝑝(𝜃|𝜃MAP) =
∫ 𝛿(𝜃0 − 𝜃′)𝑃(𝜃′|𝐷)d𝜃′
∫ 𝛿(𝜃MAP − 𝜃′)𝑃(𝜃′|𝐷)d𝜃′
. (8.23)
Using this definition, we can set a relative probability level 𝛼 and regard as acceptable only
those parameters within a credible region (CR)
CR = {𝜃 | 𝑝(𝜃|𝜃MAP) ≥ 𝛼} . (8.24)
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parameter MAP estimate 𝑝(𝜃|𝜃MAP) = 5% credible region probability within bounds
𝜆𝑆 0.21 day−1 [0.18, 0.25] day−1 0.99
𝜆𝐴 0.43 day−1 [0.20, 1.02] day−1 0.95
𝜆1 0.97 day−1 [0.58, 1.59] day−1 0.97
𝑑1 1.10 day−1 [0.73, 1.74] day−1 0.96
𝜇1 0.24 day−1 [0.03, 0.67] day−1 0.95
5D set 𝜃 as above 5D hypersurface where 𝑝(𝜃|𝜃MAP) = 0.05 0.61
5D set 𝜃 as above 5D hypercuboid defined by above bounds 0.88
Table 8.1.: MAP parameter estimates and information regarding their credibility, for detailed
discussion see text (8.3.2, 8.3.3). For a graphical explanation of how credible regions
were constructed see figure 8.5.
Like [Watson et al., 2015], we chose 𝛼 = 0.05, resulting in a cut-off of | log 𝛼| = 3 in logar-
ithmic probability space. Figure 8.5 shows the application of this principle to our posterior
distribution. For each of the five parameters, the figure indicates which relative probabilities
can be assumed as a function of the chosen parameter if the other four parameters are allowed
to vary freely. Thus, the realisations on the edge of the shaded regions in figure 8.5 represent
the optimal accessible parameter set as function of each parameter in turn. The red line in-
dicates where log 𝑝(𝜃|𝜃MAP) = 0.05 - corresponding parameter bounds are defined where this
line hits the accessible region of relative probability. Here we have used our MCMC-sampled
posterior to determine these profiles which are hence only close approximations of the true
optimal probabilities as a function of the fixed parameter. Similar profiles can be derived by
re-optimising (in a maximum likelihood sense) the problem for the fixed parameter assuming
a series of values around the MLE. This is known as profile likelihood method [Venzon and
Moolgavkar, 1988, Raue et al., 2009]. In analogy, we call our approach the method of posterior
profiles. The credible regions resulting from this method are quoted in figure 8.5 and table 8.1.
Choosing a cut-off in relative posterior probability as discussed above defines a five-dimensional
boundary within the posterior distribution. This boundary contains a corresponding fraction
of the posterior probability. Since an alternative definition of Bayesian credible regions [Box
and Tiao, 2011] uses the probability contained within specified bounds, and related frequent-
ist methods employing constant 𝜒2-boundaries [Press et al., 2007] are common, we quote the
fractions of posterior probability contained within our bounds in table 8.1. For comparison, in
the case of a one-dimensional Gaussian distribution over parameter 𝛽 , boundaries defined by
log 𝑝(𝛽|𝛽MAP) = 0.05would contain 98 % of the total probability. The values in table 8.1 indicate
that the marginal distributions of 𝜆𝐴 and 𝜇1 especially have heavier tails than a normal distri-
bution, corresponding to what we have observed above. The last two rows of table 8.1 illustrate
that, when quoting the five sets of upper and lower bounds as a summary of the posterior dis-
tribution, we are providing a conservative estimate. The five-dimensional surface defined by
𝑝(𝜃|𝜃MAP) = 0.05 (meaning that all parameter sets outside of it are less than five percent as
likely as the best estimate) contains 61% of the total probability, while the five-dimensional
box that we describe by the one-dimensional bounds contains 88% of the total probability. This
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inevitably means that the box contains a large fraction of highly unlikely parameter combina-
tions.
Because of this, in order to derive the confidence bounds on our MAP simulations, we use
only parameter sets from within the 𝑝(𝜃|𝜃MAP) = 0.05 - hypersurface. Several thousands of
these parameter combinations are drawn and the experiments described in sections 8.2.1 to
8.2.3 are simulated with each of them. The resulting spread in simulation outcomes defines the
bounds shown in figures 8.2 and 8.3, which thus comprise all results accessible with parameter
which are at least 1/20 as likely as the maximum probability estimate.
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9. Model Applications
In this chapter, three advanced applications of the model introduced and calibrated in sec-
tion 8 are presented. First, we predict the outcome of an experiment not used for parameter
estimation - the time course of IdU-incorporation into the DNA of Tlx+ cells - and compare
the result with experimental data (section 9.1). Second, we analyse single-cell labelling data
describing the fates of clones derived from individual labelled cells over time. Here, an ap-
parent disagreement with the model introduced in section 8.1 is identified and discussed. We
propose a resolution of the discord built on migration of individual cells through tumour and
brain as suggested in section 7 and refit the altered model to estimate this cellular migration
rate (section 9.2). Last, in section 9.3, we discuss model-based expectations of the systems re-
sponse to two different treatment approaches: chemotherapy with temozolomide and a genetic
knockdown approach affecting the maintenance of the stem-cell state. These are compared to
experimental results.
9.1. IdU incorporation study
A further experiment employs the thymidine analogues IdU and CldU in order to label dividing
cells while they are replicating their DNA [Cavanagh et al., 2011]. Here, IdU was administered
to tumour-bearing mice carrying the Tlx-GFP construct described in section 6.3.2 once every
day for a varying number of days (between once and 15 times) before mice were sacrificed and
the fraction of IdU-positive cells within the GFP-positive population was analysed.
In order to model this experiment mathematically, we make use of a number of recent es-
timations derived by colleagues in the group of Theoretical Systems Biology at DKFZ. First,
there is a threshold in the fraction of labelled DNA which needs to be surpassed for the cell
to be detected as labelled. We take this threshold to be 1/8 of the total DNA (Melania Barile,
unpublished). Second, after injection of a thymidine analogue, its concentration drops rap-
idly as the component is filtered and degraded by the animal’s body. For the related analogue
EdU (ethynyl-deoxyuridine), uptake by dividing cells ceases by five hours after administration
(Adrien Jolly, unpublished). Because of this, we assume the labelling period following IdU ad-
ministration to last for 5 hours likewise. Divisions during the remaining 19 hours of the day
result in synthesis of unlabelled DNA (containing regular thymidine). The basic arithmetics of
accumulation and dilution of labelled DNA during labelling and delabelling phases respectively
is shown in figure 9.1a.
In principle, labelling and delabelling are continuous processes in the space of IdU-carrying
DNA suggesting a mathematical model employing partial differential equations. However,
since we are only interested in the labelled and unlabelled fraction of cells and not their precise
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labeling	 labeling	
delabeling	 delabeling	
(a) Illustration of the basic principle of labelling with thymidine analogues. If an unlabelled cell rep-
licates its DNA in the surplus presence of the analogue (first arrow), the newly synthesized strands
are completely labelled. Assuming that the labelled and unlabelled strands are randomly distributed
during mitosis, each daughter cell ends up with half its DNA labelled. After another division in
presence of the label (second “labelling” arrow), three quarters of the DNA are labelled. The reverse
happens if the division happens while there is no analogue available - the newly replicated DNA con-
tains regular thymidine. Thus, the label content of the two daughter cells is halfed (two downwards
arrows, “delabelling”).
S 0 S 1/8 S 2/8 S 3/8 S 4/8 S 5/8 S 6/8 S 7/8 
(b) Illustration of the labelling model shown in equation (9.1). In principle, the fraction of labelled DNA
in a given stem cell can assume any value in [0, 1), but we group the cells into eight bins in order to
allowmodeling the process with a system of eight ordinary differential equations. Each pie describes
the population of cells in which a minimum of the red fraction and a maximum of the red part plus
the patterned part is labelled. The grey part of each pie stands for the fraction of DNA not carrying
the label. The arrows between these eight populations indicate in which population the daughter
cells of a cell from a given population of origin will end up if the DNA is replicated in the presence
of the thymidine analogue. Because at least 1/8 of the DNA has to carry the label to allow detection
(see text), the population 𝑆0 is not classified as labelled (no halo). Populations 𝑆1/8 to 𝑆7/8 carry the
label in detectable amounts (depicted by red halo).
S 0 S 1/8 S 2/8 S 3/8 S 4/8 S 5/8 S 6/8 S 7/8 
(c) As in part b, but for the delabelling model as described in equation (9.2). Here, the arrows indicate
in which population the daughter cells of a cell from a given population of origin will end up if the
DNA is replicated without the thymidine analogue being present.
Figure 9.1.: Modelling of DNA-labelling with thymidine analogues. Part a shows the basic prin-
ciple of the labelling and delabelling processes, parts b and c explain the rational
behind the mathematical models of labelling and delabelling phases.
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IdU-content, we group them into eight bins containing between 0 and 100% of IdU instead of
thymidine as shown in figures 9.1b and 9.1c. The first bin, population 𝑆0, contains all cells with
less than 1/8 of the total DNA labelled and is the only population assumed to be undetectable in
in an immunostaining assay. The following population, 𝑆1/8, contains all cells with at least 1/8
but less than 1/4 of labelledDNA et cetera. The choice of excluding the upper bound from the bin
is in agreementwith the notion that theoretically it is not possible to reach a completely labelled
cell as a small part of the original unlabelled DNA always remains. The arrows in figures
9.1b and 9.1c illustrate how cells move between the bins if they divide during the labelling or
the delabelling phase respectively. Following this discretisation in IdU-content, it is straight
forward to formulate a set of ODEs using the fractionally labelled groups and the parameters
of stem cell division introduced in section 8.1. For the labelling phase, this results in
̇𝑆0 = −(𝜆𝑆 + 𝜆𝐴)𝑆0
̇𝑆1/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆1/8
̇𝑆2/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆2/8
̇𝑆3/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆3/8
̇𝑆4/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆4/8 + (2𝜆𝑆 + 𝜆𝐴)(𝑆0 + 𝑆1/8)
̇𝑆5/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆5/8 + (2𝜆𝑆 + 𝜆𝐴)(𝑆2/8 + 𝑆3/8)
̇𝑆6/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆6/8 + (2𝜆𝑆 + 𝜆𝐴)(𝑆4/8 + 𝑆5/8)
̇𝑆7/8 = 𝜆𝑆𝑆7/8 + (2𝜆𝑆 + 𝜆𝐴)𝑆6/8 ,
(9.1)
with all populations as defined in figure 9.1. Similarly we find for the delabelling phase
̇𝑆0 = 𝜆𝑆𝑆0 + (2𝜆𝑆 + 𝜆𝐴)𝑆1/8
̇𝑆1/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆1/8 + (2𝜆𝑆 + 𝜆𝐴)(𝑆2/8 + 𝑆3/8)
̇𝑆2/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆2/8 + (2𝜆𝑆 + 𝜆𝐴)(𝑆4/8 + 𝑆5/8)
̇𝑆3/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆3/8 + (2𝜆𝑆 + 𝜆𝐴)(𝑆6/8 + 𝑆7/8)
̇𝑆4/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆4/8
̇𝑆5/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆5/8
̇𝑆6/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆6/8
̇𝑆7/8 = −(𝜆𝑆 + 𝜆𝐴)𝑆7/8 .
(9.2)
In order to simulate the IdU-labelling experiment described above, we concatenate five hours
of the labelling dynamics described in equation (9.1) with 19 hours of the delabelling dynam-
ics in equation (9.2) per day for 20 days and solve the resulting problem numerically starting
from unlabelled cells only at 𝑡 = 0 days. From the resulting solutions for each of the labelled
populations, the fraction of detectably labelled cells (cells with a red halo in figures 9.1b and
9.1c) is easily computed as
ℱ IdUmod(𝑡) = 1 −
𝑆0(𝑡)
∑7𝑖=0 𝑆𝑖/8(𝑡)
. (9.3)
Figure 9.2 shows the resulting time curves of ℱ IdUmod for the MAP-parameter set 𝜃MAP and
bounds deliminating the region accessible with parameter sets satisfying 𝑝(𝜃|𝜃MAP) > 0.05.
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Figure 9.2.: Fraction of IdU+-positive Tlx+ cells as a function of time as discussed in section 9.1.
Red dots without error bars indicate experimental results from one mouse each
(six mice in total), the first red dot at 2 hours shows mean and associated standard
error pooled from another six mice. MAP estimate and bounds were constructed
as discussed before (see section 8.3). Experimental data: M. Amir Khan.
Additionally shown are experimental results from a total of twelve mice. Importantly, these
data were not used for model calibration. Apart from one outlier on day 5, they are in good
agreement with the model prediction. The “hedgehog” shape of the curve is due to the fact that
after the daily injection of IdU a five-hour labelling phase (fraction of labelled cells increases)
followed by a 19-hour delabelling phase (fraction of labelled cells decreases) is assumed as
discussed above. The mean value of labelled cells at later times (i.e. after approximately day
7 in figure 9.2) depends solely on the ratio between the lengths of these labelling and dela-
belling phases and is almost completely independent of the parameters governing symmetric
and asymmetric divisions of Tlx+ cells. These parameters are much more important for the
initial transient phase where the daily mean labelled fraction is still rising (before day 7 in fig-
ure 9.2) - for this critical phase, there are currently few data points available. Still, significantly
slower division rates of stem cells lead to a prolonged transient phase and are thus incompatible
with the high labelled fraction found experimentally on day 7. Faster turnover rates in turn
would lead to a shorter transient phase as illustrated by the upper 𝛼 = 0.05 bounds in figure
9.2, a scenario still compatible with the currently available data.
On a side note, the agreement between the four animals on days 7 and 15 and the model
prediction can be interpreted as evidence in favour of the assumptions concerning the length
of the labelling phase and the threshold in IdU concentration necessary for detection.
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9.2. Tracing of single-cell derived clones
With the method described in section 6.3.5, individual cancer stem cells within a developed tu-
mour can be genetically altered in vivo such that they start expressing one of four fluorescent
proteins at random. The fluorescent protein is likewise expressed in all potential progeny of
the initially labelled cell, thus enabling clonal tracing: when brain tumour slices are analysed
by fluorescence microscopy a given time after the initial drug-induced labelling event, cells of
the same fluorescent colour within close proximity of each other are likely derived from the
same ancestor.
Here, a total of eight animals were sacrificed at Δ𝑡 = {5, 5, 10, 10, 20, 26, 37} days after label in-
duction and their fluorescent clones were quantified. The resulting distributions of clone sizes
are shown in the left column of figure 9.3. Each histograms is built on 𝒪(100) clones, a fairly
low number for approximating a highly skewed distribution as will become apparent in the
following. Summary statistics derived from these datasets comprise mean number of cells per
clone, coefficient of variation (CV) of the clone size, skewness of the distribution as well as the
relative fractions occupied by one-cell-clones, two-cell-clones and larger clones and are shown
in figure 9.4. Error bars accompanying data points of individual animals in this figure show
estimates of the standard error derived using bootstrapping [Efron and Tibshirani, 1994, Boos,
2003].
In a first approach at modelling this data, one would assume the observed clonal growth
dynamics to be governed by the same growth laws introduced and quantified for the popula-
tion data in section 8. However, a comparison of the experimentally observed mean clone sizes
with the model growth curve resulting from equations (8.2) and (8.4) using the MAP-parameter
set 𝜃MAP reveals a discrepancy that is both quantitative and qualitative (figure 9.5c). While the
experimental mean clone size seems to reach a steady state by day 20 at the latest and never
grows much beyond three cells per clone, the growth of the SPD-model starting from a single
stem cell is of course exponential governed by the symmetric division rate of stem cells as dis-
cussed in section 8.2.1.
How can this contradiction be resolved? In section 7 we have shown that migration and dis-
persal processes, most likely of stem cells, must be a feature of the glioblastoma mouse model
under investigation. Additionally, it is known that glioblastomas are highly invasive and can-
cer cells frequently leave the tumour bulk to spread into the surrounding brain areas where
they form metastases [Cuddapah et al., 2014, Osswald et al., 2015, Hadjipanayis and Van Meir,
2009]. This behaviour is a major contributor to poor survival prognoses following glioblastoma
diagnosis [Dandy, 1928, Carlsson et al., 2014, Campos et al., 2016]. Additionally, a spatially in-
homogeneous distribution of actively proliferating cells as well as Tlx+cells has been observed
in the glioblastoma mouse model discussed here [Zou, 2016] - both groups of cells are more
abundant towards the outside of the solid tumour as shown in figures 9.5a and 9.5b. While a
higher nutrient concentration on the outside of the tumour where normal vasculature has not
been destroyed may in part account for a higher proliferative activity, it does not explain the
accumulation of non-terminal cells there. Overall, the invasiveness of glioblastoma, the obser-
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Figure 9.3.: Histograms of clone sizes found experimentally (left, red) and in a simulation in-
cluding migration of cell types 𝑆 and 𝑃 (right, grey). The experimental figures for
day 5 and 10 contain clones pooled from two animals each, the figures for days 20 to
37 contain clones from a single animal each. Simulations were performed from an
initial 2000 labelled stem cells. Applying a Kolmogorov-Smirnov-test to the hypo-
thesis that the data was drawn from the model distribution yielded 𝑝-values of 0.24,
0.86 and 0.18 for the later time points day 20, day 26 and day 37 respectively and
thus no sufficient grounds for rejecting the hypothesis. For the early time points
(day 5 and day 10) however, 𝑝 < 10−5 indicates that data and model are incompat-
ible here. For discussion see the main text. Experimental data: M. Amir Khan.
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Figure 9.4.: Experimental summary statistics of the clone size histograms shown in figure 9.3
together with bootstrapped SE estimates from 10,000 resamplings (red). The grey
bounds show areas accessed by 1000 stochastic model simulations using parameter
sets satisfying 𝑝(𝜃|𝜃MAP) > 0.05 and starting from 1,000 initially labelled stem cells.
The roughness of the boundaries is due to the stochastic nature of the simulation -
as the skewness is specifically sensitive to rare large clones, it remains affected by
this even for the large numbers of clones simulated here. This is the reason why we
do not include the experimental skewness into the likelihood used for fitting the
single-cell data, see section 9.2. Experimental data: M. Amir Khan.
vation of sustained exponential tumour growth and the patterns of spatial heterogeneities in
the mouse model suggest cellular migration of proliferative cells.
Because of this, we refine the SPD-model introduced in section 8 by allowing migration of
cell types 𝑆 (stem cells) and 𝑃 (proliferating progeny). We define a migration event as a move
of a cell far enough away from its clone of origin so that it is no longer identifiable as a clonal
member by the observer but may instead be counted as an additional clone of its own. Figure
9.5d illustrates this principle and shows how it leads to more, but smaller, observed clones. We
assign a new parameter, the migration rate 𝛽 , to migration events. Stem cells and actively di-
viding progeny cells are assumed to leave their parent clone at equal speeds. Importantly, the
original model retains validity for population-level processes like the ones discussed in sections
8 and 9.3, because cellular migration affects system properties only at the level of individual
clones while leaving bulk properties like the total cell number or the cellular composition of
the tumour unchanged.
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Single-cell data like the clone size distributions shown in figure 9.3 contain a wealth of in-
formation that is only fractionally conserved when using first-order summary statistics such
as the mean clone size. Thus a modelling approach allowing access to higher moments of
the clone size distribution is desirable. In principal, deriving a moment-generating function
[Gardiner, 2009] from a master equation formulation of clonal growth could be considered as
it has been used successfully used for other linear problems in biology [Floßdorf, 2013, Buch-
holz et al., 2013]. Here, the state space of the jump process is given by a vector containing
the number of cells in each subpopulation, e.g. stem cells, progenitors and terminal cells in
our example. In the case of linear systems, the method allows exact derivation of any moment
of the solution probability distribution [Gillespie, 2008, Smadbeck and Kaznessis, 2013]. This
probability distribution can be interpreted as the limit of a large number of experimental repe-
titions of independent evolutions of individual clones starting from identical initial conditions.
However, because of the assumed migration events in the system discussed here, the exper-
imental distributions found at any one time cannot be interpreted as stemming from many
independent clones. Rather, some clones may have emerged at later time points than others
and initial conditions for individual clonal growth may also vary because both 𝑆- and 𝑃-type
cells are possible founders.
It is conceivable to instead formulate a jump process on a state space of clone sizes. A state
vector could then contain the number of clones of size 1, 2, …, n. Even though this vector is
a priori infinitely long, the problem could in principle be addressed by truncating it to a bio-
logically reasonable size. In this approach, new observed clones that come into existence via
migration events could be added to the count for clones of size 1 with a rate proportional to
the number of existing larger clones. However, because our model includes three different cell
types with different properties regarding cell division and migration capacity, simply keeping
track of all clone sizes in the system would not allow statements about the propensity of the
formation of new clones or even the transition rates between clones. For illustration, a clone
composed of five stem cells may produce new clones with propensity 5𝛽 and turn into a clone
of size six with propensity 5(𝜆𝑆 + 𝜆𝐴), while a clone composed of five terminally differentiated
cells can neither spawn new clones nor turn into a clone of size 6. It may, however, lose cells
via cell death with propensity 5𝜇 and thus turn into a clone of size 4.
Because of the above, a comprehensive description of the stochastic evolution of a clone size
distribution governed by three different cell types and allowing the emergence of new clones
would require a state space that keeps track of both the number of clones at each time point
and their exact composition. However, even if we cap the allowed clone size as well as the total
number of clones considered, the required state space quickly becomes prohibitively large. As
an example, looking at all possibilities of cellular combinations for clones between sizes 1 and
6 only, we would have to consider
6
∑
𝑘=1(
3 + 𝑘 − 1
𝑘 ) = 83 distinct clone types, (9.4)
each of which has up to seven possibilities of turning into other clones and/or giving rise to
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(a) Proliferating cells (stained for Ki67, white)
are more abundant on the outside of the tu-
mour (green cells). Image: Peng Zou.
(b) Tlx+cells and their recent progeny (green
after induced switch of genetic labelling
colour) are more abundant on the outside
of the tumour (tumour core is towards the
upper left corner in this case). Image: Peng
Zou.
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(c) Experimental mean clone size as a function of time (red
dots) is not compatible with the bulk SPD-model from sec-
tion 8, but could be explained when assuming that cellu-
lar migration leads to the observation of a higher number
of smaller clones (see subfigure d). Experimental data: M.
Amir Khan.
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(d) Cellular migration leads to
the observation ofmore and
smaller clones.
Figure 9.5.: Spatial heterogeneity of mouse model glioblastoma (a, b) with illustrations explain-
ingwhy the simple populationmodel from section 8 is incompatiblewith the single-
cell data (c) and how migration of individual cells can keep clone size small while
increasing the number of clones identified (d).
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new ones (three division events, two migration events, one differentiation and and cell death).
Even disregarding the fact that a maximum clone size of six would not be of much help in at-
tempting to describe the highly skewed data distributions in figure 9.3, operations on this state
space are inconvenient and numerical cost is bound to explode. As a result, even though it
may in principle be possible to define a linear master equation on a space of distributions over
types of clones, there is little hope for practical benefit. Thus, we resort to stochastic simulation.
We make use of a dynamic Monte Carlo method commonly referred to as Gillespie’s al-
gorithm in Systems Biology. It produces trajectories of stochastic equations by keeping track
of the exact numbers of each species present and choosing the next event as well as the waiting
time until this event using a Monte Carlo step based on the species’ abundance and the events’
kinetic rates [Gillespie, 1977]. In order to include the emergence of new clones via migra-
tion into this framework which a priori deals with trajectories of individual populations, every
time a cell of type 𝑆 or 𝑃 leaves the simulated clone, the size of this clone is reduced by one
and the exact time of migration is recorded. After the original clone has been simulated until
the required time, all clones spawned by migration and their offspring are likewise simulated
from their respective time points of emergence. By repeating this process for a high number
(𝒪(103)) of initially labelled clones and combining the information about the size of each clone,
including those emerged later via migration, at chosen time points, the simulated histograms
on the right side of figure 9.3 were produced.
Looking at the data summary statistics in figure 9.4, the mean clone size evolves in a pecu-
liar fashion - while it remains below 1.5 cells per clone until day 10, the four animals sacrificed
after day 20 show similar mean clone sizes between 2.5 and 3. A curve tracing all data points
would thus have to be of sigmoidal shape with a sharp rise between day 10 and day 20. Our
simple model does not offer this flexibility and it is also unclear which biological effects might
cause such behaviour. Thus, we focus on the four animals sacrificed at later time points for
quantitative comparison. As observed above, the mean clone size as well as the corresponding
coefficient of variation and the fractions of size 1 and 2 clones seem to have reached saturation
by day 20 as the statistics of all four late animals fall mostly within each others standard error
estimates and no clear trends are discernible. Therefore, using the assumption that these four
statistics have reached steady state, we calculate the mean of each of them for further com-
parison to the model. A conservative error estimate associated with these mean statistics is
derived by Gaussian propagation of the four bootstrapped standard errors resulting in
𝜇exp = (2.8 ± 0.5)
CVexp = (2.1 ± 0.5)
ℱ size 1exp = (0.56 ± 0.04)
ℱ size 2exp = (0.18 ± 0.03) .
In order to use this information in parameter estimation, the stochastic simulation starting
from a single labelled cell has to be repeated enough times so that the true clone size distri-
bution at the chosen day is sufficiently approached. Here, we find that when starting from
100 labelled cells and simulating until day 20, the four chosen summary statistics fall within a
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narrow interval of less than 5% deviation from the mean upon multiple repetitions of the entire
process (less than 1% for the fractions of size 1 and 2 clones). Additionally, a steady behaviour
of the four statistics was reached by day 20 for all tested parameter combinations 𝜃 within
the bounds given in table 8.1 supplemented by different migration rates 𝛽 . Thus, because the
simulation uncertainty of the steady state statistics is at least one order of magnitude below
the experimental error, we continue to use the parameter estimation procedure introduced in
section 8.3 as an approximation for this noisy optimisation problem - specifically, we define
the likelihood of the clonal tracing data set in the same way as for the bulk datasets using the
experimental error to weight the squared distance between model and experimental values.
Uncertainties in the model values due to the stochastic nature of their simulation are omitted.
While a gradient-based optimisation algorithm would likely have problems with the remain-
ing fluctuations in the simulation outcomes when moving through parameter space in small
steps, the MCMC-approach employed here is robust to this type of noise. In the following, the
set of six parameters comprising 𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1, 𝜇1 and 𝛽 is referred to as 𝜃†. We find for the
approximated logarithmic likelihood contribution of the single-cell data:
logℒclones(𝜇exp, CVexp, ℱ size 1exp , ℱ size 2exp , 𝜎𝜇 , 𝜎CV, 𝜎ℱ 1 , 𝜎ℱ 2 |𝜃†) = const.+
(𝜇exp − 𝜇mod(𝜃†))2
2𝜎2𝜇
+ (CVexp − CVmod(𝜃
†))2
2𝜎2CV
+ (ℱ
size 1exp − ℱ size 1mod (𝜃†))2
2𝜎2ℱ 1
+
(ℱ size 2exp − ℱ size 2mod (𝜃†))2
2𝜎2ℱ 2
.
(9.5)
We add this logarithmic likelihood contribution to equation (8.16) to arrive at a new total like-
lihood including the single-cell data,
logℒtotal(𝐷⋆|𝜃†) = logℒ𝐵𝐿𝐼 (𝜆0, 𝜎𝜆0 |𝜆𝑆 ) + logℒKi67({ℱ Ki67exp , 𝜎ℱ }|𝜃)+
logℒcomp(ℱ p/bexp, ℱ s/pexp, 𝜎ℱp/b , 𝜎ℱs/p |𝜃) +
logℒclones(𝜇exp, CVexp, ℱ size 1exp , ℱ size 2exp , 𝜎𝜇 , 𝜎CV, 𝜎ℱ 1 , 𝜎ℱ 2 |𝜃†) .
(9.6)
We assume the prior distribution of the migration rate 𝛽 to match those of the other five para-
meters, given in equation (8.17) - a uniform distribution between 0 and 4/day.
Performing theMCMC-sampling procedure in the sameway as described in section 8.3 yields
an approximation of the posterior distribution. By plotting each sampled parameter set’s pos-
terior probability as a function of each of the six parameters individually yields the posterior
profiles shown in figure 9.6. Comparing figures 8.5 and 9.6, the fuzzy boarders of the accessible
posterior probability region in the latter stand out. These arise because of the stochastic nature
of the simulation of clonal tracing data - two realisations of the simulation with the exact same
set of parameters will not result in the exact same clone size distribution and thus not in the
same summary statistics. As discussed above, we have simulated a number of initially labelled
cells high enough so that the simulation variance is negligible compared to the experimental
uncertainty.
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Figure 9.6.: Posterior profiles of the six model parameters 𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1, 𝜇1, 𝜃 and 𝛽 as discussed
in section 9.2. The logarithm of the relative probability as defined in equation (8.23)
is shown on the 𝑦-axis, with values above the red line corresponding to less than 5%
of the probability associated with the best parameter set. As above (figure 8.5), the
shaded area shows which relative probabilities are accessible for a given parameter
value (shown on the 𝑥-axis). We define the parameter values where the red line cuts
the shaded area as boundaries of the credible region of 5% relative probability. The
fuzzy boarders of the shaded area are due to the stochastic nature of the single-cell
data simulation.
The parameter estimates with accompanying 𝛼 = 0.05 bounds for the more comprehensive
model and data are shown above each posterior profile in figure 9.6. The previously determined
values 𝜆𝑆 , 𝜆𝐴, 𝜆1, 𝑑1 and 𝜇1 are in very good agreement with the earlier estimate, no signific-
ant shifts of the MAP values are observed. Through the addition of the single-cell data set, the
width of the bounds on 𝜆𝐴 a and 𝜇1 could be reduced; the bounds on 𝜆1 and 𝑑1 are still very
wide as both parameters remain strongly correlated. The newly introduced model parameter 𝛽
is fully identifiable with a MAP value of 0.33 per day - this suggest that it takes cells of type 𝑆
and 𝑃 on average roughly 3 days to migrate far enough away that they cannot be identified as
a member of the clone of origin any more by the observer. Considering that migration speeds
of the order of 10 𝜇𝑚/ℎ or higher are possible in the context of neural development [Hayashi
et al., 2015, Cayre et al., 2009] and assuming a cellular diameter of 20 𝜇𝑚, an order of magnitude
common in mammalian cells [Milo and Phillips, 2015], 72 hours would in principle allow cells
to migrate more than 30 cell diameters away from their original position. It is obvious that
this may introduce problems regarding the unambiguous identification of clonal members in
fluorescence microscopy even if initial labelling was sparse.
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In recent years, with the emergence of single-cell labelling methods, studies exploiting the
statistical information of clonal growth using stochastic modelling techniques have become in-
creasingly popular, some employing fluorescence microscopy for in situ lineage tracing [Dries-
sens et al., 2012, Blanpain and Simons, 2013, Watson et al., 2015, Davis et al., 2016] while others
rely on methods such as flow cytometry or DNA sequencing outside the tissue of origin [Buch-
holz et al., 2013, Lan et al., 2017, Pei et al., 2017]. In the latter case, unique labels are needed for
each clone because spatial information is lost during the analysis. For in situ lineage tracing
methods however, few or even a single colour can be sufficient if initial labelling is performed
sparsely. Spatial information is retained and can be exploited for identifying clonal members
which are assumed to lie within close proximity of each other. However, in such methods a
higher level of personal judgement of the experimentalist is required. Unambiguously deciding
whether a cell a certain distance from another belongs to the same clone can be impossible in
expanding tissues or systems with high cellular migration like the one at hand. Thus, when
modelling such data mathematically, caution should be exercised and potential effects of mi-
gration or expansion on the model outcome should be examined.
9.3. Treatment Approaches
In this section, two approaches to treating glioblastoma are discussed and explored both within
the modelling framework and experimentally. First, in section 9.3.1, the effect of chemotherapy
on tumour growth is examined: despite an initial strong decrease in tumour volume, relapse
is inevitable here. Second, in section 9.3.2, we look at the effects a knockdown of the stem
cell marker Tlx has on the population dynamics. Here, we find that a long-term reduction of
tumour volume should in principle be possible.
9.3.1. Chemotherapy with Temozolomide
Temozolomide (TMZ) is a chemotherapeutic anti-cancer drug that acts via DNA-methylation
of mostly N7 or O6 guanine residues. During DNA replication this ultimately results in G2/M
cell cycle arrest and apoptosis [Zhang et al., 2012]. Thus, in the presence of TMZ, division
attempts of cancerous cells result in cell death, while resting cells are not affected in the same
way [Beier et al., 2008]. In order to model the effects of this drug, we alter the basic SPD-model
given in equation (8.1) such as to incorporate them. Specifically, in the presence of the drug,
we do not allow cell division to result in two daughter cells any more, but set it to lead to cell
death instead. This concerns both symmetric and asymmetric division attempts of stem cells
as well as divisions of progeny cells. The behaviour of fully differentiated cells in turn is not
changed. This results in the following set of differential equations:
̇𝑆(𝑡) = − (𝜆𝑆 + 𝜆𝐴) 𝑆(𝑡)
̇𝑃 (𝑡) = − 𝜆1 𝑃(𝑡) − 𝑑1𝑃(𝑡)
?̇?(𝑡) = 𝑑1𝑃(𝑡) − 𝜇1𝐷(𝑡) .
(9.7)
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Of note, we have not introduced any additional parameters into the model here.
To mathematically replicate the treatment schedule, the tumour is first evolved in an un-
disturbed fashion until day 55, the approximate time point of experimental intervention (see
figure 9.7c). For this first phase, equations (8.1) are used. As treatment is experimentally ap-
plied for 10 days, equations (9.7) are used between day 55 and day 65 before returning to the
undisturbed system thereafter. The model prediction resulting from this schedule is shown in
figure 9.7a for the maximumMAP parameter set 𝜃†MAP and corresponding 𝛼 = 0.05 bounds. The
bounds were generated by simulating the system with a large sample of posterior parameter
sets satisfying 𝑝(𝜃|𝜃MAP) ≤ 0.05 and then extracting the minimum and maximum resulting tu-
mour sizes at each time point from the set of solutions.
Following the start of chemotherapy, a sharp decline in modelled tumour mass by a factor
of 59 (for the MAP estimate, black curve) is observed. The reduction phase continues after the
end of the treatment so that the minimum tumour volume is reached 18 days after the start
of chemotherapy. Relapse then ensues following the same characteristic exponential growth
displayed by the primary, and the modelled tumour regains its pre-treatment volume 40 days
after treatment begins.
Looking at the fractional composition of the tumour following treatment illustrates how pro-
liferating cells are depleted to very small amounts but nevertheless re-emerge after the end of
the treatment phase (figure 9.7b). Following the start of chemotherapy, the fast-dividing pro-
liferating progeny cells (red population) are quickly depleted, while the slower dividing stem
cells are lost more slowly (green population). At the end of the treatment, the tumour consists
almost entirely of terminally differentiated cells. However, the remaining stem cells quickly
repopulate the system and the tumour returns to its original composition about a month after
the start of treatment.
Experimental bioluminescence time curves of tumour-bearing mice receiving 10 days of
TMZ at the age of around 55 days were recorded for five individual animals. The results are
shown in figure 9.7c, with the time span of chemotherapy administration being indicated in
grey. These tumours took 14 to 34 days until they reached their smallest volume and 28 to
54 days until they grew back to their original size. The smallest volume was between 7 and
115 times smaller than the volume at the beginning of the treatment. All these values are in
excellent agreement with the model prediction; their rather wide range suggests significant
inter-animal variability in tumour growth dynamics and treatment response.
Cancer therapies such as treatment with temozolomide shape the evolution of tumour size
and genetic composition via treatment-induced mutagenesis and selective pressure [Burrell
et al., 2013, Venkatesan et al., 2017]. In glioblastoma, the relapsed tumour is often found to grow
faster and more aggressively partly due to new TMZ-induced driver mutations [Johnson et al.,
2014]. Generally, genetic heterogeneity is a major contributor to diverging and unsatisfactory
therapy results [McGranahan and Swanton, 2015]. Nevertheless we have chosen not to include
genetic heterogeneity into the mathematical models of the present study, as because of the
136
CHAPTER 9. MODEL APPLICATIONS
40 60 80 100
time (days)
10−2
10−1
100
101
no
rm
al
is
ed
tu
m
ou
r
si
ze
model, MAP
model, α=0.05 bounds
TMZ treatment window
(a) Prediction using the model including
chemotherapy in equations (9.7).
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(b) Relative model tumour composition before
and after chemotherapy (shown for 𝜃†MAP).
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(c) BLI curves of tumour-bearing animals treated with temozolomide for 10 days (treatment time points
indicated by vertical grey lines).
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(d) Exponential fits (using equation (7.1)) to the BLI values of the relapse phase (blue to salmon circle in
part d). Error model as in figure 7.1.
Figure 9.7.: Effect of 10-day chemotherapy treatment on mathematical model (parts a and b)
and experiment (parts c and d). Experimental data: Peng Zou.
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process of tumour induction used here in which surplus copies of important growth genes are
introduced into neuronal stem cells, tumour growth is already extremely aggressive from the
start. In order to further legitimise this simplification for the scope of thus study, we analysed
our bioluminescence data of TMZ-treated animals (figure 9.7c) for evidence that the relapse
growth rate is higher than the primary growth rate. To this end, we fitted the phenomenological
growth model of equation (7.1) to the relapse phase and compared the result to the previously
identified primary growth rate
𝜆0 ± 𝜎𝜆0 = (0.21 ± 0.02) day−1 .
For the five TMZ-treated animals shown in figure 9.7d, we find a mean growth rate of
𝜆relapse ± 𝜎𝜆0 = (0.27 ± 0.04) day−1 ,
which is not significantly different from 𝜆0 (Student’s t-test, 𝑝 = 0.18). Thus there is no reason
to alter the assumption that primary and relapse growth phase do not differ from each other
in this mouse model.
9.3.2. Induced knockdown of Tlx
It has previously been shown that a knock-out of Tlx has strong beneficial effects on animal
survival in the tumour model discussed in this study [Zhu et al., 2014]. In the present work, a
miRFlex system introduced via a viral vector was used to allow inducible knock-down of Tlx.
Induction was then triggered by 10 consecutive injections of tamoxifen (TAM) and a CreERT2
excision system.
In order to model this experimental approach, we assume that each administration of TAM
permanently turns a fraction 𝜖 of the current stem cell population into non-self-renewing pro-
genitors of type 𝑃 irreversibly because of the reduction of active Tlx following the knock-down.
The reason for a permanent instead of a transient switch lasting only for the time TAM is ad-
ministered is that Cre drives an irreversible genetic change that remains after the end of TAM
presence. However, because mRNA and protein have finite half-lives and the genetic switch is
thus assumed to require some time until it takes effect, we assume that the conversion 𝑆 → 𝑃
in the model does not happen instantaneously but with delay 𝜏 . Otherwise, the equation sys-
tem is preserved; cells behave as described in equations (8.1).
Figure 9.8a shows the model prediction resulting from this schedule for the maximum MAP
parameter set 𝜃†MAP and corresponding 𝛼 = 0.05 bounds when using a conversion efficiency
of 𝜖 = 50% and a conversion delay of 𝜏 = 5d. Interestingly, the tumour continues to grow for
approximately 10 days following the start of the treatment. In this time, its volume is increased
by a factor of around 3. Thereafter, the tumour mass starts to decline slowly. The similarity
between the proliferation rate of progeny cells 𝜆1 and their differentiation rate 𝑑1 plays a ma-
jor role for how long stem-cell depleted tumours can retain a stable size: if 𝜆1 = 𝑑1, the tumour
volume can in principle remain stable infinitely. For all cases where 𝜆1 < 𝑑1, a stem-cell de-
pleted tumour will shrink with a time constant dependent on Δ = 𝑑1 − 𝜆1. For 𝜃†MAP, 𝜆1 and
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𝑑1 are within 15 % of each other resulting in the slow decline shown in figure 9.8a. The beha-
viour is illustrated in figure 9.8b - following the fast depletion of stem cells (green), the progeny
compartment undergoes only a slow decay while the tumours distribution into proliferating
progeny and terminally differentiated cells remains rather stable.
The experimental data in the case of Tlx-knockdown treatment is much less regular than in
the case of chemotherapy with TMZ. The response of seven animals to the treatment is shown
in figure 9.8c. In general, following the administration of the Cre-inducing agent TAM, the
tumour volume dropped slightly before starting to grow again and reaching values generally 2
to 4 times higher than the pre-treatment volume. This peak in tumour size generally occurred
10 to 20 days after TAM administration. After this peak, tumour volume declined at varying
speeds. In several cases, tumours eventually relapsed after a few weeks of remission, indic-
ating that stem-cell depletion had worked only partially. While the model currently does not
comprise a mechanism allowing the experimentally observed initial drop in tumour mass, the
transient continued growth before remission is observed as predicted (expansion factor around
3 after 10 days before decline). Again, the wide range of experimentally observed behaviours
in the declining phase may be indicative of heterogeneous dynamics between tumours.
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(c) BLI curves of tumour-bearing the Tlx-MiRFlex construct and given tamoxifen at each time point
marked with a grey vertical line. Behaviours are heterogeneous, but tumours continue to grow after
the start of the treatment before eventually decreasing in size in most cases.
Figure 9.8.: Effect of Tlx knockdown treatment on mathematical model (parts a and b) and
experiment (part c). Experimental data: Peng Zou.
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10. Discussion - Cancer Stem Cells in
Glioblastoma
The strength of this work lies in the direct connections it makes between simple theoretical
models and experimental observations. This is true for both the three-dimensional tumour
simulation and the compartmental differential equationmodel. While more sophisticatedmod-
els have previously been developed in both categories, direct comparison to experimental data
and model quantification is still largely wanting. Here, we find that cellular dispersal is a direct
consequence of experimentally observed growth patterns and show that stem cells on average
divide with a high rate. This in turn leads to a cancer stem cell fraction of almost 20% within
tumours. In a further step, we use our quantified model to show that single-cell tracing data
have to be handled with care in the absence of unambiguous clonal bar codes. Lastly, the com-
parison of model predictions to treatment data reveals both strengths and limitations of the
model: while general features and time scales of the primary treatment response are correctly
predicted, later events and details call for model extensions.
Matching Experimental and Theoretical GrowthCurves In chapter 7, we have analysed
tumour growth curves from 23 untreated animals recorded with the help of bioluminescence
imaging. We tested which of three commonly employed tumour growth models - exponential
growth, Gompertzian growth or linear radial growth - described the experimental data best
and identified exponential growth as the most adequate description in the majority of cases.
In order to preserve information about biological variance in tumour growth, we fitted each
animal individually and thus arrived at a distribution of growth rates with a mean and standard
deviation of 𝜆0 = 0.21 ± 0.07 day−1. This translates to a tumour doubling time of only 3.3 days
on average.
Next, we set up a three-dimensional grid-based simulation of solid tumour growth which in-
cluded self-renewing and non-self-renewing species. With the help of this model we explored
three different migration scenarios: (1) neither cell type is allowed to migrate, (2) non-self-
renewing cells are allowed to migrate towards lower cell density and (3) self-renewing cells
are allowed to migrate towards lower cell density. We find that scenarios (1) and (2) are not
compatible with sustained exponential tumour growth, as self-renewing cells are unable to
find enough space for continuous replication. In scenario (3), however, as self-renewing cells
themselves migrate outwards, they routinely find themselves on the edge of the tumour and
can thus divide without hindrance. The accumulation of Tlx+ self-renewing cells on the outside
of mouse model glioblastoma could be verified experimentally. Likewise, analysis of single cell
RNA-sequencing data from human glioblastoma samples showed Tlx to be differentially higher
expressed in tumour cells extracted from the surrounding of the tumour as compared to its core.
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Time-series data of mouse model brain tumours has been produced before [Szentirmai et al.,
2006, Hashizume et al., 2010, Jarzabek et al., 2013] and, although this was not rigorously tested
in these studies, yielded growth patterns compatible with the exponential behaviour identified
here. Likewise, as introduced in section 6.2.2, spatial aspects of solid tumours including glio-
blastoma have received considerable attention in the literature and possible growth curves are
a matter of active discussion because of their relevance for prognostics in the human setting
[Murphy et al., 2016]. On the theoretical side it has been shown that migration drives tumour
expansion speed [Enderling et al., 2009, Waclaw et al., 2015]. However, we are not aware of
any previous study making the direct link between experimentally observed growth patterns
and mechanistic assumptions. Here, we show that cellular dispersal is a necessary condition
for the observed tumour expansion in our system. Furthermore, we have predicted and ex-
perimentally confirmed the resulting accumulation of self-renewing cells on the shell of the
tumour. Our result suggests that such direct confrontation of simulated and observed tumour
growth can help judge the likelihood of detailed underlying mechanisms as phenotype-specific
migration behaviour.
A Higly Active Stem Cell Population In chapter 8 we have introduced a simple compart-
mental model of three coupled ordinary differential equations describing the dynamics of glio-
blastoma stem cells, their proliferating progeny and terminally differentiated tumour cells re-
spectively. This model was motivated by direct experimental observations of our collaborators:
in clonal tracing experiments, symmetric as well as asymmetric division of Tlx-GFP+ cells was
observed in fluorescence microscopy images; Tlx− cells alone were unable to develop into full
tumours after xenotransplantation; the proliferation index within a given set of Tlx− cells de-
creases over time; and Tlx− cells are eventually lost from the system. Mathematically, we have
transcribed this into symmetric and asymmetric division of stem cells, symmetric division and
differentiation of proliferating progenitors and death of terminally differentiated cells using
mass-action kinetics. Importantly, this simple hierarchical model has previously been sugges-
ted in normal neurogenesis [Ponti et al., 2013] as well as in glioblastoma [Lan et al., 2017].
Basic properties of this model were then derived analytically. These include the fact that the
overall growth of the tumour bulk is driven by the symmetric division rate of stem cells alone,
remaining completely unaffected by the dynamics of the non-self-renewing downstream pop-
ulations. Further, after a short initial development phase, the mathematical tumour displays
constant fractions of the tree populations throughout the entire exponential growth phase.
Making use of these distilled findings as well as of the model solutions, we set out to quantify
the five event rates jointly using several experimental data sets. First of all, this included the
overall tumour growth rate extracted from the bioluminescence imaging data which was dir-
ectly linked to the symmetric division of stem cells in the model. Secondly, we used a data
set characterising the proliferation index within an initially labelled population of proliferat-
ing progeny as a function of time. Lastly, making use of the fact that the population fractions
are stationary, we included fractional measurements of cancer stem cells within the total cell
number, proliferating cells within the total cell number and stem cells within all proliferating
cells.
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Using a Bayesian approach to parameter estimation enabled by Markov Chain Monte Carlo
sampling of the parameter space we succeeded to identify all five event rates and can give
upper and lower bounds for each of them. In summary, we find that stem cells divide symmet-
rically about once in five days while they produce a proliferating progenitor via asymmetric
division about twice as often. Taken together, stem cells on average divide regularly, slightly
more often than once in two days. Lower down in the hierarchy, proliferating progenitors
divide symmetrically once per day and turn into terminally differentiated cells only slightly
faster. While the proliferating compartment is thus not able to drive tumour expansion, it can
maintain tumour volume for several days or weeks in the absence of stem cells. Our results
for the progenitor compartment are in good agreement with the findings of [Ponti et al., 2013]
for C and A cells (neural progenitors) in the normal system. This strengthens the hypothesis
that glioblastoma progenitors by themselves resemble their normal counterparts whereas glio-
blastoma stem cells are continuously driven through cell cycle, having lost their ability to stay
quiescent for prolonged periods of time.
Even though the historic idea of stem cells as a rarely dividing, quiescent population has
recently been crumbling in its generality, specifically in the cancer context [Driessens et al.,
2012], our rates do not agree with the recent results of [Lan et al., 2017] who suggest that asym-
metric divisions of stem cells should happen at a much lower rate than the turnover of these
progenitors themselves. However, the discrepancy is likely explained by the different models
used, as [Lan et al., 2017] transplant a human glioma cell line into immuno-deficient mice - an
approach resulting in much slower tumour progression. In our context, where excess growth
genes have been introduced into the genome of neural stem cells, a high overall division rate
and little evidence for a dominant quiescent population appear fitting.
While the existence of a quiescent stem cell population in this system was previously repor-
ted [Zhu, 2013], our current data does not contain enough information to explicitly include this
into the model and subsequently identify all associated rates. We thus understand the model
rates concerning the stem cell population as describing the average dynamics of this pheno-
type. This does not exclude the existence of a quiescent population, neither on a population
level nor on the level of individual cells. In the same spirit, we have included the finding by
[Zhu, 2013] that 83% of Tlx-GFP+ reside in the G0 phase of the cell cycle into the calculation of
actively dividing stem cells. Looking closer at the findings of [Ponti et al., 2013] in the normal
system, it is striking that activated B cells (neural stem cells) display a particularly short S phase
of only 4 hours. It is conceivable that this behaviour is conserved or even accentuated in the
malignant case with glioblastoma stem cells rushing through short S/G2/M phases and then
remaining in a G0-like state for slightly longer time, reminiscent of their normal behaviour.
More research into existence and nature of quiescent stem cell population in glioblastoma and
in the animal tumour model underlying this study in particular is required.
Cancer stem cells where historically believed to constitute only minor fractions on the order
of one in a thousand or even one in a million tumour cells, a notionmostly based on assays with
immuno-deficient mice [Quintana et al., 2008]. More recently, significantly higher fractions of
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tumour stem cells have been reported [Quintana et al., 2008, Enderling, 2015]. Based on our
quantified mathematical model, we are likewise able to quote the fraction of tumour mass
occupied by each phenotype, even though they are in part not accessible experimentally. We
find that stem cells make up 19% of the tumour mass while progenitors and differentiated cells
contribute 24% and 57% respectively. Since the proportion of stem cells in a tumour is directly
linked to its aggressiveness [Johnston et al., 2010], this high stem cell fraction may give another
explanation for the poor survival of glioblastoma patients.
Migration Destroys Single-Cell Tracing Data In section 9.2 we discuss data from a clonal
tracing study. Here, using inducible Cre, one of four fluorescent protein genes was randomly
chosen for expression specifically within Tlx+ cells. In the following, this genetic label was
passed on to Tlx+ as well as Tlx− progeny of the originally labelled cell. In contrast to the data
sets used for parameter estimation chapter 8, this data set is not based on an entire population
of cells, but on the fates of individual stem cells. Such data is, in principle, highly informative
because not only mean dynamics, but various higher order statistics describing the distribution
of individual cell fates are contained. These can be exploited to deduce differentiation topology
and dynamics, as has been shown in other systems [Driessens et al., 2012, Buchholz et al., 2013].
As we had described population-level growth of glioblastoma in terms of linear ordinary
differential equations up to here, we naively assumed that a stochastic description based on a
chemical master equation incorporating the exact same processes should able to capture the
dynamics of individual clones. Themean dynamics derived from this stochastic approach coin-
cide with the previous deterministic description. However, looking at the experimental mean
dynamics of clone sizes, we have discovered that these never go beyond a mean clone size of 3
cells, while obviously our exponentially growing population description quickly reaches orders
of 10,000 or 100,000 cells. How can a population that is essentially the sum of individual clones
behave this differently from its constituents? If it is not the number of cells per clone which
increases exponentially, it must be the number of clones which is increasing fast. By experi-
mental definition, where all cells derived from one initially labelled cell should be members of
the same clone, this seems impossible at first glance but is quickly resolved when considering
the highly migrative nature of the tumour as discussed above. With only four fluorescent col-
ours available as clonal “bar codes”, it becomes difficult or impossible to experimentally assign
cellular families. Migration gives rise to new subclones at distinct locations even if initial la-
belling was very sparse.
We have thus sought to integrate this difficulty into the mathematical framework. Because
of the newly emerging clones with diverse cellular compositions, application of a conventional
analytic approach using moment-generating functions is not practical. Instead, we have sim-
ulated the tree of subclones emerging from one initially labelled cell in a stochastic fashion.
The approach requires the introduction of a new parameter, which is defined as the rate with
which migrating cells move far enough away from their clone of origin to be identified as a
separate clone by the experimentalist. This allows to query statistics such as mean clone size
or variance based on all subclones present at a given moment, no matter whether they were
spawned earlier or later. Our previously introduced framework of Markov Chain Monte Carlo
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based sampling of the parameter space is able to give meaningful results even in the presence
of simulation noise as we combine likelihood-based sampling with elements of approximate
Bayesian computation as introduced by [Beaumont et al., 2002].
After re-sampling the parameter space comprised of the division and differentiation rates
of the deterministic model as well as the new migration rate, all previously determined para-
meters emerge unaltered. The new migration rate is able to absorb the entire information
contributed by the tracing data set while leaving other rates unchanged. This is an indicator
for accuracy of the assumption that the tracing data set is a result of the same rules governing
the population when additionally taking into account migration processes. The migration rate
itself is estimated around 0.33/day, meaning that it takes a migrating cell on average 3 days to
escape from its cellular union of origin. Following a rough estimation, in this time a migrating
neural cell is able to cover as much as 30 cell diameters or more which should easily be enough
to cause identification difficulties.
Two general messages can be taken from these proceedings. First, even though single-cell
data is very rich in information, it is always beneficial to be in possession of population level
experiments which serve as a control and prevent premature conclusions. This is especially
true when the system at hand is incompletely understood. In the present case, it was the strong
growth observed in the bioluminescence data which first cast doubt unto the saturating clone
sizes in the single-cell tracing data set. Second, when designing single-cell experiments with
the purpose of clonal lineage tracing, it is desirable to use a system allowing for high numbers
of bar codes and thus unambiguous identification of clonal members. As single-cell sequencing
methods become more and more readily available and affordable, such barcoding methods are
likewise on the rise. Examples include lentiviral barcoding [Lan et al., 2017], TAM-inducible
polylox barcoding [Pei et al., 2017] and CRISPR–Cas9 based barcoding [Alemany et al., 2018].
Is Treatment Futile? In section 9.3, we have adjusted the basic model from chapter 8 to
allow the description of two alternative treatment scenarios. Adjustments to the model were
kept to a minimum in order to allow quantitative predictions of treatment outcomes. In the
first case, the model was adjusted to accommodate chemotherapy using the assumption that
during administration of the drug, all attempted cell divisions fail leading to the immediate
death of the dividing cell. All division rates in the model were turned into death rates thus
avoiding the need to introduce additional parameters. In the second case, two new parameters
had to be introduced in order to model the knock-down of stemness. Experimentally, the stem
cell factor Tlx is knocked down using inducible micro RNAs. In the model, this is incorporated
by turning a given fraction of stem cells into progenitors with a given delay upon each admin-
istration. Motivated by experimental observations, the delay was chosen to equal 5 days. For
total want of information, the knock-down efficiency per single tamoxifen injection was set
to 50%. Surprisingly, as outlined below, this choice leads to decent agreement with experiment.
The predictions produced by the parametrised model showed excellent agreement with ex-
perimental data in the case of chemotherapeutic treatment. The model predicted the correct
magnitude of the treatment-induced drop in tumour volume as well as the correct timescales
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for drop and relapse. Interestingly, this strong agreement is produced by a model which does
not assume a quiescent and thus protected cell population. The fractional difference in death
events during treatment is brought about solely by the difference in division rates between
stem and progenitor cells and the general tendency of the latter to turn into terminal cells and,
eventually, die. However, because of the simple nature of the model which does not allow
for selection of cells with better survival potential or even treatment-induced mutation, the
modelled tumour volume would react in exactly the same way upon a second phase of chemo-
therapy. Even though the growth rate of experimental tumours during the relapse phase is not
significantly different from the primary growth phase, this behaviour is not observed. Here,
treatment of the relapsed tumour with the same drug leads to minor volume reduction at the
most. This indicates that a selection process for a resistant subpopulation is induced by the
first wave of treatment; what exactly is selected for has yet to be determined.
In the case of Tlx knock-down, some but not all of the experimentally observed features in
tumour volume time curves are predicted. It is particularly unclear how a regularly observed
initial drop in tumour volume which appears in 6 out of 7 animals can be explained or mod-
elled. However, the general quality and reproducibility of the knock-down data is worse than
the chemotherapy data due to many uncertainties with the miRFlex strategy. Before further in-
quiring into features of these data, the experimental strategy should be stabilised, for example
by replacing the knock-down of Tlx by inducible knock-out. With perfect or close-to-perfect
efficiency however, this strategy has the potential to significantly prolong animals survival or
even lead to a complete cure.
Overall, while our parametrised model succeeds in predicting elementary features of the
treatment response, a more detailed knowledge of escape processes would be required and have
to be implemented in order tomake themodel useful for treatment optimisation or true survival
prediction. Such escape processes my comprise induced quiescence, mutational evolution or
phenotypic plasticity. Even if the relevant mechanisms were known and incorporated into a
deterministic continuousmodel, one question remains: howmuch reduction of the cancer stem
cell population is enough reduction; when, if ever, will the body’s defense mechanisms be able
to deal with the rest?
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